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 I 
ABSTRACT 
E. coli NfsB nitroreductase (NTR) is currently being studied in combination with the prodrug 
CB1954, as a gene directed enzyme prodrug therapy. NTR reduces CB1954 at either the 2- or 
4-nitro groups to produce highly cytotoxic hydroxylamine derivatives, using either NADH or 
NADPH as cofactor. Initial clinical trials suggest activity, with reduction in PSA and apparent 
delayed progression in some patients. This thesis is concerned with engineering the NTR 
enzyme to improve the efficiency of CB1954 activation, since this would be expected to 
improve the potential clinical efficacy. Site directed mutagenesis has been used to generate 
four libraries of NTR mutants with three small libraries having a maximum diversity of 6.4 
x10
1 – 8.2 x 103 and a large library of 6.3 x 106 possible nucleotide combinations. A direct 
positive selection strategy, which utilises bacteriophage lambda and the SOS response, was 
used to select NTR variants with increase sensitivity for CB1954 from each library. NTR 
mutants with greatest sensitivity were analysed by bacterial IC50 assays. Despite considerable 
work to generate and optimise the large library, only one NTR enzyme was improved over 
WT. However the best mutant (T41G N71S) came from a small library, with an IC50 of 8 µM. 
The most promising NTR enzyme variants were column purified and their kinetic parameters 
and activity determined. T41G N71S showed good activity for CB1954 (0.52 µM s
-1
), being 
the second best mutant to date behind T41L N71S (0.90 µM s
-1
). Adenoviral vectors were 
generated and their ability to sensitise SKOV3 cancer cells tested. T41G N71S was ~2-fold 
improved relative to WT NTR. Purified enzymes were also tested with SKOV3 cells, with 
T41G N71S being ~2.6-fold improved relative to WT NTR. My best enzyme should be 
considered when planning future clinical trials using prodrug activation gene therapy with 
NTR.  
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CHAPTER 1: INTRODUCTION 
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1.1 CANCER 
Cancer is a complex group of diseases that affect a wide range of cells and tissues. A genetic 
link to cancer was first put forward in the 20th century, and is currently one of the major 
foundations of cancer research. Mutations which increase or decrease the expression of 
certain genes are common features of cancers.  
 
1.1.1 Incidence  
One in three people will be diagnosed with cancer at some point in their life and a quarter of 
all deaths are due to cancer. Cancer tends to affect older people with 74 percent of diagnoses 
occurring in people over 60 years. Figure 1.1 shows the number of new cases and rates in the 
UK based on age and sex.  
 
                      
Figure 1.1 Number of new cases and rates by age, sex and type of cancer, UK 2007 
(CRUK website info.cancerresearchuk.org October 2009) 
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Less than 1 percent of cancers are in children (0-14 years) which accounts for around 1,400 
cases. Leukaemia makes up a third of all child cases and brain and spinal tumours account for 
more than a fifth. A further 1,875 teenagers and young adults (15-24 years) were diagnosed in 
2006. In this age group Hodgkin‟s lymphoma, testicular cancer, malignant melanoma, 
leukaemia and bone cancer are common. Around 10 percent of all cancer cases are in adults 
between the ages of 25-49 years. In this age group breast, malignant melanoma, colorectal and 
cervical cancers are most common.  
 
In 2006 293,601 people were diagnosed with cancer in the UK with 147,223 cases in men 
(Figure 1.2a) and 146,378 cases in women (Figure 1.2b). Prostate cancer is the most 
commonly diagnosed cancer in males. In women breast cancer is the most common. 
 
 
            
 
 
 
Figure 1.2 Ten most common cancers in the UK for males and females in 2006 
a) Ten most common male cancers, b) Ten most common female cancers. This table excludes non-
melanoma skin cancer (CRUK website info.cancerresearchuk.org October 2009) 
 
 
a) b) 
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There are more than 200 different types of cancer, however 54 percent of all cancer diagnoses 
were breast, lung, colorectal and prostate cancer. Breast cancer is the most common cancer in 
the UK (see Figure 1.3).  
 
                      
Figure 1.3 Twenty most common diagnosed cancers in the UK in 2006 
This table excludes non-melanoma skin cancer and N-H-L stands for non-hodgkin‟s lymphoma 
(CRUK website info.cancerresearchuk.org October 2009) 
 
 
1.1.2 Mortality 
The second largest cause of death in the UK is cancer only slightly behind heart disease with 
155,484 deaths in 2007. The vast majority of deaths from cancer occur in the elderly with 76 
percent occurring in people aged 65 years and over. Figure 1.4 shows the number of deaths 
and specific mortality rates based on age and sex.  
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Figure 1.4 Number of deaths and mortality rates by age, sex and type of cancer, UK 2007 
(CRUK website info.cancerresearchuk.org October 2009) 
 
 
In 2007 155,484 people died from cancer in the UK with 80,907 cases in men (Figure 1.5a) 
and 74,577 cases in women (Figure 1.5b). Lung cancer is the most common cause of both 
male and female deaths from cancer. 
 
 
            
 
 
Figure 1.5 Ten most common causes of cancer deaths in the UK for males and females in 2007 
a) Ten most common causes of cancer death in males, b) Ten most common causes of cancer death 
in females (CRUK website info.cancerresearchuk.org October 2009) 
a) b) 
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47 percent of all cancer deaths in the UK in 2007 were from lung, bowel, breast and prostate 
cancer. Lung cancer causes the most cancer deaths accounting for 22 percent. This was 
followed by colorectal cancer with 10 percent and breast cancer with 8 percent. Figure 1.6 
shows the most common causes of death from cancer.  
                
Figure 1.6 Twenty most common diagnosed cancers in the UK in 2007 
(CRUK website info.cancerresearchuk.org October 2009) 
 
 
1.1.3 Risk Factors  
Many factors may contribute to the development of cancer. These can generally be divided 
into cellular (intrinsic) and environmental (extrinsic) factors.  
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1.1.3.1 Cellular (Intrinsic) 
Cancerous cells lose the ability to regulate growth leading to an imbalance between 
proliferation, differentiation and cell death. Control of cell division is regulated by two broad 
classes of genes, firstly by genes which suppress cell division known as tumour suppressor 
genes and secondly by genes which promote cell division, these genes are known as proto-
oncogenes. 
 
Tumour suppressor genes encode proteins that can inhibit inappropriate cell cycle progression 
(for example: following DNA damage). In general for a tumour suppressor gene to contribute 
to cancer, both copies of the gene must lose their function or be lost. Studies have identified 
approximately 10 tumour suppressor gene that when mutated lead to a predisposition for 
specific cancers (Lewin 2000). The tumour suppressor gene RB when mutated leads to 
retinoblastoma, a cancer of the retinal cells in the eyes (Alberts et al. 1994). About 40 percent 
of cases are dominantly inherited affecting both eyes and the remaining 60 percent are 
sporadic affecting a single eye (Sudbery 2002). In normal cells retinoblastoma tumour 
suppressor protein (pRB) regulates cell proliferation by binding and sequestering transcription 
factors essential for progression to S phase. Specifically RB binds to the transcription factor 
E2F in the G1 phase of cell cycle. Following growth signal transduction pRB becomes 
phosphorylated; this triggers dissociation from E2F at the end of G1, allowing transcription of 
E2F regulated genes and S-phase entry. 
 
 
 
 8 
It is well known that in many cancers the transcription factor p53 is faulty or absent. Protein 
p53 mutations have been associated with many cancers including breast, lung, bladder and 
colon cancer. In fact approximately 50 percent of all cancers can be associated with mutations 
in the TP53 gene which encodes p53 (Campbell et al.1999 and Griffiths et al. 2002).  
 
The p53 gene encodes a phosphoprotein that plays a critical role in both regulation of the cell 
cycle and apoptosis. Following DNA damage, p53 activates the p21 gene; p21 halts the cell 
cycle by binding to cyclin-dependent kinases allowing time for the cell to repair the DNA. 
When DNA damage is irreparable p53 can activate genes whose protein products cause cell 
death via apoptosis.  
 
The gene BRCA1 is associated with breast cancer, as a dominant inherited trait. 
Approximately 60 percent of women carrying a mutation will go on to develop breast cancer 
by age 50 and 82 percent by 70. The comparable figures for women who inherit two normal 
copies are 2 percent and 7 percent respectively (Purves et al. 1999). Mutations in BRCA1 also 
increase the risk of ovarian cancer. A further breast cancer gene called BRCA2 can also be 
inherited as a dominant trait. Both BRCA1 and BRCA2 play important roles in DNA double 
strand break repair (Campbell et al. 1999). 
 
Proto-oncogenes when expressed have a positive function on cell signalling and the cell cycle, 
these genes are under strict regulation. Upon mutation proto-oncogenes can become 
oncogenic, typically retaining their positive function but losing the appropriate regulatory 
control. Approximately 100 oncogenes have been identified (Lewin 2000).  
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There are at least three mechanisms associated with the conversion of proto-oncogenes to 
oncogenes, point mutation, translocation or over-expression. The most well known proto-
oncogenes would be the ras gene family. Three well-characterised genes of the ras gene 
family H-ras, K-ras and N-ras, code for related monomeric guanosine triphosphate-binding 
proteins (G proteins) that have a role in the transduction of growth signals between growth 
factor receptors and the cytoplasmic MAP kinase pathway (Hurley et al. 1984, Bos et al. 1985 
and Rodenhuis and Slebos 1990). Most ras mutations are single nucleotide substitutions 
which lead to constitutive activation of downstream signalling pathways. Approximately 30 
percent of cancers carry a ras mutation (Zhang et al. 1993 and Campbell et al.1999).  
 
Another well characterised oncogene is c-abl which is activated by translocation and is 
associated with chronic myeloid leukaemia (CML). This proto-oncogene encodes a 
cytoplasmic and nuclear protein tyrosine kinase, which plays a role in cell differentiation, cell 
division, cell adhesion and stress responses (Zipfel et al. 2000 and Qiu et al. 2009).  
 
In human tumours, members of the myc proto-oncogene family are often amplified by over-
expression; there can have up to several hundred times greater expression. myc encodes a 
transcription factor that regulates the expression of approximately 15 percent of all genes by 
binding through Enhancer Box sequences (E-boxes). The cancer Burkitt‟s lymphoma is 
associated with myc upregulation as a result of chromosome translocation to the 
immunoglobulin loci (Walhout et al. 1997, Tsuneoka et al. 1997 and Kim et al. 2004).  
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1.1.3.2 Environmental (Extrinsic) 
Epidemiology shows that environmental factors are the leading cause of cancer. Variations of 
cancer differ from place to place, time to time and depend on peoples activities. There are 
several environmental factors which affect a person‟s risk of cancer including radiation, diet, 
smoking, chemical carcinogens and viruses. 
 
Both ionising and non-ionising radiation can physically damage DNA within the human body 
leading to mutation. In the case of ionising radiation target molecules lose electrons. These 
electrons can cause extensive chemical alterations in DNA, including strand breaks and base 
and sugar destruction (Turner et al. 1997). Examples of ionising radiation include x-rays, α-
rays, β-rays and γ-rays (Hartl and Jones 1999). Non-ionising radiation causes molecular 
vibrations within the target molecules. This can lead to the formation of new chemical bonds 
(Turner et al. 1997). Non-ionising radiation can damage DNA by causing thymidine dimers in 
single stranded DNA. An example of non-ionising radiation would be ultraviolet light.  
 
A variety of cancers such as bowel, stomach, mouth and breast can be affected by a diet. A 
diet high in red and processed meats, saturated fat and salt increases cancer risk, where as a 
diet high in fibre, fruit and vegetables is associated with a reduced risk of cancer. Experts 
think that up to a quarter of cancer deaths are caused by unhealthy diet (CRUK website 
info.cancerresearchuk.org October 2009). Excessive alcohol consumption increases the risk of 
mouth, throat and oesophageal cancer. Alcoholics also have an increased risk of liver and 
bowel cancer.  
 
 11 
Smoking is the single biggest cause of cancer in the world and causes one in four UK cancer 
deaths. Nine out of ten cases of lung cancer are caused by smoking (CRUK website 
info.cancerresearchuk.org October 2009). Smoking is also a risk factor for many other cancers 
including bladder, kidney, cervical, throat, mouth, oesophagus, stomach and pancreas cancer.  
 
Many chemicals are considered to be carcinogens that cause cancer. Some examples of 
chemical carcinogens are 2-naphthylamide, ethidium bromide, trichloroethylene, benzene, 
arsenic and acrylamide. In particular 2-naphthylamide is associated with the development of 
bladder cancer.  
 
Certain viruses have been shown to have a relationship with cancer. Approximately 15 
percent of human cancers are thought to be caused by viruses (Alberts et al. 1994 and 
Campbell et al. 1999). Individuals who develop liver cancer known as hepatocellular 
carcinoma (HCC) tend to also have hepatitis B virus (HBV) infection. The presence of HBV 
infection can increase the risk of cancer a hundred fold.  
 
The human papilloma virus (HPV) has been associated with carcinoma of the uterine cervix 
and the herpes virus Epstein-Barr (EBV) is associated with cancer of the B lymphocytes 
known as Burkitt‟s lymphoma and in the cancer nasopharyngeal carcinoma. A rare form of 
leukaemia is caused by the human T cell leukaemia virus (HTLV-1) (Purves et al. 1999).  
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1.1.4 Cancer Treatments 
The three major treatment modalities for cancer are surgery, chemotherapy and radiotherapy.  
 
Tumours that are localised to a single area can be removed by surgery. Surgery is often used 
before other forms of treatment to remove the vast majority of cancerous tissue and increase 
the success rate of chemotherapy and radiotherapy.  
 
Chemotherapy drugs are used for most forms of cancer, as the drugs can be transported 
through the blood to all areas of the body. Some chemotherapy drugs can even cross the 
blood-brain barrier for the treatment of brain tumours. Multiple drugs are often used in 
combination allowing different stages of the cancer cell life cycle to be targetted. This permits 
tumour attack from several mechanisms increasing the percentage of cells killed, reducing 
systemic toxicity and helping to avoid drug resistance. Some examples of chemotherapy 
drugs include cyclophosphamide, cisplatin, methotrexate, fluorouracil and doxorubicin (Rang 
et al. 2003). Chemotherapy treatment can be used with the intention to cure, or for palliative 
care. Hormones can significantly affect the growth of some tumours, which are considered as 
hormone dependent. Therefore a number of hormones are used in cancer chemotherapy 
including corticosteroids, estrogens, and androgens.  Alternatively a number of hormone 
antagonists can also be used such as tamoxifen an anti-estrogen and flutamide an androgen 
antagonist (Rang et al. 2003). 
 
Radiotherapy is an effective way of killing tumour cells. A high dose of ionizing radiation is 
aimed directly at the tumour. Radiotherapy is also sometimes given as a form of palliative 
care for inoperable cancers, to shrink the size of a tumour.  
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Two different types of cancer and their treatments will be discussed in greater detail below. 
Both of these cancers could benefit from the development of new and improved treatment 
strategies.  
 
1.1.4.1 Prostate Cancer  
Prostate cancer is the most common form of cancer for men in the UK with more than 34,000 
new cases per year. This accounts for 24 percent of all new male cancer diagnoses (CRUK 
website www.cancerhelp.org.uk October 2009). Prostate cancer is quite rare in men that are 
under 50 years of age. 63 percent of cases are in men over the age of 70. Prostate cancer can 
run in families, with several gene changes identified that increase the risk.   
 
A strong risk factor for prostate cancer is age; however a family history of prostate cancer in a 
first degree relative increases the risk up to three fold. The risk further increases if the relative 
is young and if more than one relative has the condition. It is estimated that a predisposing 
gene may be responsible for 10 percent of all prostate cancer cases (Elo and Visakorpi 2001). 
The tumour suppressor gene PTEN is the most frequently inactivated gene in prostate cancer 
resulting in an increased activation of Akt. (McCall et al. 2008 and Van Duijn et al. 2010). 
PTEN is associated with the regulation of the P13K cell survival pathway (Mabjeesh et al. 
2002). PTEN expression is often low or absent in hormone refractory prostate tumours and is 
associated with shorter time to relapse in hormone sensitive prostate tumours (McCall et al. 
2008). Other tumour suppressor genes associated with prostate cancer include p53, RB and 
BRCA2.  
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Scientists have recently produced evidence that the Xenotropic murine leukaemia related 
virus (XMRV) can be linked to prostate cancer in humans. It is already known that gamma 
retroviruses are oncogenic in animals, but this is the first gamma retrovirus known to infect 
humans. The virus was found in 30 percent of prostate cancers tested with protein expression 
in 23 percent. Protein expression was primarily in malignant epithelial cells, suggesting that 
the retrovirus may be directly linked to tumorigenesis. The virus was also associated with 
more aggressive high grade tumours (Schlaberg et al. 2009). However a study in Germany 
failed to detect the virus in greater than 200 prostate cancers (Hohn et al. 2009). Therefore the 
contribution of XMRV to prostate (or potentially other cancers) remains to be confirmed. 
 
The prostate is a small gland the size of a walnut, which is divided into two small lobes that 
sit left and right of a central groove. The prostate gland produces a thick clear fluid used for 
the production of semen. Prostate tumours can be both benign (non-cancerous) or malignant. 
The symptoms for both forms are very similar.   
 
Prostatectomy surgery and radiotherapy are the only forms of curative treatment currently 
available. However many patients treated with prostatectomy and radiotherapy get local 
recurrent cancer within 10 years. Few alternative treatments are available once first line 
treatment has failed. Most prostate cancers are androgen dependent, and respond well to 
androgen blockade. However many go on to develop androgen-independence within 2 years, 
leading inevitably to metastatic spread. Hormonal therapy using anti-androgens has been used 
for over 50 years; however these significantly affect the quality of life without offering a cure 
(Goktas et al. 1999).  
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The prognosis for prostate cancer is very difficult to determine and is based on several 
different factors. Approximately 99 percent of patients diagnosed with localised prostate 
cancer will live for more than 5 years.  
 
Advanced prostate cancer is much more complicated to predict. When radiotherapy and 
hormone therapy is used for treatment 70 to 80 percent will live for at least 5 years. Advanced 
metastatic prostate cancer has much lower survival rates with only 30 percent of patients 
living for at least 5 years after diagnosis. (CRUK website info.cancerresearchuk.org October 
2009) 
 
Better treatments are needed for aggressive forms of localised disease and hormone-refractory 
metastatic disease. Several gene therapy strategies have raised the possibility that gene 
therapy may have the potential to affect both localised and metastatic disease.  
 
Gene therapy for localised prostate cancer has progressed rapidly from replication deficient 
adenoviruses encoding a single therapeutic gene, to replication competent oncolytic 
adenoviruses lacking a therapeutic gene, to replication competent oncolytic adenoviruses 
encoding multiple therapeutic genes. See Table 1.1 for details of clinical trials for localised 
prostate cancer. 
 
Both in vivo and ex vivo gene therapy strategies have been used to target metastatic prostate 
cancer disease. A range of vectors have been trialled including adenovirus, retrovirus and 
vaccinia virus. See Table 1.2 for details of trials for metastatic prostate cancer. 
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There are currently 30 clinical trials recruiting prostate cancer patients in the UK. These range 
from adapting current treatments regimes, trying out new drugs to improving diagnostic 
techniques (CRUK website www.cancerhelp.org.uk October 2009). 
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Treatment  Description Results Reference 
HSV-TK + GCV Replication defective adenovirus 
(E1/E3 deleted) containing wild-type 
HSV-TK under RSV promoter 
Minimal toxicity (grade 1-2), three patients fall in PSA ≥ 50 
percent 
Follow up with repeat treatment showing prolonged PSA 
doubling time 
Herman et al. 1999 
 
Miles et al. 2001 
HSV-TK + GCV Replication deficient adenovirus type 5 
(E1/E3 deleted) containing wild-type 
HSV-TK under RSV promoter 
Minimal toxicity (grade 1-2), prolonged PSA doubling time   Shalev et al. 2000 
HSV-TK + GCV Replication deficient adenovirus 
containing wild-type HSV-TK 
Nine courses of treatment, prolongation of median serum PSA 
doubling time from 2.9 to 6.2 months 
Nasu et al. 2007 
HSV-TK + VCV + RT 
± HT 
Replication deficient adenovirus type 5 
(E1/E2 deleted) containing wild-type 
HSV-TK under RSV promoter 
Minimal toxicity (grade 1-2) 
PSA levels declined rapidly, remaining low at 14 months post 
treatment 
Teh et al. 2001 
Teh et al. 2004 
NTR + CB1954 Replication deficient adenovirus 
CTL102 containing wild-type NTR 
NTR expression seen upon immunohistochemistry staining 
Minimal toxicity, at 6 months patients 10-50% reduction, and 2 
out of 19 showed greater than 50% reduction in PSA 
Searle et al. 2004 
Patel et al. 2009 
 
IL-2 Replication deficient adenovirus 
AdCAIL-2 
Minor adverse reactions, pathology consisted of CD3
+
 CD8
+
 T 
lymphocytes, areas of tumour necrosis. PSA levels fell in 
patients 
Trudel et al. 2003 
p53 Replication deficient adenovirus INGN 
201 containing wild-type p53 under 
CMV promoter 
Immunohistochemistry staining showed wild-type p53 and an 
increase in apoptotic index from 0.39 to 1.18 was observed 
indicating some cancerous tissue had undergone apoptosis 
Pisters et al. 2004 
CV706 Replication competent PSA selective 
adenovirus CV706 
Minimal toxicity, five patients ≥ 50 percent reduction in PSA DeWeese et al. 2001 
HSV-TK + CD + 
GCV + 5-FC 
± 3D-CRT  
Replication competent adenovirus 
containing CD/HSV-TK fusion gene 
Minimal toxicity (grade 1-2), seven patients ≥ 25 and three 
patients ≥ 50 percent reduction in PSA. Two patients cancer 
free at  1 year 
Minimal toxicity, shorter PSA half lives than expected 
5 year follow up, PSA doubling time from 17 to 31 months 
Freytag et al. 2002a 
 
 
Freytag et al. 2003 
Freytag et al. 2007 
 
Table 1.1 Prostate cancer gene therapy trials for localised disease 
Abbreviations: 3D-CRT – 3 dimensional conformal radiation therapy, 5-FC – 5-fluorocytosine, CD – cytosine deaminase, CMV – cytomegalovirus, GCV – 
ganciclovir, HSV-TK – Herpes simplex virus thymidine kinase, HT – Hormone therapy, IL-2 – Interleukin-2, NTR – Nitroreductase, PSA – Prostate-specific 
antigen, RT – Radiotherapy and RSV – Rous sarcoma virus.  
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Treatment  Description Results  
HSV-TK + VACV Replication defective (E1/E3 deleted) 
adenovirus containing wild-type HSV-
TK under OC promoter 
No serious adverse events, local cell death in treated lesions, 
stabilisation of lesion for 317 days in one patient 
Kubo et al. 2003 
HSV-TK + VACV Replication defective adenovirus (Ad5) 
containing WT HSV-TK, OC promoter 
Minimal toxicity, patient 1 and 3 PSA continued to rise, patient 
2 PSA dramatically dropped, metastasis density became lower 
Hinata et al. 2006 
HSV-TK + VACV Replication defective adenovirus 
containing WT HSV-TK, OC promoter 
No serious adverse events, 1 patient PSA dropped time to 
progress 12 months 
Shirakawa et al. 2007 
CG7870 Replication competent PSA selective 
adenovirus CG7870 
Adverse events (grade 1- 3), no partial or complete PSA 
response seen, 5 patients PSA fall > 25-49 percent 
Small et al. 2006 
GM-CSF vaccine Autologous tumour cells transduced 
with replication-defective retrovirus 
encoding GM-CSF  
No serious adverse events, evidence of T cell activation, no 
PSA response 
Simons et al. 1999 
PSA vaccine ± GM-
CSF 
Recombinant vaccinia virus expressing 
PSA (PROSTVAC) 
Low toxicity, no PSA response  
Minimal toxicity, one patient undetectable PSA > 8 months 
Sanda et al. 1994 
Sanda et al. 1999 
PSA vaccine ± GM-
CSF 
Recombinant vaccinia virus expressing 
PSA (PROSTVAC) 
Minimal toxicity (grade 1-2), PSA levels stable > 6-25 months, 6 
patients progression free with stable PSA 
Eder et al. 2000 
 
PSA vaccine ± GM-
CSF 
Recombinant vaccinia virus expressing 
PSA (PROSTVAC) 
Minimal toxicity, PSA specific T-cells present, able to lyse PSA-
expressing tumour cells 
Gulley et al. 2002 
PSA vaccine Combination of vaccinia virus 
expressing PSA and fowl pox virus 
expressing PSA 
Few adverse events, 45.3 percent remained free of PSA 
progression at 19.1 months, 78.1 percent progression-free 
survival. 46 percent of patients show increased PSA-reactive T-
cells 
Kaufman et al. 2004 
PSA + B7-1 + ICAM 
+ LFA-3 vaccine 
Recombinant vaccinia virus expressing 
PSA (PROSTVAC-VF) and 
recombinant fowl pox virus expressing 
co-stimulatory molecules B7-1, ICAM 
and LFA-3 (TRICOM) 
Minimal toxicity (grade 1-2), four patients had stable disease (≤ 
25 percent increase in PSA) at week 8 
DiPaola et al. 2006 
 Table 1.2 Prostate cancer gene therapy trials for metastatic disease 
Abbreviations: GM-CSF – Granulocyte-macrophage colony-stimulating factor, HSV-TK – Herpes simplex virus thymidine kinase, OC – Osteocalcin, PSA 
– Prostate-specific antigen and VACV – Valacyclovir 
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1.1.4.2 Ovarian Cancer  
For women, ovarian cancer is the fifth most common form of cancer in the UK with around 
6,800 new cases per year. 5 percent of cancers diagnosed in women will be ovarian cancer. In 
fact the UK has one of the highest incidence rates across Europe (CRUK website 
www.cancerhelp.org.uk October 2009). Ovarian cancer is hard to diagnose due to vague signs 
and symptoms in early stages of the disease. Many of the symptoms can be related to other 
less serious conditions therefore, up to three quarters of women are in the late stage of the 
disease when they are diagnosed. Survival rates for women at this stage are very poor despite 
advances in surgical techniques.  
 
There are two main types of ovarian cancer epithelial and germ cell. Eighty to 90 percent of 
ovarian tumours are epithelial where the cancer started in the surface layer of the ovary, 
whereas germ cell tumours originate from the egg making cells and make up approximately 
10 percent of ovarian cancers. However some rare cases of sarcomas of the ovary have been 
seen (CRUK website www.cancerhelp.org.uk October 2009).  
 
Current treatments used for ovarian cancer include surgery, radiotherapy and chemotherapy. 
The amount and type of surgery used depends on several factors including the stage, grade 
and type of tumour to be treated. In early stage disease surgery can be used alone, with the 
removal of the affected ovary and fallopian tube. As the disease progresses, surgery to remove 
both ovaries and womb would be recommended to reduce the risk of cancerous cells 
remaining. In some cases adjuvant chemotherapy is offered. 
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If the cancer is more advanced, surgery will be used to remove the ovaries, womb, omentum 
and as much visible tumour as possible. Following surgery, a course of chemotherapy will 
almost certainly be used to further reduce the number of remaining cancer cells. With final 
stage ovarian cancer, chemotherapy may be used first to shrink the tumours before surgery is 
used to remove as much as possible known as „debulking‟. Following surgery chemotherapy 
may be repeated to try and shrink any remaining tumours. In some cases the cancer is too 
advanced and surgery is no longer an option. In these cases a combination of chemotherapy 
and radiotherapy is often used (CRUK website www.cancerhelp.org.uk October 2009). 
Currently carboplatin alone or in combination with paclitaxel are the most commonly used 
chemotherapy drugs for ovarian cancer treatment (CRUK website www.cancerhelp.org.uk 
October 2009). 
 
From the 6,800 women diagnosed with ovarian cancer in the UK each year overall 
approximately 36 out of each 100 will live for at least five years after their diagnosis. 
However the stage of the cancer when diagnosed is highly important when predicting 
survival. It is likely that for women diagnosed with early stage ovarian cancer 7 out of 10 will 
live for more than 5 years, but for women whose cancer has spread to surrounding tissue and 
lymph nodes the 5 year survival rate is about 3 out of 10 (CRUK website 
www.cancerhelp.org.uk October 2009). 
 
Ovarian cancer is considered as a potential target for gene therapy as it is initially confined to 
the peritoneal cavity, where it can be directly targeted away from critical organs. See Table 
1.3 for recent clinical trials for ovarian cancer. 
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Treatment  Description Results Reference 
BRCA1sv Retrovirus encoding BRCA1sv Minimal toxicity, 8 patients stable disease for 4-16 weeks, 
3 patients showed tumour reduction 
No response, no disease stabilisation, little or no vector 
stability, trial terminated after 6 patients 
Tait et al. 1997 
 
 
Tait et al. 1999 
Anti-erb-2 Anti-erb-2 Single-Chain Antibody-encoding 
Adenovirus (AD21)  
Minimal toxicity (grade 1-2), 5 patients stable disease, 8 
patients progressive disease 
Alvarez et al. 2000a 
HSV-TK + GCV Replication incompetent adenovirus (Ad5 
E1a/E1b deleted) encoding HSV-TK 
Minimal toxicity, 5 patients stable disease, 8 patients 
progressive disease 
Alvarez et al. 2000b 
HSV-TK + ACV + 
Topotecan 
Replication deficient recombinant 
adenovirus encoding HSV-TK 
Some toxicity (grade1-4) Hasenburg et al. 2000 
E1A Cationic Liposome-Mediated E1A E1A detected by immunohistochemistry staining, HER-
2/neu downregulation, increased apoptosis, reduced 
proliferation  
Hortobagyi et al. 2001 
p53 Replication deficient adenovirus encoding 
human p53 cDNA 
Some toxicity (grade 1-3), 2 patients had mixed response, 
4 patients had stable disease for 4 courses, 5 patients had 
progressive disease after 1-2 courses 
Wolf et al. 2004 
Adoptive T cells T-cells with high dose IL-2 or dual specific 
T-cells (FR and allogeneic cells) 
Some toxicity (grade 1-4), no reduction in tumour burden 
seen in any patient 
Kershaw et al. 2006 
IFN β Replication incompetent adenoviral vector 
encoding IFN β 
Minimal toxicity (grade 1-2), regression of tumour in thorax 
and abdomen observed 2 months post treatment to 
thorax, indicating a system response 
Sterman et al. 2006 
 
 
Table 1.3 Ovarian cancer gene therapy trials 
Abbreviations: ACV – Acyclovir, GCV – Ganciclovir, HSV-TK – Herpes simplex virus thymidine kinase, IFN β – Interferon β, IL-2 – Interleukin-2 and sv – 
splice variant 
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There are currently 10 clinical trials recruiting ovarian cancer patients in the UK. These range 
from adapting current treatments regimes to trying out new drugs (CRUK website 
www.cancerhelp.org.uk October 2009).  
 
1.2 GENE THERAPY 
„Gene therapy‟ can be defined as the transfer of genetic material into a patient‟s cells for 
therapeutic purposes (Bansal and Engelhard 2000). The last 20 years have shown rapid 
progress from concept to reality with a rapid advancement in molecular biology and a greater 
understanding of disease. Gene modified cells were first used in 1989 and the first gene 
therapy trial was performed in 1990. A diverse array of treatments that utilise gene therapy 
have been attempted including gene transfer for modulation of the immune system, enzyme 
prodrug therapy, oncolytic therapy, replacement gene transfer and antisense therapy (Bansal 
and Engelhard 2000). As our knowledge of gene therapy has progressed larger more complex 
therapies are being devised away from single gene defects (monogenic disease) towards more 
complex diseases such as cardiovascular disease and cancer.  
 
Gene therapy can be categorised into two broad categories ex vivo and in vivo. Ex vivo gene 
therapy usually involves the collection of cells from the patient, the correction of the defect by 
gene transfer into the isolated cells and the return of the cells to the patient by infusion or 
transplantation (Glick and Pasternak 1998). A good example of ex vivo gene therapy would 
be the treatment of severe combined immunodeficiency (SCID-X1) which will be discussed 
further later. 
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In vivo gene therapy involves the direct delivery of a therapeutic gene to targeted cells and 
tissue within the patient. In this case either viral or non-viral vectors are required to deliver 
the therapeutic gene (Glick and Pasternak 1998). A good example of in vivo gene therapy is 
the treatment of cystic fibrosis (CF) which will be discussed further later. 
 
1.2.1 Gene Delivery Vectors 
Several different types of delivery vectors can be used for the insertion of DNA into a cell. 
The vector can be either viral or non-viral and the advantages and disadvantages of the 
different types will be discussed below. The ideal delivery vector should be capable of 
targeting the cell of interest and achieving a sufficient level of expression. There are currently 
1537 active gene therapy trials worldwide. Approximately 69 percent of these ongoing 
clinical trials use viral vectors, with 24 percent being adenovirus and a further 20.9 percent 
being retrovirus. The most widely used non-viral vector is naked/plasmid DNA which makes 
up 17.9 percent of worldwide gene therapy vectors (see Figure 1.7). 
                      
 
 
Figure 1.7 Current active gene therapy clinical trials 2009  
(Wiley website www.wiley.co.uk/genmed/clinical October 2009) 
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1.2.1.1 Viral Vectors 
Many different types of viral vectors have been used for cancer gene therapy. Therapeutic 
genes and their regulatory elements are inserted in to the viral DNA. The viruses can be either 
replication competent where the virus is able to replicate in the host cells or replication 
deficient where essential viral genes have been removed. Replication deficient viruses need to 
be grown in helper cell lines that contain the removed genes allowing the viruses to grow. 
There are several advantages to viral vectors; they can have selectivity for certain cells such 
as a preference for dividing cells and generally achieve greater transduction efficiencies than 
non-viral methods. In some cases such as retroviruses and adeno-associated viruses they are 
capable of integrating the gene of interest in to the host genome. However there are several  
disadvantages to viral vectors: they can be toxic to tissues causing immunological and 
inflammatory responses and there is a limit on the size of gene that can be inserted.  
 
1.2.1.1.1 Retrovirus 
Retroviruses are lipid enveloped single stranded RNA viruses (Buchschacher 2001). Upon 
infection by the retroviral particle, the virion core enters the host cell and RNA is reverse 
transcribed into double stranded linear DNA by reverse transcriptase. The DNA gains access 
to chromatin when the nuclear membrane dissolves during mitosis and integrates at a random 
place in the host genome. The provirus DNA is transcribed by the cellular machinery. The 
WT retroviral genome encodes three essential genes gag, pol and env (Brenner and Malech 
2003).  
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All retroviruses have long terminal repeats (LTR) which are comprised of three regions U3, R 
and U5. These three regions are essential for reverse transcription and provirus integration. 
Retroviruses can be classified into seven different groups based on nucleotide sequence 
homology (Brenner and Malech 2003). The first retroviral vectors developed were gamma-
retroviruses derived from the Moloney murine leukaemia virus and until recently retroviral 
vectors were the most common vectors used for gene therapy clinical trials. This is mainly 
due to their ability to stably integrate their DNA into the host cell genome. This allows 
prolonged expression of the gene. Retroviruses are generally used as replication deficient 
vectors, with deletion of gag, pol and env, allowing the insertion of transgenes of up to 
approximately 7.5 kb. In order to generate the retrovirus particles a packaging cell line 
providing the essential gag, pol and env proteins would be used. More recently lentivirus 
vectors have become increasingly common because of their ability to infect both dividing and 
non-dividing cells. Recent focus has concentrated on the human immunodeficiency virus type 
1 (HIV-1).  
 
1.2.1.1.2 Herpes Simplex Virus 
Herpes Simplex Viruses (HSV) are linear double stranded virus with a large genome of about 
150 kb, they are able to carry up to 20 kb of additional DNA and have many dispensable 
genes. Most vectors originate from Herpes Simplex Viruses 1 (HSV-1) which has a genome 
of 152 kb (Krisky et al. 1998).  HSV-1 infection can be either latent or lytic. The ability of 
HSV-1 to establish lifelong latent infection in neurones, in which the viral genome forms a 
stable episome showing no evidence of damage to the host cell, makes these vectors ideal for 
some gene therapy systems (Efstathiou and Minson 1995 and Krisky et al. 1998).  
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Following HSV-1 expression more than 80 viral genes are expressed in a well ordered 
cascade. High titres of these viruses can be easily generated and both dividing and non-
dividing cells can be infected.  
 
1.2.1.1.3 Adeno-Associated Virus 
Adeno-Associated viruses (AAV) are single stranded icosahedral non-enveloped DNA viruses 
which belong to the parvovirus family. AAVs are among the smallest known viruses with a 
genome of 4.7 kb. Five serotypes have been identified the most extensively studied being 
AAV-2 which has identical inverted repeats (ITRs) at each end. AAV-2 particles contain two 
open reading frames rep and cap which code for regulatory elements and structural proteins 
respectively (Goncalves 2005). Adenovirus-Associated viruses require a helper virus in order 
to replicate, these helper viruses tend to be adenoviruses however vaccinia, herpes simplex 
and human papilloma viruses have also been known to complement. AAV viruses are able to 
infect both dividing and non-dividing cells and tissue (Tal 2000 and Li et al. 2005). These 
viruses have emerged as potential vectors for gene therapy as they are apparently non-
pathogenic in the absence of helper virus, with no immune response against host infected cells 
(Tal 2000). A broad range of tissues such as brain, liver, muscle, lung, retina and cardiac 
muscle can gain long term expression. They are able to give prolonged transgene expression 
via episomal concatamer formation (Li et al. 2005). One of the biggest downsides to AAV 
vectors is their inability to carry large genes. Genes of up to 4.5 kb can be inserted which is 
too small for many gene therapy applications. Also the production of AAV vectors is difficult, 
due to a requirement for helper virus which must subsequently be removed.  
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Nevertheless AAV vectors have been tested for several diseases, with the first clinical trial for 
the treatment of cystic fibrosis (Flotte et al. 1996). Most success using AAV as a vector was 
seen for the transfer of RPE65 gene to the eye of patients with Leber‟s congenital amaurosis, 
giving improvement in vision (Bainbridge et al. 2008). 
 
1.2.1.1.4 Vaccinia Virus 
Vaccinia virus (VV) is a large complex enveloped virus which belongs to the pox virus 
family. This virus is a linear double stranded DNA virus of 200 kb.  VV was the first virus 
used as a vaccine which resulted in the eradication of smallpox (Mastrangelo et al. 2000). 
This virus is capable of infecting a wide range of cell types and remains in the cytoplasm 
having little or no effect on the host genome. Until recently vaccinia virus was dismissed as a 
potential vector due to lack of immune control in immuno compromised patients 
(Mastrangelo et al. 2000). VV may be ideal for immunotherapy applications against solid 
tumours. Genetically modified vaccinia vectors have been generated with few side effects 
(Moroziewicz and Kaufman 2005). Modified Vaccinia Ankara (MVA) is less virulent 
allowing infection but not replication in human cells (Sutter and Moss 1992 and Paoletti 
1996). A recombinant vaccinia vector expressing GM-CSF has been used for a melanoma 
cancer trial. Seven patients were treated, two showing no response, four with a partial 
response and one, complete remission. The only side effect seen rarely was mild flu-like 
symptoms, showing safe use of vaccinia vector (Mastrangelo et al. 1998). 
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1.2.1.1.5 Adenovirus 
Adenovirus is a non-enveloped icosahedral virus with a linear double stranded DNA genome 
(Shenk 1996). The capsid comprises 252 capsomeres of which 240 are hexavalent and the 
remaining 12 are situated at the apices and are pentavalent (Ginsberg et al. 1966). In 1953 
adenoviruses were first isolated from human adenoid and tonsil tissue (Rowe et al. 1953). 
These viruses are linked to several human diseases including respiratory tract infections, 
gastroenteritis and conjunctivitis. These infections are generally transient and therefore self-
limiting. There are over 50 different human adenoviral serotypes. One of the main advantages 
of using adenovirus as a vector is that viral infection doesn‟t require the host cell to be 
dividing (Horwitz 1996). Very rarely adenoviral infections lead to mortality in healthy 
individuals. However there is a significant risk in immuno-compromised patients. The vast 
majority of vectors are based on species C serotypes 2 and 5 (Horwitz 1996).  
 
Wild-type adenovirus types 4 and 7 were successfully used as oral vaccines to provide 
protection from acute respiratory disease in US military recruits (Grabenstein et al. 2006). 
Very few side effects have been seen. This has suggested that adenovirus could be a safe 
vector for gene therapy. Since then adenoviruses have been successfully used as vectors for 
many clinical trials and in recent years adenoviruses have increasingly become the vector of 
choice due to high transgene transfer efficiency and the ability to infect a large range of 
dividing and non-dividing cell types (Hardy et al. 1997). WT adenoviruses can only hold an 
additional 2 kb of genetic material without affecting the virus infectivity and stability. 
Therefore much work has been undertaken on replication defective adenoviruses.  
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The vast majority of replication defective adenoviruses are E1 deleted preventing replication. 
Further deletion of E3 has made it possible to incorporate genes of up to 7.5 kb in size. This 
allows the packaging of approximately 105 percent of the normal adenovirus genome 
(Horwitz 1996).  
 
Replication after the removal of the E1 region (E1A and E1B genes) requires the use of helper 
cells for virus propagation eg: HEK 293 or 911 cells. Both of these cell lines contain 
adenovirus type 5 E1A and E1B functions (Graham et al. 1997 and Fallaux et al. 1998). More 
recently, „gutless‟ replication defective adenoviral vectors have been generated with all viral 
genes removed. Only the viral inverted repeats and packaging signals remain. This allows the 
insertion of up to 35 kb (Hardy et al. 1997). Helper virus is also required for these viruses to 
replicate (Parks et al. 1996). The main advantages of „gutless‟ vectors are the large capacity 
they can hold.  
 
Recent development of conditionally replicating adenoviral vectors allows a combination of 
inserting a therapeutic gene while still allowing cytolytic effects due to adenovirus replicating. 
Several approaches have been designed for tumour specific replication by controlling early 
adenovirus genes using tumour specific promoters. Examples are the use of prostate specific 
antigen promoter to control replication for the treatment of prostate cancer (Rodriguez et al. 
1997) and exploiting tumour specific defects such as the loss of functional p53 proteins, 
originally proposed to provide tumour selectivity to the E1B 55K-deleted adenovirus mutant 
dl1520 (ONYX 015) (Barker and Berk 1987, Heise et al. 1997 and Freytag et al. 1998).  
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During normal adenovirus infections, E1B 55K protein sequesters p53, thereby preventing 
apoptosis and allowing viral replication. However when E1B 55K is absent, viral replication 
could only take place in cells which have non-functional p53; this is often the case with 
tumours (Heise et al. 1999 and Vollmer et al. 1999). However, the tumour suppressor 
selectivity of ONXY 015 has subsequently been shown to be more complex, being attributed 
to late viral RNA export functions (O‟Shea et al. 2004). 
 
E1 promoters have also been replaced with the human telomerase reverse transcriptase 
(hTERT) promoter which restricts viral replication to cells that express telomerase. This 
enzyme is often highly expressed in cancer cells allowing the replacement of chromosomes 
ends that are normally lost after several cycles of cell division. It is usually this replacement 
that allows cancer cells to divide indefinitely (Lanson et al. 2003, Bilsland et al. 2003 and 
Irving et al. 2004). 
 
1.2.1.2 Non-viral Vectors 
In some clinical trials non-viral vectors have been used for the delivery of therapeutic DNA. 
The main advantage of non-viral vectors is the absence of an immune response allowing 
repeat treatment. However this form of vector usually express at lower levels when compared 
with viral vectors and are often less efficiently delivered.   
 
1.2.1.2.1 Cationic Liposomes and lipids 
Cationic liposomes are a mixture of plasmid DNA with lipid which leads to the formation of 
large DNA-reagent aggregates that have positively charged side chains which are used for 
gene transfer.  
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Colloidal stability of lipid/DNA aggregation is a major requirement for lipid mediated 
transfection, particularly at high concentration which is needed for gene delivery (Pitard et al. 
2001). Cationic lipid DNA complexes also known as „lipoplexes‟ have been used for many 
clinical trials and are currently the most promising non-viral vectors, however only low levels 
of gene transfer have been achieved. Several immunotherapy trials have been performed using 
lipid/DNA complexes (Roth and Cristiano 1997). 
 
1.2.1.2.2 DNA polymer conjugates 
In 1987 DNA polymer complexes were first used for gene therapy using poly-L-lysine to 
make the first conjugate (Wu and Wu 1987). Current DNA polymer complex delivery 
systems use cationic polymers polylysine, polyethylenimine and polyamidoamine. These 
confer resistance to nuclease enzymes and large size genes can be incorporated.  
 
Polylysine has been used for the majority of cationic polymer vectors. In some cases ligands 
or antibodies have been incorporated allowing targeting to specific receptors. 
Polyethylenimine has endosomolytic properties which may enhance transfection efficiency.  
 
Polyethylenimine complexes attach to the cell surface and migrate into clumps that can enter 
the cell by endocytosis. They become deaggregated within lysosomes and are then free to 
enter the nucleus (Merlin et al. 2002). A relatively successful gene therapy trial used a 
polyethylenimine vector for aerosol inhalation. The treatment was non-invasive and 
effectively transferred the gene to the respiratory tract. Permanent gene transfer was observed 
without expression in other tissues (Ferrari et al. 1999). Polyamidoamine (PAMAM) 
dendrimer has been used as a vector to target the brain (Liu et al. 2009). 
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One main constraint is that the DNA must be condensed; currently up to 45 kb of DNA has 
been successfully condensed without damage. One of the biggest problems with polymer 
complexes is that polycation can lead to cytotoxicity. A balance between polymer cationic 
density and endosomal escape resulted in less cytotoxic vectors by using two side chains, one 
being polylysine, which makes the vector cationic and the second contained an imidazole 
group allowing endosomal escape of the vector (Putnam et al 2001). 
 
1.2.1.2.3 Naked DNA 
Gene transfer of naked DNA was first demonstrated in 1990 when RNA and DNA expression 
vectors were separately injected into mouse skeletal muscle. Protein expression was readily 
detected in all cases (Wolff et al. 1990). This method has potential safety benefits because 
most side effects are usually caused by the vector.  
 
The biggest problem with injecting naked DNA is the low efficiency of gene expression. A 
variety of tissues such as skin (Titomirov et al. 1991), liver (Suzuki et al. 1998), lung (Yang 
and Huang 1996) and muscle (Kon et al. 1999) have been investigated as target tissue. A 
variety of naked DNA delivery methods have been put forward including direct injection, 
electroporation and particle mediated transfection. 
 
For electroporation small pores are made in the cell membrane by generating short electric 
pulses. This allows entry of the DNA into the cell. Electroporation has been used to insert 
DNA in to murine spleen cells (Tupin et al. 2003). Particle mediated transfection was first 
used to transfer genetic material into plants but has since been used for mammalian cells.  
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This technique is also referred to as „gene gun‟. Gold or tungsten particles of 0.5-3 µm are 
coated in the therapeutic gene and shot into the target cells with either a helium gas pulse 
acceleration gun or high voltage electrical discharge. This method has been used to introduce 
genes for IL-12 into murine tumours (Rakhmilevich et al. 1997) and GM-CSF into a mouse 
myeloma model. These methods are considered as easy and cost efficient and controls on their 
use are less stringent than when using viruses.  
 
1.2.2 Gene Therapy for Genetic Disorders 
The identification of single genes responsible for genetic disease first showed the potential for 
gene therapy. Following the development of gene delivery vectors many gene therapy trials 
for genetic disorders have been undertaken. Below are two examples of genetic disease which 
have been treated by gene therapy. 
 
1.2.2.1 Human Severe Combined Immunodeficiency (SCID)-X1 Disease 
Severe combined immunodeficiency (SCID-X1) is an X-linked inherited disease which is 
caused by a range of mutations within a 4.2 kb gene IL2RG (Noguchi et al. 1993 and Puck et 
al. 1993). This gene encodes the common gamma chain, a subunit of several cytokine growth 
factor receptors.  
 
SCID-X1 patients lack T and Natural killer cells, but tend to have normal B cells that are 
unable to perform immunoglobin class-switching and are unable to produce antibodies 
(Buckley et al. 1997 and Cooper et al. 2003). The failure to produce T and NK cells is 
thought to result from loss of signalling through the γc receptors for interleukin 7 and 15 
(Cavazzana-Calvo et al. 1996).  
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This condition only affects boys leading to severe immune compromise which results in 
bacterial, viral and fungal pathogenic infections. SCID-X1 is usually fatal, if left untreated; 
most patients die within the first few years of life (Cooper et al. 2003). The current treatment 
for SCID-X1 is immune reconstitution by bone marrow transplantation of haematopoietic 
stem cells from a HLA matched relative. Not all patients have a relative with perfect matching 
HLA, which initially led to the use of patient isolation in a germ free gnotobiotic 
environment. Transplantation from a mismatched haploidentical HLA donor has since been 
used with varying success. Mismatched donors are known to result in increased mortality and 
complication rate partly due to graft versus host disease and the requirement of chemotherapy 
to prevent rejection (Buckley et al. 1999 and Gaspar et al. 2004). SCID-X1 was considered an 
ideal disease for gene therapy. In the first clinical trial for this disease ex vivo transduction of 
CD34
+
 haematopoietic stem cells with a retroviral vector expressing the cytokine growth 
factor receptor γc was used. During a 10 month follow up T cell immunity was seen at three 
months. Evidence was seen of recovery of both B and Natural killer cells (Cavazzana-Calvo 
et al. 2000). 
 
Further clinical trials have since been performed. In one clinical trial four out of five treated 
patients showed generation of T-cells within 6-12 weeks of treatment. At three year follow up 
correction of the deficiency was maintained (Fischer et al. 2002 and Hacein-Bey-Abina et al. 
2002). In another trial at another centre, four children were treated with a similar 
gammaretroviral vector encoding the cloned human γc region; all the children showed clinical 
and immunological improvement. Two of the children no longer required antibiotic 
medication and lived normal lives (Gaspar et al. 2004). 
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However two adverse events have been seen relating to SCID trials. Three years after 
treatment two patients showed uncontrolled exponential clonal proliferation of mature T cells 
(Hacein-Bey-Abina et al. 2003a and Hacein-Bey-Abina et al. 2003b). Both patients showed 
retroviral vector integration on the short arm of chromosome 11 within the LMO2 proto-
oncogene promoter, which lead to over expression of LMO2 resulting in childhood acute 
lymphoblastic leukaemia. A third patient has since developed the condition. One of the three 
children died from the resulting leukaemia.  
 
1.2.2.2 Cystic Fibrosis 
The most common genetic disease in the Caucasian population is cystic fibrosis (CF). This 
disease effects 1 in 2500 live births in the UK (Johnson 1995 and Wilson et al. 1994). Cystic 
fibrosis results from a single gene defect which is recessive in nature, therefore two defective 
genes must be inherited to have the condition. Mutations in the CFTR gene are responsible for 
this condition. Multiple mutations in the gene have been detected which lead to a CFTR 
protein that is abnormally metabolised, dysfunctional or sometime both (Boucher et al. 1994). 
This makes this disease an ideal target for gene therapy treatment. The disease usually 
manifests in early childhood leading to progressive loss of lung function, eventually leading 
to an early death. More than 95 percent of CF patients die from lung disease (Boucher et al. 
1994). Other organ systems can also be involved eg: the pancreas. Treatment involves 
physiotherapy, antibiotics and steroid treatment. This has improved the life expectancy for CF 
sufferers; however mean survival is still only 30 years in developed countries with good 
health care. The disease manifests because of decreased chloride ion conductance across 
epithelial cells leading to thick mucus, chronic airway infections and inflammation. 
Staphylococcus aureus and Pseudomonas aeruginosa infections are common for CF sufferers. 
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Attempts to restore the CFTR function were first attempted in the early 1990‟s. In the first 
trial an E1 deficient adenovirus encoding CFTR was administered to the nasal airway 
epithelia of three CF sufferers. Chloride ion transport was corrected allowing normal 
responses. There was no evidence of viral replication (Zabner et al. 1993) however 
inflammation was seen. Further trials have been performed (Boucher et al. 1994, Wilson et al. 
1994 and Crystal et al. 1995). It has been found that as few as 6-10 percent corrected cells 
within an epithelial sheet are able to generate chloride transport similar to 100 percent 
corrected cells (Johnson et al. 1992). In some trials inflammatory responses were seen most 
probably from the adenoviral vector used. Due to concerns over the inflammation potential of 
viral vectors, most attention has turned to non-viral approaches, although adeno-associated 
viral vectors are also of interest. A phase I study for CF patients with mild lung disease was 
performed with an adeno-associated vector (Flotte et al. 1996). A DNA/liposome vector was 
tested on ten CF patients. Modest gene expression was observed, however repeat 
administration was required for long-term expression. There was no evidence of inflammation 
and toxicity. Six of the ten patients showed some CFTR gene correction in nasal cells (Hyde 
et al. 2000). 
 
1.3 CANCER GENE THERAPY 
In order for gene therapy to be effective for cancer treatment it is essential for 100 percent of 
cancer cells to be killed requiring either highly efficient gene delivery or additional 
mechanisms to kill non-transduced cancer cells. Over the last 10 years research and clinical 
trials developing gene therapy as a form of cancer treatment have increased greatly with more 
than 50 percent of all gene therapy trials being for cancer. Four main different strategies for 
cancer gene therapy treatment have been developed and each will be discussed below. 
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1.3.1 Immunotherapy 
Immunotherapy as a cancer treatment utilises the ability of the immune system to recognise 
and kill cancer cells. Cytokines control and regulate many aspects of the immune response. 
The cytokine interleukin-2 (IL-2) is an important stimulator of T cell proliferation and has 
been used for several clinical trials for the treatment of metastatic melanoma. In one study 
forty-seven patients were treated with recombinant IL-2. Responses were seen in ten patients, 
two had complete responses and eight partial responses (Parkinson et al. 1990). In another 
study patients were divided into four groups IL-2 alone, IL-2 with chemotherapy, IL-2 with 
IFNα and IL-2, chemotherapy and IFNα. The addition of IFNα to IL-2 was associated with 
prolonged survival but the effect of chemotherapy was less obvious (Keilholz et al. 1998). 
Tumour necrosis factor (TNF-α) has also been tested in clinical trials and has been found to 
have cytolytic activity against tumour cells (Meany et al. 2008).  
 
However there have been some side-effects from cytokine treatment with flu like symptoms 
seen following systemic administration. Gene therapy has the potential to overcome dose 
limiting toxicity by producing the cytokine only within the target cells. Adenovirus and 
modified vaccinia Ankara vectors have been used to express IL-2 and IFN-γ. In each case the 
virus was directly injected intratumorally. Higher cytokine levels were achieved in the tumour 
than was possible by systemic administration and stabilisation of melanoma was seen in 
several patients treated. Research is now working towards using virally administered IL-2 in 
combination with chemotherapy (Liu et al. 2004). 
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1.3.2 Tumour Suppressor Genes 
Studies have shown that restoring p53 function in tumours could lead to controlled cell death 
and prevention of tumour growth. A clinical trial using a retroviral vector encoding wild-type 
p53 has been undertaken. The virus was delivered by direct intratumoral injection into human 
non small cell lung carcinoma (NSCLC). In total of nine male patients were treated, with 
tumour regression seen in three patients and stabilisation of the tumour observed in another 
three patients (Roth et al. 1996).  
 
A phase I clinical study has used an adenoviral vector encoding wild-type p53. In this case 
twenty eight NSCLC patients were treated. These were patients where other treatments had 
failed to stop progression of the cancer. Again direct intratumoral injection was used as the 
method for introducing the virus. Therapeutic activity was observed in twenty five patients 
with a partial response in two and disease stabilisation in a further sixteen patients. The 
remaining seven patients showed disease progression (Swisher et al. 1999).  
 
A further clinical study assessed the effect of recombinant adenovirus-p53 combined with 
radiotherapy for the treatment of nasopharyngeal carcinoma. Patients were divided into two 
groups; 42 patients received rAd-p53 with radiotherapy and a further 40 patients radiotherapy 
alone. Postinjection tumour biopsy showed downregulation of vascular endothelial growth 
factor. An 11.7 percent increase in 5 year disease free survival rate was seen when rAd-p53 
and radiotherapy were used in combination (Pan et al. 2009). rAs-p53 is commercially 
licensed in china under the name Gendicine and is used for a large range of cancers (Guo and 
Xin 2006). 
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1.3.3 Oncogenes 
Studies have shown that direct alteration of oncogene expression in human cancer cells can 
decrease cell proliferation and tumorigenicity. A retroviral vector system has been developed 
for the transduction of a fragment of antisense K-ras into human cancer cells. The vector was 
allowed to infect a lung carcinoma cell line with defective K-ras. Transcription of the 
defective K-ras RNA was specifically inhibited. The proliferation of the cancer cell line was 
inhibited 10-fold (Zhang et al. 1993). 
 
An alternative approach involves the use of either small interfering RNAs (SiRNA) or small 
hairpin RNAs (ShRNA). SiRNA is a class of double stranded RNA molecules of 
approximately 20-25 nucleotides in length. SiRNA has potential for human therapy, without 
producing an interferon response. SiRNA has been used to overcome drug resistance in 
cancer with tamoxifen (Iorns et al. 2009) and doxorubicin (Chen et al. 2010). A phase I 
human clinical trial involving the systemic administration of SiRNA to patients with solid 
cancers using a targeted, nanoparticle delivery system has been undertaken. Results showed 
that SiRNA administered systemically to a human can produce specific gene inhibition 
(reduction in messenger RNA and protein) by an RNAi mechanism of action (Davis et al. 
2010). ShRNA are sequences of RNA that make tight hairpin turns, and use RNA interference 
to silence gene expression (Bernards et al. 2006). Stable transfection of heparanase-specfic 
shRNA has been used to knockdown herparanase, leading to a decrease in invasiveness and 
angiogenesis of human gastric cancer cells (Zheng et al. 2009).  
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1.3.4 Prodrug Activation Therapies 
Chemotherapy is currently one of the best forms of treatment for cancer. However 
chemotherapeutic agents have limited selectivity affecting all rapidly dividing cells. Therefore 
healthy tissue that rapidly divides will also be targeted. In the early 1990‟s an alternative 
approach to standard chemotherapy was put forward; antibody-directed enzyme prodrug 
therapy (ADEPT). This approach allows a prodrug-activating enzyme to be targeted to a 
tumour using a tumour specific monoclonal antibody, followed by systemic delivery of a non-
toxic prodrug. The prodrug is activated to its toxic form in the presence of the 
antibody/prodrug activating enzyme conjugate. Therefore the active drug is only activated 
within the tumour vicinity reducing systemic toxicity. Not all tumour cells are required to 
have bound the antibody/prodrug activating enzyme conjugate as the active drug can diffuse 
locally to kill other surrounding tumour cells, a phenomenon known as the „bystander effect‟. 
Essential requirements for ADEPT include the use of small high affinity monoclonal 
antibodies which are able to penetrate tumour quickly and be rapidly cleared from the rest of 
the body. The choice of enzyme used is subject to several constraints; the optimum pH should 
be close to the pH of the target tumours‟ extracellular fluid and the enzyme should be non-
immunogenic and specific (Bagshawe et al. 1994).  A clinical trial using ADEPT to target 
carcinoembryonic antigen (CEA) has been used for the treatment of colorectal, breast, 
peritoneal and oesophageal cancer.  This antigen is abundant in a variety of adenocarcinomas. 
31 patients with CEA-expressing tumours were treated. The best response seen at 6 weeks 
after treatment was a 10 percent reduction in tumour diameter in a patient that had peritoneal 
cancer. At 6 weeks 11 patients showed stable disease the rest showed disease progression 
(Mayer et al. 2006).  
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A variation on this theme is that of gene-directed enzyme prodrug therapy (GDEPT) also 
referred to as „suicide‟ gene therapy. This follows a similar principle to ADEPT except a gene 
encoding an activating enzyme is delivered to the tumour cells, which then express the 
enzyme. If a virus is used to administer the gene to the tumour cells it is also referred to as 
virus-directed enzyme prodrug therapy (VDEPT) (see Figure 1.8).  
 
                
Figure 1.8 Mechanism of Virus Directed Enzyme Prodrug Therapy  
Adapted from (McNeish et al. 1997) 
 
The most important consideration for any VDEPT strategy is the method of delivery to 
tumour cells, the choice of enzyme and prodrug combination and how to regulate the 
enzyme‟s expression. Non-toxic prodrugs which are converted intracellularly to highly 
cytotoxic metabolites that are not cell cycle-specific in their mechanism of action are ideal for 
GDEPT.  
 
The active drugs released should also be readily diffusible and exert a good bystander effect. 
Bacterial and viral enzymes tend to be ideal for VDEPT because they tend to have little or no 
endogenous effect on normal human cells (Connors 1995).  
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The enzyme should ideally consist of a single polypeptide species of reasonably low 
molecular weight and be independent of post-translational modifications. The desirable 
parameters for the enzyme-prodrug combinations are a high differential toxicity of the active 
species relative to the prodrug with a low Km and high kcat (McNeish et al. 1997). Current 
prodrug activating enzymes systems being studied for VDEPT will be discussed below. 
 
1.3.4.1 Herpes simplex virus thymidine kinase with ganciclovir  
The most widely studied and used gene directed enzyme prodrug therapy system is herpes 
simplex virus thymidine kinase (HSV-TK) enzyme with the prodrug ganciclovir. This system 
was first described in 1986. Murine cell lines bearing HSV-TK gene were exposed to 9-{[2-
hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine (HHEMG) or ganciclovir drug leading to 
the loss of the cells‟ clonogenic potential. Mouse studies also showed complete regression of 
tumours (Moolten 1986).  
 
Ganciclovir is most toxic to cells in the triphosphate state as it competes with deoxyguanosine 
triphosphate for incorporation into DNA during S phase of the cell cycle. HSV-TK can 
phosphorylate ganciclovir to ganciclovir monophosphate. Then cellular enzymes can 
phosphorylate ganciclovir monophosphate to ganciclovir diphosphate and ganciclovir 
triphosphate. It should be noted that cellular enzymes are unable to convert ganciclovir to 
ganciclovir monophosphate (see Figure 1.9). 
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Figure 1.9 Activation of ganciclovir by thymidine kinase  
Adapted from (McNeish et al. 1997) 
 
 
When incorporated into DNA ganciclovir inhibits DNA polymerase leading to DNA strand 
breaks and ultimately cell cycle arrest and death by apoptosis (Mesnil and Yamasaki 2000). 
HSV-TK is also capable of phosphorylating several other drugs including acyclovir and 
bromovinyl-deoxyuridine. 
 
A good bystander effect can be seen with HSV-TK and ganciclovir; however the active drug 
requires gap junctions for cell-to-cell spread (Ishii-Morita et al. 1997, Mesnil and Yamasaki 
2000 and Wilson et al. 2004). This enzyme prodrug system is particularly good for rapidly 
dividing glioblastoma, as it only targets proliferating cells leaving the surrounding normal 
brain tissue undamaged. 
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HSV-TK in combination with ganciclovir was first approved for gene therapy trials in 1991. 
Since then many trials using this combination have been performed. In 2000 the first phase III 
clinical trial was completed for glioblastoma. The HSV-TK was delivered by a retroviral 
vector. This large scale trial treated two hundred and forty eight patients in three test groups 
treated with either surgery alone, radiotherapy alone or HSV-TK with ganciclovir in 
combination with surgery and radiotherapy. No benefit was seen relative to surgery and 
radiation. However the therapy was well tolerated and very little toxicity was seen. It was 
concluded that vector delivery was a limiting factor in this trial as very little HSV-TK gene 
was delivered to the tumour cells (Rainov 2000). In 2004 a further clinical trial for malignant 
glioma treated 17 patients with AdHSV-TK gene therapy by local injection, followed by 
intravenous ganciclovir (GCV). Median time of survival increased relative to radiotherapy 
(Immonen et al. 2004). Adenovirally delivered HSV-TK in combination with ganciclovir has 
since has been granted Orphan Drug Status under the name of Cerepro (Arktherapeutics 
website www.arktherapeutics.com/CEREPRO October 2009). 
 
1.3.4.2 Cytosine deaminase with 5-fluorocytosine  
The enzyme cytosine deaminase is found in both bacteria and fungi but absent in higher 
eukaryotes. The enzyme is able to catalyse the conversion of cytosine to uracil by the process 
of deamination. Cytosine deaminase can convert a clinically used anti-fungal agent 5-
fluorocytosine to the active drug 5-fluorouracil (see Figure 1.10). 
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Figure 1.10 Conversion of 5-fluorocytosine into 5-fluorouracil by cytosine deaminase  
Adapted from (McNeish et al. 1997) 
 
 
Recent studies have shown that the cytosine deaminase from fungi significantly increases the 
conversion of 5-fluorocytosine into 5-fluorouracil relative to bacterial cytosine deaminase 
(Kievit et al. 1999 and Kievit et al. 2000). 5-flourouracil is a widely used anticancer agent, in 
mammalian cells the 5-flourouracil is metabolised to 5-flouro-deoxyuridine-5‟-triphosphate. 
This in turn inhibits thymidylate synthase preventing DNA synthesis and ultimately leading to 
cell death. The incorporation of 5-fluorouracil metabolites into nucleic acid also has a toxic 
effect. High doses of 5-fluorouracil are required for tumour regression, leading to high 
systemic toxicity when used for chemotherapy. However using a prodrug system for efficient 
targeting of tumour cells could greatly reduce the systemic toxicity and therefore improve 
efficacy. A good bystander effect is also seen with this system; in this case the metabolite is 
able to diffuse across the cell membrane (Wilson et al. 2004). Cytosine deaminase with 5-
fluorocytosine has been used for a variety of cancers including colorectal (Huber et al. 1993 
and Kievit et al. 2000) and breast cancer (Pandha et al. 1999). 
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1.3.4.3 Combination cytosine deaminase/Herpes Simplex Virus thymidine 
kinase with 5-fluorocytosine and ganciclovir 
 
A novel system looking for synergistic cytotoxicity using double suicide gene therapy has 
been investigated over the last 7 years. A combination of cytosine deaminase and herpes 
simplex virus thymidine kinase enzymes was used with the addition of both prodrugs 5-
fluorocytosine and ganciclovir. Prostate cancer was the target of this treatment. A replication 
competent Ad5 CD/TK adenovirus delivering the two enzymes as a fusion gene was used for 
expression. Two days later 5-fluorocytosine and ganciclovir were administered for a week 
(Freytag et al. 2002a). This system was put into phase I clinical trial for prostate cancer. The 
virus was intraprostatically injected using transrectal ultrasound guidance to sixteen patients. 
Two days later patients were given 5-flourocytosine and ganciclovir for one to two weeks. 
Seven of the patients showed a 25% decrease in prostate specific antigen (PSA) and a further 
three 50% decrease. Two patients were negative for adenocarcinoma one year after treatment 
(Freytag et al. 2002b). A similar study included three-dimensional conformal radiation 
therapy (3D-CRT) has also been through phase I clinical trials. In this case fifteen patients 
were treated, and patients were given 5-fluorocytosine and valganciclovir for one to three 
weeks along with 3D-CRT. PSA levels significantly declined. The results demonstrated that 
double suicide gene therapy could be successfully combined with 3D-CRT. (Freytag et al. 
2003). In 2006 a slightly different approach was taken; prostate carcinoma cells were infected 
by adenovirus containing a CD/HSV-TK fusion gene. The cells were incubated for 24 hours 
with 5-fluorocytosine followed by 24 hours with ganciclovir. This gave greater growth 
inhibition compared with simultaneous administration of the prodrugs. It was proposed that 
CD/5-FC reduction of dTTP also results in decreased dGTP production. 
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dGTP is the endogenous competitor for ganciclovir triphosphate. Therefore more ganciclovir 
triphosphate was incorporated in the DNA allowing greater cell killing. This shows 
synergistic cytotoxicity interaction (Boucher et al. 2006).  
 
1.3.4.4 Escherichia coli purine nucleoside phosphorylase with 6-methylpurine-
2’deoxyribonucleoside 
 
Purine nucleoside phosphorylase (PNP) can catalyse the phosphorolysis of purine 
nucleosides. The human nucleoside phosphorylase is a homotrimeric enzyme which is highly 
specific for 6-oxopurine nucleosides (Agarwal et al. 1975). By contrast E. coli DeoD 
nucleoside phosphorylase is a homohexameric enzyme, which allows phosphorolysis of a 
large range of substrates including 6-oxopurines and 6-aminopurines. This allowed the 
construction of prodrugs that are not substrates for the human PNP enzyme but that can be 
phosphorolysed by the E. coli enzyme. For example the prodrug 6-methylpurine-
2‟deoxyribonucleoside is readily converted by the E. coli PNP enzyme to 6-methylpurine (see 
Figure 1.11).  
        
 
Figure 1.11 Conversion of 6-methylpurine-2’deoxyribonucleoside into 6-methylpurine by 
Escherichia coli purine nucleoside phosphorylase 
Adapted from (Hughes et al. 1995) 
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The resulting cytotoxic purine bases inhibit protein, RNA and DNA synthesis and are 
membrane permeable allowing effective killing of neighbouring cells (Hughes et al. 1995).  
Research has shown that expression of E. coli PNP in less than 1% of human colon carcinoma 
cells leads to the death of virtually all bystander cells following treatment with 6-
methylpurine-2‟deoxyribonucleoside (Sorscher et al. 1994).  
 
1.3.4.5 Cytochrome P450 with cyclophosphamide 
Cyclophosphamide is a commonly used chemotherapy agent which becomes bioactivated in 
the liver by cytochrome P450 enzymes. The active metabolite 4-hydroxy-cyclophosphamide 
is then transported round the body via the bloodstream. Further metabolism results in 
phosphoramide mustard and acrolein which alkylate DNA and protein respectively (see 
Figure 1.12).  
               
Figure 1.12 Conversion of cyclophosphamide into phosphoramide mustard and acrolein by 
cytochrome P450 
Adapted from (Chen and Waxman 1995) 
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As a GDEPT approach cytochrome P450 enzyme is delivered directly to the tumour for 
localised prodrug activation.  A strong bystander effect is seen for phosphoramide metabolites 
which are stable and diffuse easily between cells. A phase I clinical trial for breast cancer 
used recombinant retroviral vector encoding human cytochrome P450 enzyme. The vector 
was intratumorally injected followed by oral administration of cyclophosphamide. Twelve 
patients were treated, one patient showed a partial response, four showed stable disease for 
more than three months and the remaining four patients showed progressive disease 
(Braybrooke et al. 2005).  
 
1.3.4.6 Carboxypeptidase G2 with aromatic mustard compounds 
Carboxypeptidase enzymes hydrolyse peptides, resulting in the formation of shorter peptides 
and amino acids. Several prodrugs have been designed using aromatic mustard compounds 
which are stabilised by a glutamic acid residue. The active mustard compound is then released 
by the cleavage of the glutamic acid by the bacterial enzyme carboxypeptidase G2 (CPG2). 
The active mustards behave as alkylating agents and are therefore able to kill both dividing 
and non-dividing cells. They are also relatively lipophilic and can therefore pass directly 
through cell membranes (Hedley et al. 2007). The first report of CPG2 based GDEPT was in 
1996. The system was tested using a range of different human cancer cell types that had been 
transduced with CPG2. The cells were found have greater sensitivity to the nitrogen mustard 
prodrug 4-[(2-chloroethyl)(2-mesoyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA) 
relative to control cells which expressed bacterial β-galactosidase (Marais et al. 1996). A 
substantial bystander effect was seen for many of the cell lines with between 5-12% of cells 
needed to express CPG2 for total cell killing to be observed (Marais et al. 1996). 
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In 2002 three alternative prodrugs have been designed for use with mutant CPG2. These new 
drugs can be readily converted and give greater cell killing than CMDA (Friedlos et al. 2002). 
An adenoviral vector has been used for the expression of glycosylphosphatidylinositol (GPI) 
anchored CPG2. Greater than 50% cell killing was observed in all the cell lines tested 
following exposure to the prodrug [4-[bis(2-iodethyl)-amino]phenyl oxy carbonyl]-L-
glutamic acid. A phase I clinical trial has been conducted using the prodrug CMDA and 
CPG2 enzyme. The prodrug was well tolerated and in some of the patients an anti-tumour 
response was observed (Cowen et al. 2002). 
 
In 2008 an attenuated Salmonella typhimurium bacterium vector was used to target the 
delivery of CPG2 delivery to tumours. CPG2 was expressed within the bacterial periplasm. 
Prodrugs were activated inducing cytotoxicity in human tumour cells but not in the bacteria. 
After systemic administration to tumour bearing mice the bacteria multiplied preferentially in 
the tumour. The bacteria alone reduced tumour growth and addition of the prodrug further 
significantly reduced the tumour (Friedlos et al. 2008). 
 
1.3.4.7 Escherichia coli NfsB Nitroreductase with CB1954 
The prodrug 5-(aziridin-1-yl)-2, 4 dinitrobenzamide (CB1954) can be converted to cytotoxic 
2- and 4-hydroxlamine derivatives by E. coli NfsB Nitroreductase. The 4-hydroxlamine 
derivative can then subsequently react with cellular thioesters to produce a potent cytotoxic 
difunctional alkylating agent that is capable of introducing interstrand crosslinking into 
cellular DNA (see Figure 1.13) (Knox et al. 1988a). 
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Figure 1.13 Products of CB1954 nitroreduction 
Two equimolar products the cytotoxic 4-hydroxylamine derivative and the relatively non-toxic 2-
hydroxylamine are yielded.  
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Initial investigations for the potential of E. coli NfsB nitroreductase (NTR) with CB1954 as a 
VDEPT system used a recombinant retrovirus for the delivery of the NfsB NTR gene.  Upon 
systemic administration of CB1954, NTR encoding cells were killed (Bridgewater et al. 
1995). A significant bystander effect was also observed in a mixing experiment. Similar 
killing potential has been seen in human melanoma, ovarian carcinoma and mesothelial cells 
using a retrovirally delivered NfsB NTR gene (McNeish et al. 1998). More recent 
investigations using replication-defective adenoviral vectors have been used to express NfsB 
NTR in a large range of tumour cell types (Weedon et al. 2000).  
 
Both CB1954 and E. coli enzyme NfsB NTR will be discussed in detail as this system forms 
the basis for this thesis.  
 
1.4 NITROREDUCTASE FOR PRODRUG ACTIVATION 
Nitroreductases form a family of flavoenzymes which are defined by their dependence on a 
flavin cofactor for catalysis. Nitroreductases catalyse the reduction of a broad range of 
quinone and nitroaromatic compounds to either quinone or hydroxylamine derivatives. These 
enzymes use either NADH or NADPH as an electron donor (Anlezark et al. 1992). A wide 
range of nitroreductases have been identified in prokaryotic organisms including Escherichia 
coli, Enterobacter cloacae (Bryant et al. 1991a and Bryant et al. 1991b), Salmonella 
typhimurium (Watanabe et al. 1990 and Watanabe et al. 1998) and Helicobacter pylori (Jenks 
and Edwards 2002). 
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The role of nitroreductase is not fully known. It has been proposed that NTR plays a role in 
the metabolism of xenobiotics (Lovering et al. 2001). The theory behind this is 
nitroreductases are able to metabolise a large range of antibiotics and foreign compounds 
preventing toxicity to the bacteria.  
 
1.4.1 Discovery of the flavoenzyme nitroreductase 
In the late 1940‟s it was first noted by Smith and Worrel that E. coli are capable of reducing 
the nitro group from the antibiotic chloramphenicol. By the mid 1950‟s it was confirmed that 
an NADH specific flavoenzyme was present that could reduce nitroaromatic compounds 
including the antibiotics nitrofurazone and nitrofurantoin (Saz and Slie 1954). Further 
analysis later showed the presence of two types of E. coli nitroreductases (Asnis 1957). These 
were later termed as type I nitroreductase and type II nitroreductase (McCalla et al. 1970).  
 
1.4.1.1 Type I Nitroreductases 
Type I NTR‟s are insensitive to oxygen (can perform the reaction in the presence and absence 
of oxygen) using NADH or NADPH as electron donor (Asnis 1957 and McCalla et al. 1970). 
Type I NTR catalyses redox reactions where pairs of electrons are transferred. E. coli has 
three type I NTR‟s which will be discussed below.  
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1.4.1.1.1 Escherichia coli NfsA Nitroreductase  
The first type I NTR is known as the major E. coli oxygen-insensitive nitroreductase encoded 
by the NfsA gene. The NfsA enzyme is a physiological homodimer with each subunit having a 
flavin mononucleotide (FMN) cofactor. The subunit mass of NfsA is 26.8 kDa. This enzyme 
has a marked preference for NADPH as electron donor (Bryant et al. 1981, Zenno et al.1996a 
and Vass et al. 2009). 
 
1.4.1.1.2 Escherichia coli NfsB Nitroreductase  
The second type I NTR is known as the minor E. coli oxygen-insensitive nitroreductase 
encoded by the NfsB gene. The NfsB enzyme is a physiological homodimer with each subunit 
having a FMN cofactor. The subunit mass of NfsB is 23.9 kDa. This enzyme can use either 
NADPH or NADH as electron donor with similar efficiency (Bryant et al. 1981 and Michael 
et al.1994). 
 
1.4.1.1.3 Escherichia coli NfsC Nitroreductase  
The third type I E. coli oxygen-insensitive nitroreductase is encoded by the NfsC gene. NfsC 
enzyme can use either NADPH or NADH as electron donor. Very little else is known about 
this enzyme (Bryant et al. 1981). 
 
1.4.1.2 Type II Nitroreductases 
In contrast type II NTR is sensitive to oxygen using NADH as an electron donor. Type II 
NTR‟s use two single-electron transfer reactions to reduce their substrates allowing the 
formation of superoxide radicals. Two type II NTR have been identified these are termed IIa 
and IIb. Very little research has been undertaken on these enzymes (McCalla et al. 1975). 
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Type I NTR NfsB enzyme was used for this study therefore all information following this 
point will concern NfsB nitroreductase unless otherwise stated. 
 
1.4.2 CB1954 
5-(aziridin-1-yl)-2, 4 dinitrobenzamide (CB1954) was originally identified from a series of N-
substituted ethylamine derivatives synthesised in the early 1950‟s. The first indication of its 
potential as an anti-cancer agent came when it was seen that the compound was able to inhibit 
tumour growth of the Walker 256 rat carcinoma cell lines. The therapeutic potential of 
CB1954 was greater than many clinical agents available at that time such as 
cyclophosphamide and cisplatin. However CB1954 was later found to be ineffective in many 
animal and human tumours (Cobb et al. 1969). It was proposed that toxicity stemmed from 
activation of the drug by an enzyme that was present in the Walker cells. DT-diaphorase 
enzyme was purified from Walker rat cells and found to reduce CB1954 when in the presence 
of NADH/NADPH. The reduction of CB1954 by DT-diaphorase resulted in a 4-
hydroxylamine derivative that reacted with cellular thioesters to form a highly cytotoxic agent 
(Knox et al. 1988b).  
 
Hopes of using CB1954 for the treatment of human tumours was halted when it was 
discovered the human form of the enzyme was unable to reduce CB1954. However in 1992 it 
was found that E. coli NfsB nitroreductase can reduce CB1954 and has much better kinetic 
parameters compared to both the rat and human enzymes (Anlezark et al.1992). See Table 1.4 
for kinetics parameters for rat and human NQO1 and E. coli NfsB NTR.  
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Table 1.4 CB1954 Kinetic parameters for rat and human NQO1 and E. coli NfsB NTR  
(Anlezark et al. 1992 and Knox et al. 1992) 
 
A more recent kinetic study here in Birmingham has shown that NfsB NTR global kinetics for 
both kcat and Km for CB1954 are approximately twenty-fold higher than previously estimated, 
however the measured specificity constant, kcat/Km remains the same (Jarrom et al. 2009). 
 
 
Table 1.5 CB1954 and NADH kinetic parameters for E. coli NfsB NTR  
(Jarrom et al. 2009) 
 
 
1.4.3 Catalytic Mechanism 
NTR catalyses the reduction of quinone and nitroaromatic compounds using NADH and 
NADPH, via a ping pong bi-bi mechanism. The „bi-bi‟ indicates a two substrate, two product 
reaction, while the „ping pong‟ indicates the order in which the substrates are bound and the 
products released. A single substrate is bound to the active site at any one time being released 
as product before the second substrate is bound. 
 
 
 
 
Enzyme Km CB1954  
(µM) 
kcat  
(s
-1
) 
kcat/Km CB1954  
(µM
-1
 s
-1
) 
Rat NQO1 826 0.0683 0.00008 
Human NQO1 1403 0.0107 0.000008 
NfsB NTR 862 6 0.007 
Enzyme kcat  
 (s
-1
) 
Km CB1954  
(µM) 
kcat/Km  
(µM
-1
 s
-1
) 
Km NADH  
(µM) 
kcat/Km 
 (µM
-1
 s
-1
) 
NfsB NTR 140 ± 32 17200 ± 4800 0.007 ± 0.0006 40 ± 12 3.46 ± 0.6 
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In the case of NTR the first step („ping‟) involves a reaction between oxidised NTR and 
NADH or NADPH, resulting in two electron reduction of the FMN cofactor. Reduced NTR 
and NAD/NADP
+
 products are released. The second step („pong‟) involves a reaction 
between the reduced NTR and the second substrate eg: quinone or nitroaromatic compound. 
The quinone or nitroaromatic compound undergoes a two or four electron reduction 
respectively, which returns the NTR enzyme to its oxidised form. See Figure 1.14 for a 
schematic of the ping pong mechanism of NTR. 
 
It was originally proposed that NTR followed a ping pong mechanism in 1992 after initial 
kinetic analysis (Anlezark et al. 1992). Further evidence was provided after extensive kinetic 
analysis and inhibition studies were performed, these showed that the kcat/Km of the first 
substrate was independent of the second substrate (Zenno et al. 1996b).  
 
Crystallographic study of NTR has also shown that the active site is too small to 
accommodate both NADH/NADPH and its substrate at the same time, providing clear 
evidence that a ping pong mechanism must be used (Parkinson et al. 2000, Lovering et al. 
2001 and Haynes et al. 2002). A reduced form of NTR has also since been crystallised 
(Johansson et al. 2003).  
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Figure 1.14 Schematic of ping pong mechanism for NTR showing flavin cofactor  
a)‟ping‟ step – electron donation by NADH/NADPH and production of the reduced FMN, b) „pong‟ step-
re-oxidation of FMN cofactor after electron donation to an oxidised substrate, c) Complete NTR ping 
pong mechanism. Adapted from (Race 2003) 
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1.4.3.1 Reduction of Quinones 
NTR can catalyse the two-electron reduction of quinone compounds eg: Menadione and 1,4-
Benzoquinone yielding quinol products (see Figure 1.15) (Anlezark et al. 1992). 
 
Figure 1.15 Quinone substrates of NTR 
a) Menadione, b) 1,4-Benzoquinone  
 
1.4.3.2 Reduction of Nitroaromatic Compounds 
NTR can catalyse the four-electron reduction of nitroaromatic compounds eg: Nitrofurazone, 
CB1954, 2-Nitrobenzamide (2-NB) and 4-Nitrobenzamide (4-NB) to their hydroxylamine 
derivatives (see Figure 1.16) (Anlezark et al. 1992).  
 
Figure 1.16 Nitroaromatic substrates of NTR 
a) Nitrofurazone (NFZ), b) CB1954, c) 2-Nitrobenzamide (2-NB), d) 4-Nitrobenzamide (4-NB) 
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The reduction of nitroaromatic compounds is believed to be performed in two sequential 
steps. The first step involves the two electron reduction of the nitro group to produce a nitroso 
intermediate followed by a second step where the two electron reduction of the nitroso 
intermediate yields the hydroxylamine product (see Figure 1.17) (Anlezark et al. 1992). 
  
                         
 
 
 
Figure 1.17 Four electron reduction of a nitro group to its hydroxylamine product 
Conversion from nitro to nitroso intermediate, then nitroso to hydroxylamine 
 
However it has also been observed that the nitroso compound can also be converted to the 
hydroxylamine product non-enzymatically by NADH/NADPH in solution (Anlezark et al. 
1992). Therefore it is possible that the second step may not always be enzyme catalysed.  
 
1.4.4 Crystallographic studies 
The determination of NfsB NTR crystal structure has provided information on its structure, 
substrate binding, conformational changes and catalytic mechanism. 
 
1.4.4.1 Structure 
The structure of NfsB NTR was first published in 2000, showing that the enzyme consists of a 
dimer of two identical monomers with each subunit having a mass of 24 kDa (Parkinson et al. 
2000). This study generated a low resolution structure by comparison with the FMN 
oxidoreductase from Vibrio fisheri (FRase I), based on its high sequence identity to NfsB 
NTR (Parkinson et al. 2000).   
      Nitro                                Nitroso                                   Hydroxylamine 
 61 
The following year a high resolution structure for NfsB NTR was published. The enzyme 
structure was determined when bound to the substrate analogue nicotinic acid. From this 
structure it was possible to determine that the enzyme has a large hydrophobic core, each 
monomer consists of a five-stranded β sheet surrounded by α helices. Two active sites lie on 
opposite sides of the molecule, in solvent-exposed clefts at the dimer interface. The FMN is in 
a butterfly conformation as seen in other flavoenzymes. The nicotinic acid stacks between the 
re face of FMN and residue Phe 124 (Lovering et al. 2001). 
 
Further reduced NfsB NTR crystal structures have since been published bound with the 
inhibitor dicoumarol and three dinitrobenzamide prodrugs (Johansson et al. 2003). In this 
study it was proposed that the prodrug binds the two active sites in different binding 
orientations allowing equal amounts of 2- and 4-hydroxylamine to be produced for CB1954. 
However our group is sceptical of these structures, and consider it likely that the crystals 
actually contain acetate (from crystallisation buffer) rather than prodrug CB1954 in the active 
site. 
 
1.4.4.2 Active Site 
The active sites of NfsB NTR are constructed from residues from both monomers and FMN 
cofactors. The FMN cofactor forms a tight non-covalent bond, and is able to form hydrogen 
bonds to one monomer and hydrophobic contacts with both monomers (Parkinson et al. 2000 
and Lovering et al. 2001). Figure 1.18 shows the crystal structure of NfsB NTR. 
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Figure 1.18 Crystal Structure of NfsB NTR 
Showing the active site with bound FMN cofactor (Lovering et al. 2001) 
 
1.4.5 Clinical Trials 
Two phase I/II clinical trials using the NTR/CB1954 system have been trialled here in 
Birmingham. These trials used a replication defective adenovirus CTL102 encoding NfsB 
NTR in conjunction with systemic prodrug CB1954, for the treatment of either resectable 
liver cancer (Palmer et al. 2004) or localised prostate cancer (Patel et al. 2009).  
 
The liver trial was the first phase I clinical trial for this system investigating feasibility, safety 
and determining levels of transgene expression. For this trial each patient with resectable 
primary or secondary liver cancer received a single dose of CTL102 delivered intratumorally 
(dose range 1 x 10
8
 – 5 x 1011 virus particles) followed by surgical resection 3-8 days later. 
The vector was tolerated well with no dose limiting toxicity and nitroreductase expression 
was measured by immunohistochemical staining (see Figure 1.19) (Palmer et al. 2004). 
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Figure 1.19 Immunohistochemical staining of tumour sections with anti-nitroreductase 
antibody 
a) 1 x 10
8
 virus particles, b) 1 x 10
9
 virus particles, c) 1 x 10
10
 virus particles, d) 1 x 10
11
 virus particles,  
e) 1 x 10
11
 virus particles f) 5 x 10
11
 virus particles x200 magnification. Nitroreductase expressing cells 
restain red (Palmer et al. 2004) 
 
 
The prostate trial was a phase I/II clinical trial. Patients underwent TRUS-guided 
intraprostatic injection of virus in escalating doses (5 x 10
10
 - 1 x 10
12
 virus particles) with 
subsequent prostatectomy (gene expression group) or intravenous CB1954 24 mg/m
2
 
(therapeutic group) 48-72 hours post injection.  Primary endpoints for this trial were safety 
and tolerability in both groups, with secondary endpoints of gene expression (gene expression 
group) and efficacy of TRUS, repeat biopsies and PSA (therapeutic group). The vector was 
well tolerated with minimal side effects. Immunohistochemical staining of resected prostate 
showed NTR staining at all dose levels (see Figure 1.20) (Patel et al. 2009).  
 64 
                  
Figure 1.20 Immunohistochemical staining of tumour sections with polyclonal sheep anti-
nitroreductase (NTR) antibody and counter stained with Mayer’s haematoxylin  
(Patel et al. 2009) 
 
 
19 patients received virus plus prodrug, minimal toxicity was observed, with preliminary 
evidence of efficacy indicated by a drop in PSA level (see Figure 1.21). 4 out of 19 showed a 
10-50 percent reduction, and 2 out of 19 showed greater than 50 percent reduction in PSA 6 
months after treatment (Patel et al. 2009). 
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Figure 1.21 PSA kinetics  
Examples of PSA kinetics in patients classified at 6 months showing a) progressive disease, b) stable 
disease, c) partial response and d) good response (Patel et al. 2009) 
 
 
1.4.6 Improving the NTR system 
As stated previously the prodrug CB1954 is not an optimum substrate for NTR. At a clinical 
achievable dose of CB1954, the peak serum concentration is 5-10 µM (Chung-Faye et al. 
2001a). However kinetic analysis has shown that the Km of NTR is approximately 100-fold 
greater than this (Anlezark et al. 1992 and Jarrom et al. 2009). Therefore the amount of 
CB1954 that can be activated is limited. Several ways for improving clinical efficacy will be 
discussed below. 
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1.4.6.1 Alternative Enzymes 
The search for enzymes able to efficiently reduce CB1954-HAs mainly focussed on 
prokaryotes. Many nitroreductases species have been studies, however only three alternative 
enzymes have showed potential relative to Escherichia coli NfsB.  
 
1.4.6.1.1 Bacillus amyloliquefaciens YwrO  
The Bacillus amyloliquefaciens YwrO nitroreductase is capable of reducing CB1954 using 
NADPH as electron donor. This NTR produces only the 4-hydroxylamine product. Kinetic 
parameters for CB1954 showed that both the kcat and Km are similar to NfsB NTR with a kcat 
618 µM and Km 8.2 µM (Anlezark et al. 2002). 
 
1.4.6.1.2 Escherichia coli YieF  
YieF a chromate reductase from Escherichia coli also shows CB1954 reducing activity. 
Mutation in the YieF enzyme for enhanced chromate reduction has also enhanced the CB1954 
reductase capacity of the enzyme with ~ 5-fold improvement in efficiency at killing HeLa 
cells than the wildtype YieF enzyme and NTR enzyme NfsA (Barak et al. 2006).   
 
1.4.6.1.3 Escherichia coli NfsA 
NfsA nitroreductase from Escherichia coli is considered as the major nitroreductase and is 
NADPH specific for electron donation (Zenno et al. 1996a). NfsA has a kcat of 20.9 µM and 
Km of 140 µM for CB1954 using NADPH as the electron donor. This gives a kcat/Km of 0.15 
µM which is ~25-fold higher than that of NfsB (Vass et al. 2009).  
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NfsA shares approximately 7 percent of its sequence with NfsB, but has similar overall folds. 
Many structural features are shared. Both enzymes are homodimers with a α/β fold and two 
active sites at the dimer interface. The biggest difference between NfsA and NfsB NTR is the 
active site. NfsA has a more open structure with a lack of residues at positions corresponding 
to NfsB Phe 123 and Phe 124 (Kobori et al. 2001). 
 
1.4.6.2 Alternative Prodrugs 
In addition to CB1954 two other classes of compounds have been used as prodrugs for NTR: 
dinitrobenzamide mustards and nitroaromatic phosphoramides. 
 
1.4.6.2.1 Dinitrobenzamide mustards 
Dinitrobenzamide mustards are analogues of CB1954, where the aziridine ring has been 
replaced by nitrogen mustard. SN23862 is the most well known dinitrobenzamide mustard, 
which was first used as a prodrug for targeting tumour hypoxia. Anlezark later used SN23862 
with NTR (Anlezark et al. 1995). Reduction of SN23862 by NTR produces only the highly 
toxic 2-hydroxylamine product and is also more lipophilic than CB1954, giving a better 
bystander effect. Kinetic parameters for SN23862 with NfsB NTR as substrate showed a Km 
of 2.5 mM and a kcat of 26.4 mM (Anlezark et al. 1995) (see Figure 1.22).  
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Figure 1.22 Nitroreduction of SN23862 Dinitrobenzamide mustard by NTR 
Production of 2-hydoxylamine  
 
1.4.6.2.2 Nitroaromatic phosphoramides 
The most well known nitroaromatic phosphoramide, cyclophosphamide has been successfully 
used as an anticancer agent for many years. Like CB1954 cyclophosphamide is toxic towards 
both dividing and non-dividing cells. Cyclophosphamide is metabolised in hepatic cells by 
cytochrome P450 enzymes, releasing acrolein and phosphoramide mustard. 
Cyclophosphamide is effective for the treatment of slow growing tumours. The by product 
acrolein however can lead to life threatening haemorrhagic cystitis.  
 
Nitroaromatic phosphoramide prodrugs have been designed to allow activation of the 
phosphoramide mustard in the tumour rather than in hepatic cells. The nitroaromatic 
phosphoramide prodrug LH7 (an acyclic 4-nitrobenzyl phosphoramide mustard) contains a 
nitro group, allowing NTR reduction to release phosphoramide mustard (see Figure 1.23). 
Kinetic analysis of LH7 shows it to be a better substrate for NTR than CB1954 with a Km of 
195 µM and kcat of 14 µM. Giving a kcat/Km 19 times better than CB1954 (Hu et al. 2003). 
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Figure 1.23 Nitroreduction of LH7 nitroaromatic phosphoramide by NTR 
Production of phosphoramide mustard 
 
1.4.7 Improving Nitroreductase Efficiency 
In view of the fairly modest improvements obtained by using alternative prodrugs, or 
alternative enzymes for activation of CB1954, a third strategy adapted by our group was to 
attempt to improve the efficiency of CB1954 activation, through molecular engineering of 
nitroreductase. Based on the crystal structure (Lovering et al. 2001), nine residues around the 
active site were identified as targets for mutagenesis (see Figure 1.24) (Grove et al. 2003).  
                                         
Figure 1.24 Crystal Structure of NfsB NTR with mutated residues highlighted 
Showing the active site with bound FMN cofactor and residues S40, T41, Y68, F70, N71, G120, F124, 
E165 and G166 (Lovering et al. 2001 and Grove et al. 2003) 
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For each targeted residue a pool of all possible codon variants was generated and cloned into 
bacteriophage lambda vector JG3J1. The resulting libraries of NTR mutants were used to 
generate E. coli bacterial lysogens and screened for increased sensitivity to CB1954 by 
plating out on agar plates containing a range of CB1954 concentrations. Mutants with 
improved NTR enzyme activity were expected to cause increased sensitivity to CB1954.  
 
50 amino acid substitutions were identified across the nine residues that gave greater 
sensitivity that wild-type NTR (see Figure 1.25). The best mutants achieved gave 2-6 fold 
improvement over WT when sensitising E. coli to CB1954 (Grove et al. 2003). Mutations at 
F124 gave the greatest increase in activity when compared to wild-type. 15 amino acid 
changes at this position gave rise to improved mutants. The F124K mutant was inserted into 
an adenovirus vector, and shown to confer ~5-fold greater sensitivity to SKOV3 ovarian 
carcinoma cells than WT NfsB NTR. 
                                     
 
Figure 1.25 CB1954 prodrug sensitivity of NTR mutants  
Comparing WT NTR with mutant NTR encoding any amino acid at S40, T41, Y68, F70, N71, G120, 
and F124 (Grove et al. 2003) 
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Following on from these improvements a second generation of NfsB NTR mutants was 
generated by combining beneficial single mutants (S40A or G, T41L, Y68G, F70A or V, 
N71S, and F124H, K, M, N, Q, S or W) giving a total of 53 double mutants. All mutants were 
again screened for increased sensitivity to CB1954. Six double mutants showed the most 
improvement: S40A F124K, S40A F124M, S40A F124N, T41L N71S, N71S F124K and 
N71S F124N.  
 
The double mutant T41L N71S gave the most improvement with an IC50 for CB1954 of 12 
µM in E. coli 12.5-fold better than WT. When tested in human carcinoma cells, an IC50 for 
CB1954 of 0.9 µM was determined giving a 14-fold reduction in IC50 relative to WT enzyme. 
These results show significant improvement over the two single mutants T41L and N71S. 
Kinetic analysis has shown that the kcat/Km for T41L N71S is 100-fold greater than the kcat/Km 
for WT (Jaberipour et al. 2010).  
 
Both Grove and Jaberipour screened clones for improved sensitivity by replica plating. This 
method is both labour intensive and laborious. However there is greater potential for further 
improvement using a direct positive selection strategy allowing the study of multiple residue 
combinations. One such strategy was designed by the Gene Therapy group here in 
Birmingham which uses bacteriophage lambda and the SOS response (Guise et al. 2007). 
Before this strategy is discussed a brief overview of bacteriophage lambda, its life cycle and 
the SOS response will be given for clarity.   
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1.4.7.1 Bacteriophage Lambda  
Bacteriophage lambda was first discovered by Ester Lederberg in 1951 as a prophage in 
Escherichia coli K12 (Court et al. 2007). Lambda has since become a model system for the 
study of molecular biology (Murray and Gann 2007). Lambda phage contains a linear double-
stranded DNA genome of 48.5 kb, a capsid and a tail (see Figure 1.26). The finished capsid is 
an icosahedron shape approximately 0.05 µ in diameter, whereas the tail is a thin flexible tube 
that ends in a small conical part and a single fibre approximately 0.15 µ long. Lambda phage 
particles consist of half protein and half double-stranded DNA (Hershey and Dove 1971 and 
Arber 1983). 
                                                                                                                             
Figure 1.26 Structure of lambda bacteriophage  
This image demonstrates the capsid, tail and fibre of the bacteriophage 
 
1.4.7.1.1 Lambda life cycle  
Bacteriophage lambda is a temperate bacteriophage, allowing reproduction and development 
in a lytic or lysogenic state (Oppenheim et al. 2005 and Court et al. 2007). Early stages of 
infection are the same whichever pathway is eventually followed.  
 
Capsid 
Tail 
Conical part 
Tail fiber 
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A phage identifies a host bacterium by binding or adsorbing to a specific structure on the 
surface of the cell. Lambda binds to an outer membrane protein called LamB via a protein that 
resides at the tip of the tail called the J protein (Arber 1983). Lambda DNA is then injected by 
the phage and taken up by the bacterium. Lambda gains entry to the cytoplasm by using an 
inner membrane protein PstM (Arber 1983). Once inside the cytoplasm the lambda DNA 
circularises via cos sites situated at each end of the DNA, to prevent degradation by 
exonucleases. 
 
The lambda genome contains six major promoters known as PL for promoter leftward, PR for 
promoter rightward, PRE promoter for repressor establishment, PRM promoter for repressor 
maintenance, PI promoter for integration and PR‟ for secondary rightward promoter. 
Transcription begins from the PL and PR promoters, transcribing and translating a series of 
genes which are known as early genes. The protein products of these genes are required for 
phage development see Figure 1.27 showing protein products produced from the PL and PR 
promoters.  
 
The decision between lysogeny and lysis depends on the relative amounts of CI and Cro and 
their promoter binding, both bind to the same promoter known as OR (Oppenheim et al. 
2005).  The OR is comprised of three parts OR1, OR2 and OR3.  
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 Figure 1.27 Initial transcription and translation events that take place on the lambda genome after infection  
a) Transcription from PL leads to the production of N protein and transcription from PR leads to Cro protein, b) Protein N is an anti-terminator which 
allows RNA polymerase to read through tL and tR1 terminators. This allows the transcription of CIII protein from PL‟ and CII, O, P, and Q protein from PR‟, 
c) N binds to the nutL site on the DNA. In conjunction with four bacterial proteins, NusA, NusB, NusD, and NusE, N allows RNA polymerase to read 
through the terminator tL. 
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Protein CI binds to OR1 with high affinity; as CI concentration increases it binds to OR2 and 
then OR3. This inhibits the PR promoter preventing Cro production, and the phage enter 
lysogeny. Alternatively protein Cro binds to OR3 with high affinity; as Cro concentration 
increases it binds to OR2 and then OR1. This inhibits the PRM promoter preventing CI 
production leading to lytic growth (Oppenheim et al. 2005).   
 
1.4.7.1.1.1 Lysogeny  
A continuous supply of CI from the PRM promoter represses transcription from both PR and PL, 
and leads to the activation of the PI promoter, which produces integrase protein. This protein 
facilitates recombination of lambda DNA into the bacterial chromosome. Recombination 
occurs between attP on the lambda and attB on the bacterial chromosome.  Once in the 
chromosome the DNA is bound at hybrid att sites known as attL and attR. The lambda DNA 
can now replicate when the bacterial chromosome is replicated allowing stable transmission 
to daughter cells. Once a lysogen is established it is stable, with the prophage remaining 
dormant almost indefinitely, and only approximately one cell per thousand cell generations 
will spontaneously revert to phage production. However if the cell is threatened, this state can 
easily be reversed, switching into lytic cycle by a process known as induction.  
 
1.4.7.1.1.2 Lysis  
Continuous expression from PR promoter allows Q protein to accumulate in the cell. This 
leads to the activation of the PR‟ promoter. PR‟ transcribes late genes that are essential for lytic 
infection eg: the production of head, tail and lysis proteins. Phage replication proceeds using 
O and P proteins. Initial replication uses theta replication which is later changed to rolling 
circle replication (Furth and Wickner 1983).  
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Construction of phage particles proceeds first with the assembly of the phage capsid using ten 
phage encoded proteins and the host proteins GroEL and GroES (Georgopoulos et al. 1983). 
The capsid consists of eight proteins E, D, B, W, FII, B*, X1 and X2. Addition of the major 
coat protein results in the formation of the phage head, into which DNA is inserted. The 
phage head is stabilised by the addition of two further proteins, which also allows connection 
of the tail. The completed phage tail is composed of twelve genes Z, U, V, G, T, H, 208, M, 
L, K, I and J (Katsura 1983). Once the phage particles have been generated the next step is to 
get out of the bacterial cell into the environment.  Two proteins R and S are required for this. 
S is a 15K protein used to form a hole in the inner membrane allowing protein R endolysin a 
17K protein access to the cell wall for degradation of the bacterial peptidoglycan (Friedman 
and Gottesman 1983). This entire lytic cycle takes approximately 35 minutes and 
approximately 100 intact phage particles are released. Figure 1.28 demonstrates lytic 
replication of lambda.  
                       
Figure 1.28 DNA replication cycle for bacteriophage lambda 
(1) Phage particle attaches to the host cell, (2) Injection of linear duplex DNA molecule, (3) DNA 
circularises by base pairing of complementary single stranded ends, (4) Nicked circle closed by DNA 
ligase, (5) Supercoils are introduced by DNA gyrase, (6) DNA replication initiates on supercoiled circle, 
(7) termination of a round of replication yields two daughter circles, (8) At later point replication 
proceeds by rolling circle replication, cut at cos sites (arrows), (9) packaged into phage heads, (10) 
Addition of a tail completes maturation of phage particles (Adapted from Firth and Wickner 1983).       
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1.4.7.2 SOS response 
The exposure of E. coli to agents that can damage DNA or interfere with DNA replication eg: 
ultraviolet light (UV) or mitomycin can induce a diverse set of physiological responses that 
have been termed as SOS responses. Single-stranded DNA in the bacterial cell binds to the 
protein RecA with assistance from RecFOR and RecBC proteins (Michel 2005). RecA in turn 
becomes activated and binds to another protein LexA. Proteolytic cleavage of LexA by 
autocleavage allows activation of approximately 30 DNA damage genes (Matic et al. 2000). It 
is believed that RecA acts in an indirect stimulatory role to help facilitate LexA autocleavage 
(Walker 1984). These DNA damage genes play several roles such as delaying cell division 
until the damage is repaired or allowing the cell to replicate past the DNA damage (Snyder 
and Champness 2003).  
 
The regulation of the SOS response through cleavage of the LexA repressor is very similar to 
the induction of lambda. The activated RecA also initiates autocleavage of lambda CI protein 
at a rate ten times slower than the cleavage of LexA (Walker 1984, Matic et al. 2000 and 
Janion 2001). This switches lambda from lysogeny to lytic reproduction, by de-repressing 
transcription from the PR and PL promoters, ensuring lambda survival from a bacterial cell 
that‟s under stress.  
 
1.4.7.3 Selection Strategy  
A direct positive selection strategy using bacteriophage lambda and the SOS response has 
been developed. In order to use this system the lambda genome has been modified for the 
expression of NTR from an inducible Ptac promoter (see Figure 1.29).  
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Figure 1.29 Schematic of lambda vector JG16C2 integrated to the E. coli chromosome by its att 
sites 
PL, PR, lytic cycle promoters. The cI repressor encoded in immunity (imm) region. NTR is inserted 
between Sfi I sites downstream of the IPTG-inducible Ptac promoter. KanR indicates a Kanamycin 
resistance gene for lysogen selection (Adapted from Guise et al. 2007) 
 
 
This strategy utilizes lambda‟s ability to switch between a lytic (lysis) and latent (lysogenic) 
state. In a lysogenic state the lambda‟s genome integrates into the bacterial E. coli host DNA 
and is stably transmitted to daughter cells. The bacterial SOS response is used, to trigger NTR 
expressing lambda lysogens to enter the lytic cycle. The SOS response is triggered when 
CB1954 activation leads to DNA cross linking. Therefore phages that encode NTR, which 
more readily activates CB1954, will enter the lytic cycle at low prodrug concentration. This 
allows preferential enrichment of phage encoding improved NTR (Guise et al. 2007).  
 
A phage library containing mutant NfsB NTR with randomised codons encoding for F124, 
F70 or N71, and S40 or T41 was generated, giving greater than 1 x 10
6
 possible nucleotide 
combinations. 6.8 x 10
5
 independent clones were then put through multiple rounds of 
selection. The most active mutant identified was the triple mutant T41Q N71S F124T, which 
was found to have an IC50 of 3 µM CB1954 in E. coli, 50-fold lower than wild type (Guise et 
al. 2007). However, it may be possible to further improve NfsB NTRs ability to sensitise cells 
to CB1954.  
 79 
1.5 AIM OF THESIS 
ULTIMATE AIM:  
To improve the efficacy of VDEPT using NTR and CB1954 by improving our knowledge of 
the contribution of different active site residues of NfsB NTR to the efficacy of CB1954 
activation, and using this understanding, together with the direct positive selection method to 
select NTR mutants with greater efficiency of CB1954 activation. 
 
 OBJECTIVES: 
1. To investigate the contribution of specific active site amino acid residues, or combinations 
of residues, via construction and selection of small libraries. 
 
2. To design and select a large library of NTR mutants containing mutations at multiple sites, 
to obtain one or more improved enzymes. 
  
3. To purify and kinetically characterise the NfsB NTR mutants of greatest interest, and to 
compare with WT and other previously purified mutant NfsB NTR enzymes. 
 
4. To construct adenoviral vectors expressing the most promising NfsB NTR mutants and 
assess their ability to sensitise tumour cells to CB1954.  
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 INTRODUCTION 
Molecular biology techniques were derived from Current Protocols in Molecular Biology 
(Wiley), and Molecular Cloning: a Laboratory Manual (Sambrook et al. 1989).  
 
2.2 MOLECULAR BIOLOGY 
2.2.1 Oligonucleotide Primers 
The following Oligonucleotide primers were used during this study: 
 
PS1013A  GCTTCAGCCAGACATCCGTCC    
PS1013B GTTGCCAAATCCGCTGCCG                        
JG2A  TGGCGGAAAGGTATGCATGC   
JG2B  CAGAGCATTAGCGCAAGGTG   
JG138A GCACGCTAGCAAGCTTCCACCATGGATATCATTTCTGTCGCC  
JG138B GCACAAGCTTGCTAGCTCATTACACTTCGGTTAAGGTGATG 
SH1A  GCCAGCAAAAAACTTACCCCG 
SH1B     CCGGGGTAAGTTTTTTGCTGGCATCAAATGCNNNAGTGGAATGACGCTTTAAGGC 
JG126A CCCAGCCGTGGCATTTTATTGTTG 
CG4041 CAACAATAAAATGCCACGGCTGGGAGTTNNNNNNGG 
JG122A TTGACGCCGCCATCCTCGATGCAG 
CG165166 CTGCATCGAGGATGGCGGCGTCAAANNNNNNGATGG 
SH33A ATGCACCGTAAAGATCTGCATGATG 
SH33B CATCATGCAGATCTTTACGGTGCATATCSNNSNNSNNCTTSNNACCTTTATCGTTCGCGGCTT 
            TCGC  S = C or G 
PS1296F CTGCGATTAATGCATTCTGC 
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2.2.2 Growth Media 
Luria Broth (LB): 20 g LB (Sigma) per litre.  
Tris buffered Luria Broth (TBLB): 20 g LB (Sigma) and 62.5 ml Tris (1 M pH 7.5) per litre. 
SOB Broth: 20 g Bacto-tryptone (Difco), 5 g yeast extract (Difco) and 2 ml NaCl (5 M), 10 
ml MgSO4 (1 M), 10 ml MgCl2 (1 M) and 2.5 ml KCl (1 M) per litre.  
SOB Agar: 20 g Bacto-tryptone (Difco), 5 g yeast extract (Difco), 2 ml NaCl (5 M), 10 ml 
MgSO4 (1 M), 10 ml MgCl2 (1 M), 2.5 ml KCl (1 M) and 7.5 g Bacto Agar (sigma) per litre.  
SOC Broth: 20 g Bacto-tryptone (Difco), 5 g yeast extract (Difco) and 2 ml NaCl (5 M), 10 
ml MgSO4 (1 M), 10 ml MgCl2 (1 M), 2.5 ml KCl (1 M) and 20 ml glucose (1 M) per litre.  
SM Buffer: 5.8 g NaCl, 8 g MgSO4, 2.5 ml Gelatin (2% W/V) and 50 ml Tris (1 M pH 7.5) 
per litre. 
NZYCM Broth: 10 g NZ Amide (Sigma), 5 g NaCl, 5 g yeast extract (Difco) 1 g Casamino 
acids (Sigma), 2 g MgSO4. The pH was adjusted to 7 using NaOH. 
NZYCM Top Agar: 10 g NZ Amide (Sigma), 5 g NaCl, 5 g yeast extract (Difco), 1 g 
Casamino acids (Sigma), 2 g MgSO4, 7 g Agarose (Sigma). The pH was adjusted to 7 using 
NaOH. 
NZYCM Agar: 10 g NZ Amide (Sigma), 5 g NaCl, 5 g yeast extract (Difco), 1 g Casamino 
acids (Sigma), 2 g MgSO4 and 7.5 g Bacto Agar (Sigma). The pH was adjusted to 7 using 
NaOH. 
 
2.2.3 Bacterial Strains  
Table 2.1 provides a summary of the bacterial strains used in this study 
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Table 2.1 Escherichia coli strains used in this study 
 
2.2.4 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) was used for the amplification of DNA. Standard Taq DNA 
polymerase (Roche Applied Sciences, Germany) was used for phage library preparation. Two 
PCR reactions were used. An initial PCR was performed using 5 μl of DNA encoding WT or 
mutant NTR as template. The PCR was performed using 5 μl 10x buffer, 5 μl dNTP‟s (2 
mM), 1 μl primer 1 (25 μM), 1 μl primer 2 (25 μM), 0.5 μl Taq polymerase and 32.5 μl water. 
A second combined PCR also using Taq Polymerase was used to join PCR fragments together 
making full length NTR (encoding mutations at specific residues). This PCR was performed 
using 5 μl 10 x buffer, 5 μl dNTP‟s (2 mM), 1 μl primer 1 (25 μM), 1 μl primer 2 (25 μM), 50 
ng PCR fragment 1, 50 ng PCR fragment 2, 0.5 μl Taq polymerase and water to 50 μl.  
 
KOD DNA polymerase (Novagen, USA) was used for cloning purposes, allowing the 
amplification of specific NTR‟s for subsequent cloning into plasmids. KOD polymerase 
increases fidelity when amplifying and ensures blunt ends for cloning. These PCR‟s were 
performed using 5 μl of DNA template, 5 μl 10x buffer, 5 μl dNTP's, 3 μl MgSO4, 1 μl primer 
1 (25 μM), 1 μl  primer 2 (25 μM), 0.5 μl KOD Polymerase and 29.5 μl water. 
 
 
E. coli strain Genotype of strain 
UT5600 F
-
 ara-14 leu B6 azi-6 lacY1 proC14 tsx-67 ∆ (omp T- fep C) 266 ent A403 
gln V44 (AS) λ
-
 trp E38 rfb D1 rps L109 (str R) xyl A5 mtl-1 thi-1  
C600 BNN93 hflA150: Tn10 (Tet
r
) 
XL-2 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac (F‟proAB lacI
q
Z∆M15 
Tn10 (Tet
r
) Amy Cam
r
)
a
 
BL21 λDE3 PhysS trc tac  λPL araD T7 Ion
-
 ompT
-
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Routinely, PCR reactions were run as a total volume of 50 µl in a thermalcycler (PE 
Biosystems) under the following conditions: 
Initial denaturation  95 °C   5 minutes 
Denaturation   95 °C  50 seconds 
Annealing   55 °C  50 seconds            x 25 cycles 
Extension   72 °C  60 seconds 
Final Extension   72 °C  7 minutes 
Hold    4 °C 
 
2.2.5 Agarose Gel Electrophoresis 
Analytical gels were used to visualise DNA products eg: PCR fragments or restriction 
enzyme digests of DNA. Agarose gels (0.6% to 1% agarose) were prepared in 1x TAE 
running buffer (diluted from 50x TAE stock solution: 242 g of Tris HCl, 57.1 ml of glacial 
acetic acid, 18.2 g of disodium EDTA in 1 litre H2O). Gels were placed in a gel tank 
containing 1x TAE. DNA was mixed with glycerol loading buffer and loaded into appropriate 
lanes. DNA marker was loaded into the first lane, and the gel run at 100 volts for 
approximately 2 hours dependent on the clarity and separation of bands required. Gels were 
stained in water containing 0.5 µg/ml ethidium bromide and visualised under UV illumination 
using a Kodak DC290 camera in combination with a Spectroline TVC312A UV 
transilluminator.   
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2.2.6 DNA Purification 
2.2.6.1 Gel Purification with QIAquick gel extraction kit 
Specific DNA fragments (70 bp to 10 kb in size) were separated on preparative agarose gels 
made using SeaKem GTG agarose (Cambrex Bio Science Wokingham, Ltd). The DNA 
sample was mixed 1:1 with Ficoll loading buffer plus the addition of 2 µl per 100 µl of 
sample of SYBR Gold before loading. (Molecular Probes, Inc). After electrophoresis, the 
desired fragment was visualised on a blue light transilluminator and cut from the gel using a 
sterile scalpel. Appropriate size excised bands were purified using QIAquick gel extraction 
Kit (Qiagen). Extraction and purification followed the manufacturer‟s recommendations. 
 
2.2.6.2 Phenol/chloroform extraction 
Phenol/chloroform extraction was performed to remove enzymes and other contaminating 
proteins from DNA samples. An equal volume of phenol/chloroform was added to the DNA 
sample and mixed thoroughly to form an emulsion. The sample was centrifuged at 13,000 
rpm for 1 minute to separate phases, and the lower organic phase removed. An equal volume 
of chloroform was added, and the process was repeated. The aqueous phase was carefully 
removed and transferred to a clean tube.  
 
2.2.6.3 PCR purification with Roche High Pure Purification kit 
To remove primers, DNA polymerase, unincorporated nucleotides and other components 
following a PCR reaction High Pure PCR Product Purification Kit (Roche Applied Science, 
Germany) was used. Methods followed manufacturer‟s instructions. 
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2.2.7 DNA Precipitation 
NaCl was added to the solution containing DNA, to a final concentration of 0.1 M, diluted 
from a 5 M stock solution. DNA was precipitated by the addition of 2 volumes of absolute 
Ethanol. Samples were incubated at -20 °C for 30 minutes to aid precipitation. DNA was 
recovered by centrifugation at 13,000 rpm for 10 minutes in a bench top microcentrifuge. The 
supernatant was aspirated and the pellet dried at room temperature. DNA was resuspended in 
a convenient volume of T10E1 (10 mM Tris, 1 mM EDTA, pH 7.5). 
 
2.2.8 DNA quantitation 
DNA was quantified using the DNA binding reagent PicoGreen (Molecular Probes, USA). 
Sample DNA and diluted standard DNA (phage λ DNA, supplied with kit) were diluted in 
T10E1 (10 mM Tris, 1 mM EDTA, pH 7.5). 100 µl sample DNA was loaded in triplicate on a 
96 well plate. DNA standards were prepared containing 0, 20, 40, 60, 80 and 100 ng of DNA 
per 100 μl. 100 μl PicoGreen reagent diluted 1 to 200 in T10E1 was added to each well and 
samples were mixed by pipetting. Following 2 minute incubation in the dark, fluorescence at 
485/535 nm was determined using a Wallac victor 1420 plate reader (Perkin Elmer, Italy). 
DNA concentration was calculated from a standard curve of the known diluted DNA 
standards. 
 
2.2.9 Restriction Endonuclease Digestion 
DNA restriction enzymes from New England Biolabs (Hitchin, Herts) or Roche (Roche 
Diagnostics) were used. These were used in accordance with the reaction conditions described 
in the manufacturer‟s instructions using the appropriate buffers, supplied with the enzymes. 
Restriction enzymes used during this study can be seen in Table 2.2           
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Restriction Enzyme Temperature  
(
o
C) 
BSA Buffer Heat Inactivation 
Bam HI 37 Yes NEB 3 No 
Bgl II 37 No NEB 3 No 
Cla I 37 Yes NEB 4 Yes 
Eco RV 37 Yes NEB 3 No 
Hind III 37 No Roche B Yes 
Hpa I 37 No Roche A Yes 
Nco I 37 No Roche H Yes 
Nde I 37 No NEB 4  Yes 
Pac I 37 Yes NEB 1 Yes 
Sfi I 50 Yes NEB 4 No 
Swa I 25 Yes NEB 3 Yes 
 
Table 2.2 Restriction Enzymes used and the conditions required 
 
 
Typically, for diagnostic DNA digestions, 0.5 g of DNA was cut in a total volume of 20 l, 
with 2 l of appropriate 10x enzyme buffer and 1 unit of restriction endonuclease. This was 
incubated at 37 C unless otherwise stated for at least four hours. For digestion of larger 
quantities of DNA, (e.g. for fragment purification) restriction endonuclease digestion was 
scaled up accordingly.  
 
2.2.10 Dephosphorylation  
The removal of 5 prime phosphate groups from the ends of linear DNA was achieved using 
calf alkaline phosphatase (CAP) and incubated at 37 C for one hour with 1x concentration of 
supplied buffer. The enzyme was then heat inactivated at 75 C for 10 minutes before 
cleaning the DNA by phenol/chloroform extraction and ethanol precipitation. This prevents 
plasmid vectors re circularising themselves without insert. 
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2.2.11 Ligation 
T4 DNA ligase (Roche Diagnostics) was used for the construction of recombinant DNA 
products (phage λ, plasmids and viral vectors). Usually a 3:1 molar excess of insert to vector 
was used in sticky end ligation and a 10:1 excess for blunt ended ligation. Ligation reactions 
were incubated overnight at 14 C. After overnight incubation, DNA was cleaned by 
phenol/chloroform extraction and ethanol precipitation. The resulting pellet was then 
resuspended in 10 l T10 E1. 
 
2.2.12 Preparation of competent cells 
Competent E. coli cells for the transformation of plasmid DNA were prepared based on a 
method by Hanahan (Hanahan 1983). Competent XL-2 and BL21λDE3 cells were used for 
this study. E. coli cells taken from a frozen stock were streaked onto a fresh SOB agar plate 
and incubated overnight (approximately 16 hours) at 37 C. A single isolated colony was 
transferred into 1 ml SOB with 20 mM MgSO4, and the bacteria dispersed by vortexing. This 
was then added to 100 ml SOB containing 20 mM MgSO4. The cells were shaken at 37 C for 
4-6 hours until the OD600 had reached 0.5.  
 
The cells were then transferred into sterile, ice cold 50 ml tubes and stored on ice for 10 
minutes, before being centrifuged for 10 minutes at 4,000 rpm in a Beckman GSR6 table top 
centrifuge using GH-38 rotor at 4 
o
C. The pellet was resuspended in 20 ml ice cold FSB 
transforming buffer per 50 ml tube (10 mM Potassium acetate (pH 7.5), 45 mM MnCl2, 10 
mM CaCl2, 100 mM KCl, 3 mM hexamine cobalt chloride, and 10% v /v glycerol, pH 6.4), 
and again stored on ice for 10 minutes before centrifugation for 10 minutes at 4,000 rpm.  
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The pellets were resuspended in 4 ml FSB per 50 ml tube prior to mixing with 140 l DMSO 
and incubating on ice for 15 minutes. An additional 140 l DMSO was added and the cells 
were quickly dispensed into 300 l aliquots in sterile eppendorf tubes and immediately snap 
frozen in liquid nitrogen. The aliquoted competent bacteria were stored at -80 C until 
required. 
 
2.2.13 Bacterial Transformation 
For bacterial transformation 100 l of competent E. coli cell suspension was mixed with 
approximately 10 ng of recombinant plasmid DNA or ligation mixture in an eppendorf and 
stored on ice for 45 minutes. Cells were then heat shocked at 42 C for 2 minutes. 900 l of 
room temperature SOC was then added, mixed thoroughly by inverting several times and 
incubated at 37 C for 1 hour with gentle agitation. Cells were then plated on SOB agar plates 
(containing either 100 g/ml Ampicillin or 30 g/ml Kanamycin antibiotic) and incubated 
overnight at 37 C.  
 
2.2.14 Plasmid Mini Preparation  
Bacterial colonies were picked into 5 ml of SOB medium (Difco Laboratories, UK) 
containing the appropriate antibiotic and grown overnight at 37 C. The bacterial culture was 
pelleted by centrifugation at 5,000 rpm for 5 minutes in Sorvall SM24 rotor. The supernatant 
was discarded and the pellet was thoroughly resuspended in 100 l of ice-cold solution I (50 
mM glucose, 10 mM EDTA pH 7.5, 25 mM Tris HCl pH 8.0).  
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To this solution, 200 l of freshly prepared solution II (0.2 M NaOH, 1% w/v SDS) was 
added to lyse the bacteria, and the tube inverted five times, before leaving the contents for 5 
minutes on ice. 150 l of ice-cold solution III (5 M acetate and 3 M potassium, pH 4.8-5.0) 
was added, and the tube mixed by inversion before leaving on ice for 5 minutes. Samples 
were centrifuged at 13,000 rpm for 5 minutes and the clear supernatants were transferred to 
clean tubes before DNA recovery was carried out via phenol/chloroform extraction and 
ethanol precipitation. DNA pellets were washed with 70% ethanol and resuspended in 50 l 
10 mM Tris. Cl (pH8.5) containing 50 g/ml heat treated RNase A. DNA was checked by 
digestion of 5-10 l of the DNA with appropriate restriction enzymes, before analysis by 
agarose gel electrophoresis. 
 
2.2.15 Plasmid Bulk Preparation  
Bacterial colonies containing the desired plasmid were inoculated into 200 ml of SOB 
medium supplemented with an appropriate antibiotic and grown overnight at 37 C in a 
shaking incubator. The bacterial culture was centrifuged for 5 minutes at 5,000 rpm in a 
Sorvall GSA rotor at 4 C. The supernatant was discarded and the bacterial pellet thoroughly 
suspended in 4 ml ice-cold solution I (50 mM glucose, 10 mM EDTA pH 7.5, 25 mM Tris 
HCl pH 8.0). 1 ml of freshly prepared 10 mg/ml lysozyme (in solution I) was added and the 
suspension left on ice for 10 minutes. Complete lysis proceeded by the addition of 10 ml of 
solution II (0.2 M NaOH, 1% w / v SDS). The pot was gently inverted a few times to ensure 
complete mixing before being left on ice for a further 10 minutes. 7.5 ml of solution III (5 M 
acetate and 3 M potassium, pH 4.8-5.0) was added and the pot was vortexed to ensure 
thorough mixing. After storage on ice for a further 10 minutes, bacterial debris was pelleted 
by centrifugation at 8,000 rpm for 15 minutes at 4 C in a Sorvall GSA rotor.  
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Plasmid containing supernatant was carefully removed into a fresh 250 ml centrifuge bottle 
and all nucleic acids were precipitated by the addition of 22.5 ml of propan-2-ol. Precipitation 
was assisted by incubation at -20 C for 30 minutes. The centrifuge bottle was then 
centrifuged at 8,000 rpm for 20 minutes at 4 C. Pellets were allowed to drain before being 
dissolved overnight at room temperature in 2.5 ml of T50E10 (50mM Tris HCl and 10 mM 
EDTA). 3.03 g of caesium chloride (CsCl) was added to the plasmid solution. The liquid 
weight of the plasmid solution was made up to 2.75 ml by the addition of T50E10, and 275 l 
of ethidium bromide solution (10 mg/ml) before storing on ice for 10 minutes. The plasmid 
solution was then centrifuged at 9,000 rpm for 10 minutes in a Sorvall SM24 rotor to 
precipitate contaminating RNA. The plasmid preparation was then transferred into 3.9 ml 
Beckman Quick-Seal centrifuge tubes, with any gap between the liquid and neck of tube filled 
with isopycnic CsCl solution (1 g CsCl:1ml T50E10). Tubes were heat sealed and ultra 
centrifuged at 100,000 rpm for 4 hours followed by a 95,000 rpm spin for 2 hours, followed 
by a 65,000 rpm gradient relaxation step for 30 minutes in a Beckman Optima TLX bench top 
ultracentrifuge using a TLN-100 near vertical tube rotor. The plasmid band was carefully 
removed by puncturing the side of the tubes with a 21 gauge needle and 2 ml syringe. DNA 
was diluted with 3 volumes of T10E1N100 and the ethidium bromide was removed by two 
phenol/chloroform extractions. One volume of propan-2-ol was added to precipitate the DNA 
followed by centrifugation at 9,000 rpm for 10 minutes in a Sorvall SM24 rotor at 4 C to 
pellet it. The DNA pellet was suspended in 500 l of T10E1N100 and transferred to a clean 
eppendorf tube before precipitation with 2 volumes of absolute ethanol. The pellet was finally 
suspended in a suitable volume of T10E1 and the concentration of the plasmid DNA was 
determined. 
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2.2.16 Sequencing 
PCR based sequencing reactions were performed with an appropriate primer in a 20 l 
reaction volume using ABI Prism Big Dye Terminator cycle sequencing ready reaction kits 
(PE Biosystems), according to the manufacturer‟s protocol. The reaction solution consisted of 
4 l of 5x buffer, template DNA, 2 l of 2.5 M sequencing primer, 1 l terminator mix, and 
the appropriate volume of water. The reaction was run in a thermal cycler under the following 
condition: 94 °C for 2 seconds  followed by 25 cycles: 96 °C for 10 seconds, 50 °C for 5 
seconds and 60 °C for 4 minutes 
 
Following the above reaction, the extension products were transferred to eppendorf tubes and 
precipitated by addition of 80 l 75% propan-2-ol. The mixtures were well mixed, left at 
room temperature for 10 minutes before centrifuging at 13,000 rpm for 8 minutes. Each 
resultant pellet was washed with 180 l 70% ethanol, followed by centrifugation at 13,000 
rpm for 4 minutes. The final DNA pellets were left to air dry for 15 minutes and stored at -20 
°C for subsequent sequencing.  
 
Immediately prior to loading the sequencing, the pellets were resuspended in 10 l of loading 
dye (5:1 mixture of de ionised formamide and 50 mg/ml dextran blue in 25 mM EDTA, pH 
8), vortexed and spun down briefly. The samples were heated at 90 °C for 2 minutes in a heat 
block. 10 l of each sample was loaded onto a 96 well plate and analysed on a Prism DNA 
sequencer, using a base calling algorithm ABI100.  
 
 
 93 
2.3 PHAGE LAMBDA 
2.3.1 Plating cells  
E. coli plating cells UT5600 and C600 were required for phage lambda work. E. coli cells 
taken from a frozen stock were streaked onto a fresh LB plate and incubated overnight 
(approximately 16 hours) at 37 
o
C. A single isolated colony was transferred into 50 ml LB; 
the cultures were shaken at 37 
o
C for 4-6 hours until the OD600 had reached 0.5. The cells 
were then transferred into a sterile, 50 ml tube and centrifuged for 5 minutes at 1,500 rpm at 4 
o
C. The pellet was resuspended in 25 ml ice cold 10 mM MgS04. Plating cells can be stored at 
4 
o
C and can be used for approximately 1 week. 
 
2.3.2 Phage Purification 
10 ml of C600 plating cells were infected with λJG3J1 and λSV054 (5 x 105 - 1 x 107 pfu) and 
incubated at 37 
o
C for 30 minutes, before adding to 250 ml of pre-warmed NZYCM in a 1 
litre flask. The culture was incubated at 37 
o
C shaking until clear lysis was observed. The 
OD600 of the culture was monitored every 15 minutes. Once clear lysis had been observed 5 
ml of chloroform was added and the culture shaken for a further 10 minutes to ensure 
complete lysis.  
 
2.3.2.1 Qiagen Lambda Maxi Kit 
Bacterial debris was removed from the culture by centrifuging for 20 minutes at 9,000 rpm in 
a Sorvall GSA rotor at 4 C.  Purification proceeded according to the manufacturer‟s 
instructions. 
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2.3.2.2 Sambrook PEG and CsCl gradient centrifugation 
The lysed culture was cooled to room temperature and DNase I and RNase A were added at a 
concentration of 1 µg/µl, before swirling for 30 minutes at room temperature. NaCl was 
added to 1M and the culture incubated on ice for 1 hour. Bacterial debris was removed by 
centrifuging for 20 minutes at 9,000 rpm in a Sorvall GSA rotor at 4 C. PEG 6000 at 10% 
w/v was added to the supernatant and dissolved slowly on a magnetic stirrer. The culture was 
then cooled on ice before precipitating overnight at 4 
o
C. Precipitated phage was retrieved by 
centrifugation for 20 minutes at 9,000 rpm in a Sorvall GSA rotor at 4 C. The supernatant 
was discarded and the phage pellet thoroughly resuspended in 4 ml SM buffer by slow 
shaking in a desktop shaker. 4 ml of chloroform was added to extract PEG and cell debris 
from the phage suspension. The solution was mixed thoroughly before centrifugation at 4,500 
rpm for 20 minutes. The aqueous phase containing the phage was recovered. This was 
repeated four times to ensure thorough PEG extraction. 0.75 g of caesium chloride (CsCl) was 
added per ml of phage preparation and dissolved by inverting several times. The phage 
preparation was then transferred into 3.9 ml Beckman Quick-Seal centrifuge tubes, with any 
gap between liquid and neck of tube filled with isopycnic CsCl solution. Tubes were heat 
sealed and ultra centrifuged at 100,000 rpm for 4 hours, followed by 60,000 rpm for 4 hours 
in a Beckman Optima TLX bench top ultracentrifuge using a TLN-100 near vertical tube 
rotor. The phage band was carefully removed by puncturing the side of the tubes with a 21 
gauge needle and a 2 ml syringe. The phage DNA was transferred to 1.5 ml eppendorfs and 
50 µl of 1 x SET (1% SDS, 1 mM EDTA, 10 mM Tris pH 8) and 0.5 µl Proteinase K (20 
mg/ml) were added per 500 µl of DNA before incubating at 50 
o
C for 1 hour. The DNA was 
cooled to room temperature and diluted with 3 volumes of T10E1N100.  
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Phenol/chloroform extraction was used to remove protein debris. 2 volumes of absolute 
ethanol were added to precipitate the DNA followed by centrifugation at 13,000 rpm for 20 
minutes in a Sorvall SM24 rotor at 4 
o
C. The pellet was finally suspended in 150 µl of T10E1 
and concentration of the phage DNA was determined. 
 
2.3.3 Packaging into phage particles 
Recombinant lambda phages were generated using Giga Pack Gold III packaging extract 
(Stratagene, USA). Ligation reactions using digested λJG3J1 and λSV054 DNA and insert 
were packaged according to the manufacturer‟s instructions.  
 
2.3.4 Phage titre 
Serial, ten fold dilutions of phage were made in SM buffer. 100 µl of each phage dilution was 
added to 3.5 ml of NZYCM top agar (heated in microwave and cooled to 45 
o
C) and inverted 
several times before pouring out onto LB plates. The plates are then rocked to ensure an even 
layer is produced. The plates were allowed to set before incubated upside down at 37 
o
C 
overnight. The resulting plaques were counted and phage titres determined.  
 
2.3.5 Phage Amplification  
2.3.5.1 Plate Lysate 
100 µl of plating cell bacteria UT5600 was mixed with between 1 x 10
4
 to 1 x 10
6
 pfu of 
phage in SM buffer. The plating cell/phage mix was added to 3.5 ml of NZYCM top agar 
(heated in microwave and cooled to 45 
o
C) and inverted several times before pouring out onto 
LB plates. The plates are then rocked to ensure an even layer is produced.  
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The plates were allowed to set before incubation upside down at 37 
o
C overnight until the 
phages have spread out over the plate. 5 ml SM buffer was added to plate and incubated at 37 
o
C for several hours with intermittent swirling. The SM buffer now containing diffused 
bacteriophage was removed and filter sterilised with a 0.45 µm Acrodisc (Pall, UK).  
 
2.3.5.2 Liquid Culture 
10 µl of plating cell bacteria C600 was added to 20 ml NZYCM and allowed to grow at 37 
o
C 
to an OD600 of 0.5. 300 µl of the bacterial culture was added to 1 x 10
6
 pfu of pre-warmed 
bacteriophage library and incubated at 37 
o
C for 30 minutes to allow phage binding. The 
bacteria/phage mix was then added to 2.7 ml of NZYCM and incubated at 37 
o
C shaking until 
lysis. Large bacterial debris was pelleted by centrifugation at 5,000 rpm for 5 minutes in 
Sorvall SM24 rotor. The supernatant was filter-sterilised with a 0.45 µm Acrodisc (Pall, UK). 
 
2.3.6 Selection  
200 µl of plating cell bacteria UT5600 was mixed with 10
8
 pfu of unselected phage library 
and grown at room temperature with shaking in LB/kanamycin, to an OD600 of 0.1. IPTG was 
then added to a final concentration of 0.1 mM to induce NTR expression. At OD600 0.5, 1 ml 
of the culture was added to 4 ml of pre-warmed LB/kanamycin containing 0.1 mM IPTG, 
62.5 mM Tris pH 7.5 and CB1954 at final concentrations of 100, 200 and 300 µM. After 
shaking for 15 minutes at 37 
o
C, 5 ml of each culture was added to 45 ml fresh, pre-warmed 
LB to dilute out CB1954. The 50 ml culture was centrifuged at 2,500 rpm for 5 minutes at 
room temperature to pellet bacteria. 
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The pellet was resuspended in 5 ml LB and incubated for 1 hour, to allow lysogens induced 
by the prodrug exposure to enter lysis. Remaining bacteria and debris were removed by 
centrifugation, followed by filter sterilisation through a 0.45 µm Acrodisc (Pall, UK), to 
recover the released bacteriophage in the flow through.   
 
2.3.7 Lysogen Generation 
200 µl of the plating cell bacteria was mixed with 10
8
 pfu phage stock and grown overnight at 
room temperature with shaking in LB/kanamycin. At OD600 0.5, the culture was diluted 
10,000 fold and 100 µl spread onto LB agar plates containing 50 mM Tris pH 7.5 and 30 
µg/ml kanamycin. Plates were incubated overnight at 37 
o
C for colony growth. Each colony 
represents an individual lysogen.  
 
2.3.8 Replica Plating  
Individual lysogens were grown in 96 well plates for 24 hours at 37 
o
C in LB/kanamycin. 
Resulting clones were replica-plated using a 48-pin metal plate onto freshly prepared 
LB/kanamycin agar plates containing 50 mM Tris (pH 7.5), 0.1 mM IPTG and a range of 
CB1954 concentrations. The plates were incubated at 37 
o
C; the growth of each clone was 
examined and photographed. 
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2.3.9 Colony Forming and IC50 Assays  
Either representative phages after selection (mixed with 200 µl plating cells) or individual 
lysogens were grown to OD600 of 0.1. NTR expression was then induced by adding IPTG to a 
final concentration of 0.1 mM. The culture was allowed to grow to OD600 of 0.5 and diluted 
10,000 fold. CB1954 sensitivity was determined by plating out 100 µl of culture onto freshly 
prepared LB/kanamycin agar plates containing 50 mM Tris (pH 7.5), 0.1 mM IPTG and a 
range of CB1954 concentrations. The plates were incubated at 37 
o
C overnight, and the 
numbers of colonies on each plate counted. The plating efficiency at each prodrug 
concentration was calculated as a percentage of the number of colonies obtained in the 
absence of prodrug. IC50 of individual lysogens (prodrug concentration required for 50% 
reduction in colony number) were estimated by interpolation.  
 
2.4 PROTEIN ANALYSIS 
2.4.1 Bradford Assay 
Bradford assays in Chapters 6 were performed using Biorad Bradford reagent (Biorad, UK). 
The Bradford reagent was diluted 1 in 5 with deionised water and filtered with an Acrodisc 
with a 0.45 µm pore size (Pall, UK). 180 µl was added to wells in a 96 well Falcon flat 
bottomed plate containing 20 µl of 0-20 µg dilutions of 1 mg/ml bovine serum albumin (BSA) 
diluted in the same buffer as the protein being measured. The plate was incubated for 10 
minutes at room temperature and then the absorbance at 595 nm was determined using a 
Wallac Victor 1420 plate reader (Perkin Elmer, Italy (Formerly Wallac, Finland)). Protein 
concentration was calculated from a standard curve of the known diluted BSA standards 
(Bradford 1976). 
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Bradford Assays in Chapter 5 were performed using Sigma Bradford Reagent (Sigma-
Aldrich, UK). Standard curves were prepared from a BSA stock 1 mg/ml using a range from 
0-10 µg. Each standard and sample was made up in 500 µl deionised water, to this 500 µl of 
Bradford reagent was added. The samples/standards were thoroughly mixed and left for 10 
minutes before reading at 595 nm on a Uvikon 923 spectrophotometer (Kontron). 
 
2.4.2 SDS PAGE Gel Electrophoresis 
SDS PAGE polyacrylamide gels usually consisted of a 12% resolving gel and a 5% stacking 
gel. Gels were all made fresh in the Biorad apparatus (Biorad, UK), with 30% acrylamide mix 
(37.5:1 acrylamide/bisacrylamide ratio), 10% Ammonium persulphate (0.1g in 1 ml) made 
fresh and TEMED which was always added last. See Table 2.3 for details. The resolving gel 
was poured; a thin layer of butanol/water was overlayed and the gel was then left to set for 
approximately 10 minutes. The layer of butanol/water was removed and the stacking gel 
poured and a comb for the wells added. The gel was left to set for approximately 1 hour.  
 
Solution components 12% resolving gel  
(10 ml) 
5% stacking gel  
(4 ml) 
H20 3.3 ml 2.7 ml 
30% acrylamide mix 4 ml 670 µl 
1.5 M Tris (pH 8.8) 2.5 ml - 
1.0 M Tris (pH 6.8) - 500 µl 
10% SDS 100 µl 40 µl 
10% APS 100 µl 40 µl 
TEMED 10 µl 6 µl 
 
Table 2.3 Reagents of an SDS PAGE gel 
 
 
 
 
 100 
2.4.3 Western Blotting 
Proteins were transferred from a polyacrylamide gel to a nitrocellulose membrane (Biotrace, 
UK) by means of a semi-dry blotting tank (Biometra, USA) running at 100 volts for 1-2 
hours. Following transfer, membranes were blocked in 5% non-fat milk protein (made up in 
PBS-Tween (0.1% Tween 20 in PBS) for 1 hour with agitation. Primary antibody was diluted 
according to the manufacturer‟s guidelines in 10 ml of 5% milk protein and sealed in a 50 ml 
screw cap tube (Sartstedt Limited, UK) with the nitrocellulose membrane. The tube was 
incubated at room temperature on a 3D rotary shaker for 2 hour after which time the 
membrane was removed and washed 3 times over 30 minutes in PBS-Tween. The secondary 
antibody was diluted and used as for the primary antibody. 
 
Immobilon Western Detection Reagents were used for detection. This was carried out 
according to the manufacturer‟s protocol (Millipore Corporation, USA). Kodak X-OMAT AR 
8 x 10 inch film was cut to size and exposed for times between 10 seconds and 1 minute. 
Exposed radiographs were developed in a Kodak X-O-graph developer. 
 
2.5 TISSUE CULTURE 
2.5.1 Cell lines  
The cell lines used throughout this thesis are shown in Table 2.4 
 
Cell Line Origin Reference 
SKOV3 Ovarian carcinoma (Fogh et al. 1977) 
HEK 293 Human embryonic kidney expressing Ad5 E1  (Graham et al. 1977) 
HER 911 Human embryonic retinoblast (Fallaux et al. 1998) 
 
Table 2.4 Human cell Lines used for this study 
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2.5.2 Routine tissue culture 
Cells were grown in a Galaxy R humidified incubator (RS Biotech, UK) at 37 °C with 5% 
CO2. All cell lines were maintained in Dulbecco‟s Modified Eagles Medium (DMEM) 
(Gibco, UK), containing 10% Foetal Bovine Serum (FBS), 2 mM Glutamine, and 20 mM 
HEPES. Cell lines were routinely grown in 75 cm
2
 tissue culture flasks (Iwaki, Japan) 
containing 20 ml medium.  
 
Cells were passaged before reaching confluence by removing medium, washing cells in 5 ml 
Dulbecco‟s phosphate buffered saline (without Ca+ or Mg+), and incubated in 2 ml trypsin 
EDTA (1 mM) until cells detached. Cells were collected in 10 ml medium containing 10% 
FBS to inhibit trypsin, counted, and either diluted 1:10 for maintenance of live cells or used 
for experimental purposes. 
 
2.5.3 Cell counting 
10 µl of cell suspension was mixed with 10 µl of Trypan blue (5 mg/ml). 10 µl of this was 
pipetted into a chamber of a Hycor KOVA Glasstic® Slide 10 with grid cell counter (Hycor 
Biomedical Inc, USA). Individual cells were counted on the grid. The cell concentration was 
calculated using the following formula:  
 
              9000 x    10        squaresgridsmallincellsofnumbermlpercellsofnumber   
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2.5.4 Cryogenic storage of cell lines 
To freeze cells for long term storage, cells were grown to approximately 75% confluence, 
trypsinised as usual, and re suspended in 10 ml medium. Cells were transferred to a 15 ml 
Falcon tube and centrifuged at 1,000 rpm for 5 minutes (Beckman GS-6R bench top 
centrifuge). The supernatant was decanted, and the pellet resuspended in 1 ml ice cold FBS 
containing 10% (v/v) DMSO. Cells were transferred into cryovials (Nunc), and frozen to -80 
°C at 1 °C per hour overnight in an isopropanol containing Cryofreezing Container (Nalgene, 
UK). Cells were then transferred to the vapour phase of liquid nitrogen storage tank. 
 
Cells revived from long term storage were quickly defrosted in a 37 °C water bath, followed 
by the drop wise addition of 10 ml pre warmed medium. Cells were then centrifuged at 1,000 
rpm for 5 minutes, medium decanted, and cells were resuspended in fresh medium and 
transferred to tissue culture flasks. 
 
2.6 MICROSCOPY 
A Zeiss Axiovert 25 inverted microscope was used for all phase-contrast and fluorescence 
microscopy using 5x, 10x, 20x, and 40x objectives with 21x, 42x, 84x, and 168x overall 
magnification. Pictures were taken using a Spot camera and processed using Spot Advanced 
software (Diagnostic Instruments, USA). 
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CHAPTER 3: GENERATION AND CB1954 
PRODRUG SELECTION OF THREE SMALL 
LIBRARIES OF NTR MUTANTS 
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3.1 INTRODUCTION 
The aim of this chapter is to determine whether mutations at several residues around the 
active site improve the efficiency of CB1954 activation. Two small libraries will be 
constructed with mutations at adjacent sites S40/T41 and E165/G166 and a third library with 
mutations at a single site K14. All possible nucleotide conditions will be incorporated at each 
targeted codon in the libraries, allowing any amino acid to be incorporated, this will be 
denoted as * throughout this chapter.  
 
3.1.1 Library S40*/T41* ± N71S 
S40 and T41 are residues which lie deep within the active site cavity. These residues have 
previously been mutated individually; mutations at either residue gave improvements over 
WT. At residue S40 alanine, glycine and threonine showed improvement and at T41, leucine 
and glycine. T41L N71S has been generated as a double mutant which is 12-fold better than 
WT. This library will allow comparison of the remaining T41 amino acid combinations with 
N71S and examine S40 and T41 combinations alone and in the context of N71S.  
 
3.1.2 Library E165*/G166* ± N71S 
Residues E165 and G166 have previously been mutated individually. No single mutations at 
either E165 or G166 were recovered with activity close to or better than WT. Glutamate is a 
large residue close to the FMN at the active site, while glycine has no side chain. It was 
considered possible that varying both residues simultaneously might allow improved 
combinations of amino acid residues to be discovered. 
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3.1.3 Library K14* 
K14-HAs never previously been mutated and gives two hydrogen bonds to FMN. The 
rationale behind mutating this residue is that other residues that interact with FMN such as 
N71S give good mutants and therefore it is possible that mutations at K14 could also improve 
catalysis. 
 
A PDB image showing each residue selected for mutation in these libraries is shown in Figure 
3.1. 
                         
 
Figure 3.1 Relative positions of residues K14, S40, T41, N71, E165 and G166 in the active site 
cavity of WT NTR enzyme 
The structures shown are of the NTR/nicotinic acid complex. The FMN cofactor, nicotinic acid ligand 
and selected residues are represented in stick form. This image was created from the 1ICR crystal 
structure using SWISS PDB Viewer 4.0.1 and rendered in Pov-Ray V3.6.  
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These libraries will be put through a powerful selection system to quickly select best variants 
(Guise et al. 2007). The three libraries are relatively small, so would expect efficient selection 
within a small number of cycles. Three cycles of selection were chosen.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Library Construction 
3.2.1.1 PCR mutagenesis  
Two templates were used for PCR to give limited diversity at residue N71. λ lysogens 
encoding WT NfsB NTR and mutant N71S were streaked onto LB plates containing a fresh 
lawn of E. coli UT5600. Resulting lysis areas were picked with a tip and used as templates for 
PCR mutagenesis using Taq DNA polymerase.  
 
Mutations were introduced using PCR primers that amplify overlapping left and right ends of 
the NTR gene. Randomisations at residues of interest were achieved using degenerate PCR 
primers CG4041, CG165166 and SH1B (see section 2.2.1). Resulting PCR products were 
resolved by agarose gel electrophoresis to confirm DNA fragments of the correct size were 
amplified. PCR products of the correct size were purified using Roche High Pure PCR 
Product Purification Kit. Left and right ends were subsequently combined in a second PCR 
reaction using flanking primers (see Figures 3.2-3.4). A total of 50 ng of template DNA was 
used at a 1:1 molar ratio of left and right ends. Full length PCR products were resolved by 
agarose gel electrophoresis to confirm DNA fragments of the correct size were amplified and 
purified using Qiagen QIA-Quick Gel Extraction Kit. 
 
 107 
               
Figure 3.2 S40*/T41* ± N71S Library - schematic of degenerate PCR’s making left and right 
ends of NTR gene and joining together by combined PCR’s 
Degenerate primer CG4041 was used to randomise residues S40 and T41. Left end fragment made 
using primers JG2A and CG4041 gave a fragment size of 392 bp and the right hand fragment made 
using primers JG126A and JG2B gave a fragment size of 715 bp. Primers CG4041 and JG126A 
overlap by 24 nucleotides, allowing the left and right fragments to be joined in a second PCR step 
using the flanking primers JG2A and JG2B. Note this schematic is not to scale 
CG4041 
  NTR TEMPLATES  
  (WT and N71S)  
Sfi I 
Initial PCR‟s 
Sfi I 
Combined PCR‟s 
        S40 T41          WT 
                              N71S 
Left end 
Right end 
        S40* T41*   
JG2A 
JG2B 
NTR GENE 
JG126A 
Sfi I Sfi I NTR GENE 
JG2A 
JG2B 
        S40* T41*       WT 
                               N71S 
                                WT 
                              N71S 
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Figure 3.3 E165*/G166* ± N71S Library - schematic of degenerate PCR’s making left and right 
ends of NTR gene and joining together by combined PCR’s 
Degenerate primer CG165166 was used to randomise residues E165 and G166. Left end fragment 
made using primers JG2A and CG165166 gave a fragment size of 774 bp and the right hand fragment 
made using primers JG122A and JG2B gave a fragment size of 342 bp. Primers CG165166 and 
JG122A overlap by 24 nucleotides, allowing the left and right fragments to be joined in a second PCR 
step using the flanking primers JG2A and JG2B. Note this schematic is not to scale 
 CG165166 
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                          N71S 
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Figure 3.4 K14* Library - schematic of degenerate PCR’s making left and right ends of NTR 
gene and joining together by combined PCR’s 
Degenerate primer SH1B was used to randomise residue K14. Left end fragment made using primers 
JG2A and SH1B gave a fragment size of 324 bp and the right hand fragment made using primers 
SH1A and JG2B gave a fragment size of 790 bp. Primers SH1B and SH1A overlap by 21 nucleotides 
allowing the left and right fragments to be joined in a second PCR step using the flanking primers 
JG2A and JG2B. Note this schematic is not to scale 
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3.2.1.2 Insertion of NTR PCR products into lambda vector 
PCR fragments for each small library, encoding full length mutant NTR genes were digested 
with Sfi I restriction enzyme and the digestion products resolved by agarose gel 
electrophoresis. NTR genes of 751 bp were excised from preparative agarose gels and 
purified using Qiagen QIA-Quick Gel Extraction Kit. The DNA concentrations for each 
library of digested PCR‟s were measured using PicoGreen.  
 
The three libraries (S40* T41*, E165* G166* and K14*) were prepared by ligating 67.5 ng of 
NTR with 1.5 µg λ DNA vector (λJG3J1 stock was grown, purified and digested with Sfi I 
and Pac I by Dr Chris Guise and given as a generous gift for this work). See Figure 3.5 for a 
schematic of λJG3J1 vector. The ligation reaction was cleaned and concentrated by ethanol 
precipitation and resuspended in 2 µl T10E1. Resulting ligation products were packaged into 
phage particles using Stratagene Giga pack III gold packaging extract and plaque titres 
determined by plating out onto an E. coli UT5600 lawn.  
 
3.2.1.3 Library Amplification 
100 µl of each phage library stock was amplified by plate lysate and 4 ml of amplified stock 
was retrieved for each library.  
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Figure 3.5 Schematic diagram of λ phage construct λJG3J1 
Showing Sfi I and Pac I sites. The two Sfi I sites have non-matching 3 base pair sticky ends, thus ensuring that the inserts are in the correct 
orientation. A Pac I site sits between the two Sfi I sites and can be used as a failsafe. Any vector not digested with Sfi I will be Pac I digested 
preventing carryover of empty vector 
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3.3 RESULTS 
3.3.1 Validation of PCR mutagenesis 
For each library PCR fragments were determined by agarose gel electrophoresis (see Figure 
3.6). Bands of the correct size were the major products of each PCR reaction and were 
purified by gel purification.  
 
                                           
                                           M   1    2   3   4    5   6   7    8    9   10   11 12  13  14  15 
 
Figure 3.6 Agarose gel for PCR products from initial right and left end NTR PCR products and 
combined PCR’s  
Total PCR products amplified from NTR. PCR products were run on a 0.7% agarose gel. M = Marker 1 
kb plus ladder, Lanes 1-2 library S40/T41 left end PCR using alternative templates WT and N71S 
respectively (392 bp), Lane 3-4 library S40/T41 right end PCR using alternative templates WT and 
N71S respectively (715 bp) Lanes 5-6 combined PCR for library S40/T41 WT and N71S respectively 
(1093 bp). Lane 7-8 library E165/G166 left end PCR using alternative templates WT and N71S 
respectively (774 bp), Lane 9-10 library E165/G166 right end PCR using alternative templates WT and 
N71S respectively (342 bp) Lanes 11-12 combined PCR for library E165/G166 WT and N71S 
respectively (1093 bp). Lanes 13 library K14 left end PCR (324 bp), Lane 14 library K14 right end PCR 
(790 bp) and Lane 15 combined PCR for library K14 (1093 bp) 
 
 
 
 
 
  506 
3054 
  396 
1018 
1636 
2036 
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3.3.2 Preparation of PCR product for inserting in lambda vector 
The PCR fragments encoding libraries of full length mutant NTR genes were digested with Sfi 
I and the digestion products were resolved by agarose gel electrophoresis (see Figure 3.7).  
 
                                        
                                        M      1       2        3      4       5   
 
Figure 3.7 Agarose gel of Sfi I digested NTR PCR products 
PCR products were run on a 0.7% agarose gel. M = Marker 1 kb plus ladder, Lanes 1-2 Sfi I digested 
S40/T41 WT and N71S fragments. Lane 3-4 Sfi I digested E165/G166 WT and N71S fragments. 
Lanes 5 Sfi I digested K14 fragment. Two Sfi I sites cut for each fragment. Bands of the expected size 
were excised from a preparative gel. Digestion failed to go to completion as shown on the above gel, 
therefore the major 751 bp band containing NTR was purified prior to ligation into a lambda vector 
 
3.3.3 Insertion of PCR products into lambda vector 
The DNA concentration for each digested PCR was measured and 67.5 ng of each was ligated 
with 1.5 µg of λJG3J1 λ DNA vector (λJG3J1 stock was grown, purified and digested with Sfi 
I and Pac I by Dr Chris Guise and given as a generous gift for this work). See Figure 3.5 for a 
schematic of λJG3J1 vector. The resulting ligation reaction was cleaned by ethanol 
precipitation and resuspended in 2 µl T10E1.  
Input undigested fragment 
Fully Sfi I digested NTR fragment  
 
1018 
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1636 
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  396 
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3.3.4 Phage production and amplification 
The resulting ligation products were packaged into phage particles and plaque titres for each 
library were determined by plating out a series of 10-fold dilutions onto E. coli UT5600 cells. 
Phage yields were between 1.1 x 10
5
 – 3.5 x 105 (see Table 3.1). These yields range from 13-
5469 times greater than calculated numbers of possible nucleotide variants. Therefore each of 
the three small libraries should contain the majority of variants. However the process of 
generating bacterial lysogens from lambda phage, as required for selection method, is only 
1% efficient (the remainder of infected cells enter the lytic cycle. Therefore, in order to 
maintain maximum diversity when selecting from lysogens each library was amplified by 
plate lysate (100 µl of each phage library stock was amplified by making a plate lysate and 4 
ml of amplified stock retrieved), giving 8.4 x 10
8
 – 7.2 x 109 phage particles as shown in 
Table 3.1. 
 
Template Initial phage yield of 
independent clones 
(pfu total) 
Number of possible 
nucleotide variants  
Phage yield after 
amplification  
(pfu total) 
S40/T41 1.2 x 10
5
 8.2 x 10
3
 8.4 x 10
8
 
E165/G166 1.1 x 10
5
 8.2 x 10
3
 7.2 x 10
9
 
K14 3.5 x 10
5
 6.4 x 10
1
 1.7 x 10
9
 
 
Table 3.1 Initial phage yield of independent clones, number of possible nucleotide variants and 
phage yield after amplification by plate lysate 
 
 
PCR was used to check NTR presence, 5 phage plaques from each small library were 
analysed, using primers JG2A and JG2B. NTR presence is indicated by a band of 1093 bp and 
empty vector a band of 385 bp (see Figure 3.8). 
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                                                M    1    2    3    4    5    6    7    8    9   10   11  12   13  14  15 
 
Figure 3.8 Agarose gel of PCR products, for confirmation of NTR presence in individual clones 
from the three libraries 
Primers JG2A and JG2B were used for each PCR, the PCR products were run on 0.7% agarose gel. 
M = Marker 1 kb plus ladder, Lanes 1-5 S40/T41, Lanes 6-10 E165/G166 and Lanes 11-15 K14. NTR 
insert PCR‟s a band at 1093 bp and no NTR insert (empty vector) a band at 385 bp 
 
3.3.5 Selection 
1 x 10
8
 pfu of phage were infected into 2 x 10
8
 UT5600 cells to generate lysogens for 
selection. Kanamycin was used to select for lysogens. Aliquots of mid log culture were 
exposed to CB1954 for 15 minutes, diluted and pelleted before being resuspended in prodrug 
free media as described in Materials and Methods. Phage released after 1 hour were separated 
from lysogens by 0.2 µm filtration. See Figure 3.9 for a flow diagram of selection.  
 
 
Infect E. coli 
with λ library 
Select lysogens using 
Kanamycin 
Harvest released phage 
Liquid culture of lysogen library 
15 minutes CB1954 exposure  
         Analyse for NTR activity 
Figure 3.9 Flow diagram representing stages of selection 
Diagram adapted from Guise et al. 2007 
  506 
1018 
3054 
2036 
  396 
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The concentration of CB1954 prodrug required for effective selection of each library was hard 
to predict. Guise et al. 2007 examined the prodrug dose required to activate lysogens into 
lytic cycle. It was found that too low a concentration of prodrug gave no selection. However if 
too high a concentration was used the most improved mutants were not selected. See Figure 
2b Guise et al. 2007 for further details. Several concentrations of CB1954 prodrug were used 
in parallel for selection in order to allow comparison of the effect of selection at different 
prodrug concentrations. The best conditions for each library after three rounds of selection 
were examined further by testing individual clones for CB1954 sensitivity.  Clones with the 
most sensitivity were sequenced and IC50 assays used to determine the concentration of 
CB1954 required for 50% reduction in plating efficiency. Results for each library are 
discussed below.  
 
3.3.6 Library S40*/T41* ± N71S 
3.3.6.1 Monitoring population sensitivity of the library under selection 
The effect of selection was monitored using lysogen colony forming assays. Mid log 
lysogenic cultures were split into four parallel aliquots and exposed to 0, 100, 200 and 300 
µM CB1954. After three rounds of selection with no CB1954 almost all of the lysogens were 
resistant when plated out on agar plates containing CB1954 up to a concentration of 200 μM. 
Therefore the vast majority of lysogens were less sensitive than wild type; with wild type 
NTR having an IC50 of 150 μM.  
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After three rounds of selection using 100 μM CB1954, colony forming efficiency was just 
below 50% at 25 μM CB1954, dropping further to approximately 30% at 150-200 μM. This 
shows enrichment of improved prodrug sensitive clones to about 50% of the selected library, 
while the remainder were relatively insensitive. After selection with 200 μM and 300 μM 
CB1954, a reduction in colony forming efficiency was seen relative to the library selected 
with no CB1954, but to a lesser extent than selection at 100 μM CB1954 (see Figure 3.10).  
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Figure 3.10 Dose Response curves for colony forming assay for S40*/T41* ± N71S library in E. 
coli UT5600 
After three rounds of selection with 0, 100, 200 and 300 µM CB1954, mid log lysogenic cultures of the 
whole library were plated out onto agar plates containing a range of CB1954 concentrations. The 
colonies were counted after overnight growth and the number compared to colony growth on plates 
with no prodrug. No CB1954 selection (black), 100 µM CB1954 selection (red), 200 µM selection 
(blue) and 300 µM selection (green) 
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3.3.6.2 Screening CB1954 sensitivity of individual clones from selected library 
180 individual lysogen colonies were picked from the library following selection with 100 
µM CB1954. Individual cultures were grow overnight in 96 well plates and replica plated 
onto agar plates containing a range of CB1954 concentrations up to 200 µM. All lambda 
lysogens showed strong growth in the absence of CB1954. Two lysogens disappeared at 25 
μM showing sensitivity to this concentration, thirty one at 35 μM, twelve at 50 μM, fourteen 
at 100 μM and a further eight at 200 μM. The remaining lysogens were not sensitive to the 
highest CB1954 concentration (see Figure 3.11). 
 
The NTR genes from sixty seven lysogens that were unable to grow at low CB1954 
concentrations were sequenced. Seventeen different amino acid changes were observed as 
well as many silent mutations. Table 3.2 shows these amino acid changes and details of their 
codon usage. Fifty two of the sequenced NTR genes had amino acid substitutions only at 
targeted residues, leaving fifteen NTR genes with one or more amino acid substitutions at 
non-targeted residues. 
 
IC50 assays were used to determine the concentration of CB1954 required for 50% reduction 
in plating efficiency. This assay is more stringent than replica plating, showing the survival of 
individual bacteria. IC50 assays are quantitative with individual colonies being counted as 
opposed to just scoring the presence or absence of bacterial growth for a mass of bacterial 
cells. A single IC50 assay was performed for a single representive clone for each of the 
thirteen amino acid sequences. Low IC50 values indicate a greater sensitivity to CB1954 due 
to either more efficient catalysis of CB1954 activation or higher levels of NTR enzyme 
expression.  
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N71S and WT were the starting points for this library; these have IC50 values of 62 μM and 
150 μM CB1954 respectively. Nine mutants had IC50 values less than 25 μM. The most 
sensitive mutant was T41G N71S (IC50 value 8 μM) followed by T41L N71S (IC50 value 14 
μM) (see Figure 3.12 and Table 3.2). 
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Figure 3.11 Replica plating of individual lysogens after three rounds of selection using 100 μM 
CB1954 for the S40*/T41* ± N71S library 
Individual lysogen colonies were picked and grown overnight in 96 well plates and replica plated onto 
agar plates containing a range of CB1954 concentrations. Following overnight growth each mass of 
bacterial cells were scored as present or absent at each CB1954 concentration. CB1954 
concentrations of 0 μM, 25 μM, 35 μM, 50 μM, 100 μM and 200 μM concentrations were used. The 
first three lysogens on top left of each plate are controls WT, F124N and T41L N71S respectively. Red 
circles indicate the lowest concentration at which growth was absent   
 No CB1954 
25 µM 
35 µM 
50 µM 
 100 µM 
 200 µM 
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Amino acid substitution Codon Usage Number of 
mutants  
Replica Plating  
Prodrug susceptibility 
(µM CB1954) 
IC50 
Prodrug susceptibility 
(µM CB1954) 
T41L  N71S L = CTT (22) L = TTA (3) L = CTC (1) 26 35-50 14 
N71S S = AGT 14 100 62 
T41G  N71S G = GGA (1) G = GGT (2) 3 25 8 
S40T T41L N71S T = ACG L = CTA (1) T = ACC L = CTT (2) 3 35 17 
T41I N71S I = ATT (1) I = ATA (2) 3 50 24 
T41N  N71S N = AAT (1) N = AAC (1) 2 35 14 
T41N N71S E197K N = AAT K = AAA 2 35-50 18 
N71S F124L L = CTC 2 35 24 
T41Q V69A N71S Q = CAA A = GCA 2 35-50 16 
S43A N71S A = GCC 2 100 54 
N71S K119E E = GAA 2 100 65 
T41L S43A N71S L = CTT A = GCC 1 35 14 
T41Q N71S Q = CAG 1 35 21 
T41H S43A N71S H = CAC A = GCC  1 50 38 
S40T T41L V69L N71S T = ACA L = CTC L = CTG 1 100 45 
K9N N71S N = AAC 1 100 - 
E55V N71S V93I V = GTA I = ATC 1 100 - 
 
 
Table 3.2 Summary of NTR mutants isolated for the S40*/T41* ± N71S library  
Shown are the amino acid substitution in each NTR clone, the codon usage, the number of mutants that had each mutation, prodrug susceptibility based on 
replica plating indicating the lowest concentration of CB1954 required to prevent growth of an individual clone and IC50 assay indicating the lowest 
concentration of CB1954 required for a 50% reduction in colony growth. All sequenced NTR‟s had AGT at residue N71 which corresponds with the original 
start template. Targeted amino acid substitutions are shown in black and non-targeted amino acid substitutions in blue  
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Figure 3.12 CB1954 IC50 assays of selected lysogens from S40*/T41* ± N71S library in UT5600 
cells  
Lysogenic cultures of individual clones were spread onto agar plates containing a range of CB1954 
concentrations. The number of colonies were counted after overnight growth and compared to colony 
growth on plates with no prodrug. T41G N71S (red), T41L N71S (purple), T41N N71S (brown), T41Q 
V96A N71S (orange), S40T T41L N71S (blue), T41N N71S E197K (pink), T41Q N71S (dark green), 
T41I N71S (grey), N71S F124L (dark blue), T41H S43A N71S (cyan), S43A N71S (yellow), N71S 
(green), WT (black) (a) shows detail T41H S43A N7S, N71S, S43A N71S and WT (b) shows detail 
T41G N71S, T41L N71S, T41N N71S, T41Q V96A N71S, S40T T41L N71S, T41N N71S E197K, 
T41Q N71S, T41I N71S, N71S F124L 
 
(a) 
(b) 
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3.3.7 Library E165*/G166* ± N71S 
3.3.7.1 Monitoring population sensitivity of the library under selection 
As with the previous library the effect of selection was monitored using lysogen colony 
forming assays. Three rounds of selection were performed using 100 µM, 200 µM and 300 
µM CB1954 and with no CB1954 as a control. After three rounds of selection with no 
CB1954 almost all of the lysogens were resistant when plated out on agar plates containing 
CB1954 up to a concentration of 200 μM.  
 
After three rounds of selection with 100 μM CB1954 25% of the lysogenic library were 
sensitive to 125 μM CB1954, showing some enrichment for active NTR‟s. After selection 
with 200 μM CB1954 10% of the library was sensitive to 125 μM CB1954 showing an 
intermediate level of enrichment. Selection with 300 μM CB1954 showed no enrichment of 
the library with most lysogens still resistant to 200 μM CB1954 (see Figure 3.1). 
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Figure 3.13 Dose Response curves for colony forming assay for E165*/G166* ± N71S library in 
UT5600 cells  
After three rounds of selection with 0, 100, 200 and 300 µM CB1954, mid log lysogenic cultures of the 
whole library were plated out onto agar plates containing a range of CB1954 concentrations. The 
number of colonies were counted after overnight growth and compared to colony growth on plates with 
no prodrug. No CB1954 selection (black), 100 µM CB1954 selection (red), 200 µM selection (blue) 
and 300 µM selection (green) 
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3.3.7.2 Screening CB1954 sensitivity of individual clones from selected library 
180 individual lysogen colonies were picked from the library after three rounds of selection 
with 100 µM CB1954. Individual cultures were grown overnight in 96 well plates and replica 
plated onto agar plates containing a range of CB1954 concentrations up to 200 µM. All the 
lambda lysogens tested showed strong growth in the absence of CB1954 and at CB1954 
concentrations of 25 μM and 35 μM. One lysogen disappeared at 50 μM showing sensitivity 
to this concentration, twelve at 100 μM and forty six at 200 μM. The remaining lysogens were 
not sensitive to the highest CB1954 concentration (see Figure 3.14). 
 
The NTR genes from fifty nine lysogens that failed to grow between 50-200 μM CB1954 
were sequenced. No mutations were seen at either residue 165 or 166. The vast majority of 
NTR genes had either no mutation (being WT) or a single mutation at N71 to serine which 
was the starting templates. Seven other random mutants were observed, only one of these 
N71S A125T showed any improvement relative to N71S and WT (see Table 3.3).  
 
An IC50 assay was performed for mutant N71S A125T. WT and N71S are also demonstrated 
for comparison (see Figure 3.15 and Table 3.3). 
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Figure 3.14 Replica plating of individual lysogens after three rounds of selection using 100 μM 
CB1954 for E165*/G166* ± N71S library 
Individual lysogen colonies were picked and grown overnight in 96 well plates and replica plated onto 
agar plates containing a range of CB1954 concentrations. Following overnight growth each mass of 
bacterial cells were scored as present or absent at each CB1954 concentration. CB1954 
concentrations of 0 μM, 25 μM, 35 μM, 50 μM, 100 μM and 200 μM concentrations were used. The 
first three lysogens on top left of each plate are controls WT, F124N and T41L N71S respectively. Red 
circles indicate the lowest concentration at which growth was absent   
  No CB1954 
25 µM 
35 µM 
50 µM 
 100 µM 
 200 µM 
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Amino acid substitution Codon Usage Number of mutants  Replica Plating  
Prodrug susceptibility 
(µM CB1954) 
IC50 
Prodrug susceptibility 
(µM CB1954) 
WT - 31 200 150 
N71S S = AGT 20 100 62 
T13A A = GCT 2 100 - 
N71S A125T T = ACT 1 50 18 
P111S S = TCG 1 100 - 
H194R R = CGC 1 100 - 
Y69H H = CAC 1 200 - 
F70S N71S R = CGC S = TCC   1 200 - 
K21R R = AGA 1 200 - 
Table 3.3 Summary of NTR mutants isolated for E165*/G166* ± N71S library 
Shown are the amino acid substitution in each NTR clone, the codon usage, the number of mutants that had each mutation, prodrug 
susceptibility by replica plating indicating the lowest concentration of CB1954 required to prevent growth of an individual clone and IC50 assay 
indicating the lowest concentration of CB1954 required for a 50% reduction in colony growth. Targeted amino acid substitutions are shown in 
black and non-targeted amino acid substitutions in blue 
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Figure 3.15 CB1954 IC50 assays of selected lysogens from E165*/G166* ± N71S library in 
UT5600 cells  
Lysogenic cultures of individual clones were spread onto agar plates containing a range of CB1954 
concentrations. The number of colonies were counted after overnight growth and compared to colony 
growth on plates with no prodrug. N71S A125T (orange), N71S (green) and WT (black) 
 
 
3.3.8 Library K14* 
3.3.8.1 Monitoring population sensitivity of the library under selection 
The K14* library was also monitored using lysogen colony forming assays. Following three 
rounds of selection with no CB1954 almost all of the lysogens were resistant when plated out 
on agar plates containing CB1954 up to a concentration of 200 μM.  
 
After three rounds of selection with 100 μM CB1954 no enrichment of the library was 
observed with most lysogens resistant to 200 μM CB1954. However after selection with 200 
μM CB1954 25% of the library was sensitive to 175 μM CB1954 and with 300 μM CB1954 
15% of the library was sensitive to 175 μM (see Figure 3.16). 
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Figure 3.16 Dose Response curves for colony forming assay for K14* library in UT5600 cells  
After three rounds of selection with 0, 100, 200 and 300 µM CB1954, mid log lysogenic cultures of the 
whole library were plated out onto agar plates containing a range of CB1954 concentrations. The 
number of colonies were counted after overnight growth and compared to colony growth on plates with 
no prodrug. No CB1954 selection (black), 100 µM CB1954 selection (red), 200 µM selection (blue) 
and 300 µM selection (green) 
 
 
3.3.8.2 Screening CB1954 sensitivity of individual clones from selected library 
180 individual lysogen colonies were picked from the library after three rounds of selection 
with 200 µM CB1954. Individual cultures were grow overnight in 96 well plates and replica 
plated onto agar plates containing a range of CB1954 concentrations up to 200 µM. All 
lambda lysogens showed strong growth in the absence of CB1954 and at CB1954 
concentrations of 25 μM, 35 μM and 50 μM. One lysogen disappeared at 100 μM showing 
sensitivity to this concentration and twenty eight at 200 μM. The remaining lysogens were not 
sensitive to the highest CB1954 concentration tested (see Figure 3.17). 
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The NTR genes from twenty eight lysogens that failed to grow between 100-200 μM CB1954 
were sequenced. Seven mutants showed substitutions at residue K14. Two were stop codons 
and five had additions at a residue downstream resulting in a frame-shift. Many silent 
mutations were seen, along with a few other random mutations. None of the mutations 
sequenced gave any distinctive advantage over WT (see Table 3.4). 
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Figure 3.17 Replica plating of individual lysogens after three rounds of selection using 200 μM 
CB1954 for K14* library 
Individual lysogen colonies were picked and grow overnight in 96 well plates and replica plated onto 
agar plates containing a range of CB1954 concentrations. Following overnight growth each mass of 
bacterial cells were scored as present or absent at each CB1954 concentration. CB1954 
concentration 0 μM, 25 μM, 35 μM, 50 μM, 100 μM and 200 μM concentrations were used. The first 
three lysogens on top left of each plate are controls WT, F124N and T41L N71S respectively. Red 
circles indicate the lowest concentration at which growth was absent   
 
  No CB1954 
25 µM 
35 µM 
50 µM 
 100 µM 
 200 µM 
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Amino acid substitution Codon Usage Number of mutants  Replica Plating  
Prodrug susceptibility 
(µM CB1954) 
K14 A86 K = AAA  A = GCG 13 200 
K14 STOP STOP = TAA 2 200 
K14R ADDITION AT P24 R = CGG 3 200 
K14 A65T K = AAA  T = ACC 3 100-200 
A86 A = GCG 2 200 
K14R ADDITION AT P24 A64 R = CGG A = GCC 2 200 
V6 A7R K14 A86 V = GTG R = CGC K = AAA A = GCG 1 200 
K14 A15P A86 K = AAA P = CCA  A = GCG 1 200 
WT - 1 200 
Table 3.4 Summary of NTR mutants isolated for K14* library 
Shown are the amino acid substitution in each NTR clone, the codon usage, the number of mutants that had each mutation and prodrug susceptibility 
by replica plating indicating the lowest concentration of CB1954 required to prevent growth of an individual clone. Targeted amino acids are shown in 
black, single frame-shift additions in red, stop codons in pink and non-targeted amino acids in blue 
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3.4 DISCUSSION 
The basis for this chapter was to generate NTR mutants with improved catalysis for the 
prodrug CB1954. A PCR based method was utilised for the generation of three small libraries 
of NTR mutants, where NNN was inserted at each codon targeted for mutation. This allowed 
complete randomisation, giving all possible codon changes. The PCR products were then 
cloned into lambda vectors and put through three rounds of selection at three different 
CB1954 concentrations. Individual clones from the selected phage libraries were analysed for 
their sensitivity to CB1954, and sequenced to determine any changes in the encoded amino 
acid. 
 
3.4.1 Library S40*/ T41* ± N71S 
This library was cloned and put through three rounds of selection. Colony forming assays 
showed that selection with 100 μM CB1954 gave best enrichment of this library. 180 
lysogens were replica plated onto agar plates containing a range of CB1954 concentrations. 
The best sixty seven lysogens were sequenced. Seventeen amino acid changes were 
determined and there codon usages shown. Only four of the lysogens analysed had amino acid 
substitutions at residue S40. In all four the lysogen serine was changed conservatively to 
threonine, and all the S40T substitutions also had mutations at T41. At residue T41, forty five 
lysogens had amino acid substitutions. By far the most abundant was T41L N71S with twenty 
six mutants giving this amino acid combination. Several clones were N71S alone with no 
mutations at residues S40 or T41. A few random mutations at other residues were also 
observed.   
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The codon usage for each residue was examined. As previously discussed only four lysogens 
had mutation at residue S40. All four encoded S40T. There are four codons for threonine; 
three were seen (ACG, ACA and ACC). A further thirteen lysogens sequenced had silent 
mutations at residue S40. There are six codons for serine four of which were seen (TCA, 
TCT, TCC and AGT).  
 
Forty six lysogens sequenced had mutations at T41. Three lysogens had silent mutations, one 
for each of the other three threonine encoding residues (ACA, ACG and ACT). Twenty nine 
had leucine at this residue. Six codons encode leucine, four of which were observed (CTA, 
CTT, CTC and TTA). By far the most frequent leucine codon seen was CTT which accounted 
for twenty two out of the twenty nine lysogens. Four mutants encoded asparagine; both 
codons were observed (AAC and AAT). A further three encoded glutamine; again both 
codons were observed (CAA and CAG). Three had glycine; two of the four codons were seen 
(GGA and GGT). A further three encoded isoleucine; two of the three codons were present 
(ATT and ATA). Finally one encoded histidine (CAC). The diversity of synonymous codons 
recovered helps confirm the sequence diversity of the starting library. However the strong 
preference for the leucine codon CTT could indicate a non-random library. Research by 
Maloy et al has shown that E. coli bacteria has a preference for the leucine codon CTG with 
55% of residues being this codon, as opposed to CTT with 10% of residues using this codon 
(Maloy et al. 1996). CTG was not shown by any of the sequenced lysogens at residue T41. 
Codon preference clearly fails to account for CTT being most abundant. 
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Several mutants recovered had mutations at non-planned residues. In all but one case a single 
base substitution resulted in the change in amino acid. These would have been introduced by 
error-prone PCR, due to the use of Taq DNA polymerase. It has been possible to determine 
the location of unexpected residues relative to the active site by examining NTR‟s 3D crystal 
structure. Table 3.5 shows some of the unexpected residues, what affect each specific 
mutations has on CB1954 activation and there location with NTR‟s 3D crystal structure. Two 
residues were of particular interest F124 and S43. Residue F124-HAs previously been 
extensively examined (Grove et al. 2003) with 15 amino acid changes showing improvement 
relative to phenylalanine. This residue is located within the active site. Phenylalanine is a 
bulky amino acid that obstructs the active site making it more difficult for CB1954 to bind. 
Changing phenylalanine to a smaller amino acid such as leucine opens up the space allowing 
easier binding of the substrate. Residue S43 is also located within the active site. Although 
serine is a small residue alanine is even smaller being the smallest amino acid possible. This 
slight shift in amino acid size, could allowing better access for the prodrug CB1954. However 
when the residue T41 has also been mutated alanine mutation at S43 no longer has an effect. 
It appears that a mutation at T41 allows optimum confirmation in this region, with neither 
mutations at residues S40 nor an S43A mutation having a positive effect.  
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Unexpected mutation Context Deduced consequence of 
untargeted mutation 
Comment 
E197K T41N N71S E197K 1.3 fold increase in IC50 Surface residue not expected to improve CB1954 binding 
K119E N71S K199E  1.0 fold increase in IC50 Surface residue not expected to improve CB1954 binding  
S43A S43A N71S 
T41L S43A N71S  
1.2 fold decrease in IC50 
No difference 
Residue S43 is located within the active site. Serine is a small 
amino acid, however alanine is even smaller. This slight shift in 
size may allow better access for the prodrug CB1954. However 
when the residue T41 has also been mutated a mutation to S43A 
no longer has an effect 
V69A/L T41Q V69A N71S  
S40T T41L V69L N71S  
1.3 fold decrease in IC50 
2.7 fold increase in IC50 
Surface residue not expected to improve CB1954 binding 
 
F124L N71S F124L 2.6 fold decrease in IC50 Residue F124 is located within the active site. Phenylalanine is a 
bulky amino acid; smaller amino acids such as leucine allows 
more binding space 
Table 3.5 Summary of unexpected mutations seen for S40*/T41* library  
Shown are unexpected mutations, the context they were seen in, what consequence was deduced from examining the untargeted mutations and any 
comments. A decrease in IC50 indicates increased CB1954 activation; where as an increase in IC50 indicates decreased CB1954 activation 
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IC50 values were determined for each mutant; with T41G N71S being the best mutant isolated 
having an IC50 of 8 μM. The most abundant mutation seen was T41L N71S; this mutant has 
been seen in previous studies and has an IC50 of 14 μM. T41N N71S was also a good mutant 
with an IC50 virtually identical to T41L N71S. S40T T41L N71S had an IC50 of 17 μM; this 
indicates that the mutation of residue S40 to threonine was slightly detrimental with the IC50 
increasing by 3 μM.  
 
Mutations to E197K, K119E and V69L were also detrimental with T41N N71S E197K 
having an IC50 of 18 μM, 4 μM higher than T41N N71S. N71S K119E had an IC50 of 65 μM, 
3 μM higher than N71S and S40T T41L V69L N71S having an IC50 of 45 μM, 28 μM higher 
than S40T T41L N71S. Alternatively a mutation at residue V96 to alanine gave an 
improvement in combination with T41 and N71S, with T41Q V69A N71S having an IC50 of 
16 μM and T41Q N71S having an IC50 of 21 μM. This is also the case with S43A N71S 
improving the IC50 by 8 μM compared to N71S alone. However when in combination with 
T41L and N71S no improvement was seen with the IC50 remaining at 14 μM. T41H S43A 
N71S is also found within this library however it is not possible to determine what effect 
S43A has on this mutant as T41H N71S wasn‟t observed. Finally the mutant N71S F124L has 
an IC50 of 24 μM which is lower than N71S at 62 μM and F124L at 40 μM (Grove et al. 
2003). 
 
 
 137 
In conclusion most mutants analysed did not have mutations at both targeted S40 and T41 
positions. Therefore it is possible to conclude that S40 and T41 mutations do not tend to work 
well together when in combination with N71S. There was a good distribution of mutants with 
a number of improved mutations achieved at residue T41. T41G N71S was the best mutant 
determined from this library and is a very promising new mutant, which will be tested further 
in chapters 5 and 6.  
 
3.4.2 Library E165* /G166* ± N71S 
This library was cloned and put through three rounds of selection. Colony forming assays 
showed that selection at 100 μM CB1954 gave greatest enrichment of this library. 180 
lysogens were replica plated onto agar plates containing a range of CB1954 concentrations. 
The best fifty nine lysogens were sequenced. Only WT and N71S mutants were found as well 
as a few random mutations. An IC50 assay was performed for lysogen N71S A125T and an 
IC50 value of 18 μM determined. 
 
Previous work indicated that all single amino acid substitutions at E165 or G166 were 
detrimental to CB1954 activation and this work indicates that no combination of substitutions 
at these two sites can allow efficient CB1954 activation. One random mutation at a non-
targeted site was obtained (A125T in the mutant N71S A125T), which appeared improved 
relative to N71S. N71S A125T is an intriguing mutant, which will be tested further in 
chapters 5 and 6.  
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3.4.3 Library K14* 
This library was cloned and put through three rounds of selection. Colony forming assays 
showed that selection at 200 μM CB1954 gave greatest enrichment. 180 lysogens were replica 
plated onto agar plates containing a range of CB1954 concentrations. The best twenty nine 
lysogens were sequenced. Only silent mutations were found at residue K14. No IC50 assays 
were performed as no improved mutants were observed. 
 
It is possible to conclude that all single amino acid substitutions at residue K14 were 
detrimental to CB1954 activation. This correlates with the observation that lysine FMN 
contact is highly conserved in many FMN flavoproteins. The mutation of some lysine 
residues in FMN-containing flavoproteins has greatly diminished FMN binding (Watanabe et 
al. 1998).  
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CHAPTER 4: GENERATION AND CB1954 
PRODRUG SELECTION OF A LARGE LIBRARY OF 
NTR MUTANTS 
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4.1 INTRODUCTION  
Previous work has indicated that the efficiency of CB1954 activation by NTR can be 
progressively improved by specific changes at 1, 2 and 3 amino acid residues surrounding the 
active site (Grove et al. 2003, Guise et al. 2007, Jaberipour et al. 2010 and chapter 3 from this 
thesis). The selection method developed by Guise et al and used in chapter 3 potentially 
allows the isolation of rare improved mutants from even larger libraries (Guise et al. 2007). 
The aim of this chapter was to apply the selection method to a library containing mutations at 
six residues around the active site and to determine whether still further optimised NTR 
mutants could be isolated. 
 
A single large library was constructed by a PCR based method combining mutations at T41, 
N71, R121, F123, F124 and A125. Limited amino acid diversity was incorporated at T41 and 
N71 with complete randomisation of amino acids at residues R121, F123, F124 and A125. 
Throughout this chapter * denotes any codon which has been mutated to encode any amino 
acid (eg: F124*). Residues T41, N71 and F124 have previously been found to be important 
for the catalytic improvement of NTR. T41L N71S, T41N N71S, T41Q N71S and T41G 
N71S double mutants were highly beneficial for the reduction of CB1954 therefore these have 
been used as starting points for this library as well as WT and N71S. Many amino acid 
changes at F124 have been shown to greatly improve NTR catalysis by allowing greater 
accessibility to the active site. Inspection of the structure suggests changes to residues around 
F124 could further improve CB1954 catalysis. A precedent has already been set by a mutation 
at A125, which showed good improvement over WT when combined with N71S. See Figure 
3.15 for IC50 curves comparing N71S A125T with N71S and WT NTR.  
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A PDB image showing each residue for mutation is shown in Figure 4.1 
 
     
Figure 4.1 Relative positions of residues T41, N71, R121, F123, F124 and A125 in the active site 
cavity of WT NTR enzyme 
The structures shown are of the NTR/nicotinic acid complex. The FMN cofactor, nicotinic acid ligand 
and selected residues are represented in stick form. This image was created from the 1ICR crystal 
structure using SWISS PDB Viewer 4.0.1 and rendered in Pov-Ray V3.6.  
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The three small libraries used in chapter 3 contained a theoretical maximum diversity of 6.4 x 
10
1 
(64 alternatives at K14), 8.2 x 10
3
 ([2 alternative start templates] x [64 alternatives at S40] 
x [64 alternatives at T41]) and 8.2 x 10
3
 ([2 alternative start templates] x [64 alternatives at 
E165] x [64 alternatives at G166]) different nucleotide sequences including stop codons. The 
large library selected by Guise et al contained a theoretical maximum diversity of 1.1 x 10
6
 
([64 alternatives at T41] x [64 alternatives at N71] x [64 alternatives at F124]) + ([64 
alternatives at T41] x [64 alternatives at F70] x [64 alternatives at F124]) + ([64 alternatives at 
S40] x [64 alternatives at N71] x [64 alternatives at F124]) + ([64 alternatives at S40] x [64 
alternatives at F70] x [64 alternatives at F124]) disregarding any possible additional random 
mutations that may arise from the error prone PCR process. However the library generated 
was somewhat smaller than this, with just 6.8 x 10
5
 independent clones (Guise et al. 2007). In 
these previous libraries NNN was incorporated at completely randomised codons however 
due to the redundancy of the genetic code all possible amino acids can be represented by 
mutant oligos containing NNS with S being either a C or G. This allowed the reduction of 
codons from 64 to 32, allowing more residues to be analysed without a big increase to the 
overall size of the library. Theoretically the large library for this chapter had a maximum 
diversity of 6.3 x 10
6
 possible nucleotide combinations ([6 alternatives start templates] x [32 
alternatives at R121] x [32 alternatives at F123] x [32 alternatives at F124] x [32 alternatives 
at A125]. This equates to 9.6 x 10
5
 amino acid combinations and 5.5 x 10
5
 full length 
encoding proteins.  
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It previously took three rounds to successfully select the S40/T41 ± N71S small library (see 
chapter 3). Guise et al found that with his large library the best mutants were progressively 
enriched through ten cycles of selection (Guise et al. 2007). It was therefore anticipated that 
10-20 cycles of selection might be required for this library.   
 
4.2 MATERIALS AND METHODS 
4.2.1 Library Construction 
4.2.1.1 PCR mutagenesis  
The limited diversity at residues T41 and N71 was achieved by using six different templates 
for PCR, containing WT NTR and the mutants N71S, T41N N71S, T41L N71S, T41G N71S 
and T41Q N71S. λ lysogens for each were streaked onto LB plates containing a fresh lawn of 
E. coli UT5600. Resulting lysis areas were picked with a tip and used as templates for PCR 
mutagenesis using Taq DNA polymerase. 
 
As before, mutations were introduced via PCR primers used to amplify overlapping left and 
right ends of the NTR gene. Randomisation at residues R121, F123, F124 and A125 was 
achieved using the degenerate PCR primer SH33B (see Figure 4.2). Resulting PCR products 
were resolved by agarose gel electrophoresis to ensure DNA fragments of the correct size 
were amplified. PCR products of the correct size were purified using Roche High Pure PCR 
Product Purification Kit.  
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Left and right ends were subsequently combined in a second PCR reaction using flanking 
primers (see Figure 4.3). A total of 50 ng of DNA was used at a 1:1 molar ratio of left and 
right ends. Full length PCR products were resolved by agarose gel electrophoresis to ensure 
DNA fragments of the correct size were amplified and purified using Qiagen QIA-Quick Gel 
Extraction Kit. 
 
10 µl of each PCR product was sequenced to check the diversity of nucleotides at targeted 
codons.  
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Figure 4.2 Schematic of primers SH33B and SH33A  
Degenerate primer SH33B was used to randomise residues R121, F123, F124 and A125. Primer SH33A overlaps with SH33B allowing the joining of 
resulting PCR fragments. Residue to be mutated are highlighted in blue on WT template and mutagenic residues are highlighted in red on the SH33B 
degenerate primer 
5’ CCGGAAGCGAAAGCCGCGAACGATAAAGGTCGCAAGTTCTTCGCTGATATGCACCGTAAAGATCTGCATGATGATGCAG  3’ 
3’ GGCCTTCGCTTTCGGCGCTTGCTATTTCCAGCGTTCAAGAAGCGACTATACGTGGCATTTCTAGACCTACTACTACGTC  5’ 
 
   3’  CGCTTTCGGCGCTTGCTATTTCCANNSTTCNNSNNSNNSCTATACGTGGCATTTCTAGACGTACTAC  5’    
Region of homology with  
template to ensure PCR priming 
Mutagenic region Overlap with other primer  
to allow combined PCR 
WT TEMPLATE 
SH33A 
SH33B 
5’  ATGCACCGTAAAGATCTGCATGATG  3’  
 146 
 
Figure 4.3 Schematic of degenerate PCR’s making left and right ends of NTR gene and joining 
together by combined PCR’s 
Degenerate primer SH33B was used to randomise residues R121, F123, F124 and A125. Left end 
fragment made using primers JG2A and SH33B gave a fragment size of 654 bp and the right hand 
fragment made using primers SH33A and JG2B gave a fragment size of 463 bp. Primers SH33A and 
SH33B overlap by 25 non-degenerate nucleotides, allowing the left and right fragments to be joined in 
a second PCR step using the flanking JG2A and JG2B. Note this schematic is not to scale
SH33B 
  NTR TEMPLATES  
  (WT, N71S, T41N N71S, T41L N71S, T41G N71S and T41Q N71S) 
Sfi I 
R121 F123 F124 A125 
Initial PCR‟s 
Sfi I 
Combined PCR‟s 
 WT         WT 
T41L      N71S 
T41N 
T41G 
T41Q 
R121* F123* F124* A125* Left end 
Right end 
 WT        WT 
T41L     N71S 
T41N 
T41G 
T41Q 
JG2A 
JG2B 
NTR GENE 
SH33A 
 WT         WT 
T41L      N71S 
T41N 
T41G 
T41Q 
Sfi I 
R121* F123* F124* A125* 
Sfi I NTR GENE 
JG2A 
JG2B 
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4.2.1.2 Insertion of NTR PCR products into lambda vector 
PCR fragments encoding libraries of full length mutant NTR genes were digested with Sfi I 
restriction enzyme and the digestion products were resolved by agarose gel electrophoresis. 
NTR genes of 751 bp were excised from a preparative agarose gel and purified using Qiagen 
QIA-Quick Gel Extraction Kit.  The DNA concentration for each digested PCR was measured 
using PicoGreen.  
 
Fresh stocks of λJG3J1 and λSV054 DNA vectors were grown and purified using PEG 
precipitation to separate λ phage from the bacterial culture, followed by CsCl density gradient 
centrifugation. This was based on Sambrook method (Sambrook 1989). Resulting λ DNA 
preparations were digested with restriction enzyme Sfi I before being treated with Calf 
Alkaline Phosphatase to prevent self ligation. 
 
Initial small test sub-libraries were prepared by ligating the NTR fragment library with λ 
DNA and packaged into phage particles. Individual plaques were analysed by PCR to 
determine the proportion containing NTR insert, to original template ratios. 
 
Once optimised each template sub-library (starting from the templates WT, N71S, T41L 
N71S, T41G N71S, T41N N71S and T41Q N71S) was prepared by ligating 28 ng of NTR 
sub-library with 1400 ng λ DNA. The ligation reaction was cleaned and concentrated by 
ethanol precipitation and resuspended in 2 µl T10E1. Resulting ligation products were 
packaged into phage particles using Stratagene Giga pack III gold packaging extract. Plaque 
titres were determined by plating out onto an E. coli UT5600 lawn.  
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4.2.1.3 Library Amplification 
3 x 10
6
 - 5 x 10
6
 pfu of phage stock for each sub-library was amplified by liquid culture or 
plate lysate. In some experiments, the UT5600 used for amplification had been previously 
transformed with pET 24b, to increase the level of the Lac I repressor in the cells. 4-7 ml of 
amplified stock was retrieved. Plaque titres after amplification for each sub-library were 
determined by plating out onto an E. coli UT5600 lawn. 
 
4.2.1.4 Experiments to test the effects of Lac I over-expression on CB1954 
sensitivity of lysogens 
 
E. coli bacteria C600 and UT5600, were transformed with the Lac I expressing plasmids pET 
15b and pET 21b (see Figures 4.4 and 4.5). Lysogens generated using C600 and UT5600 Lac 
I over-expressing strains were constructed as described in Chapter 2 Materials and Methods. 
Lac I and NTR expression for each bacterial cell line was determined by western blotting. 
Amplification of a mixed population of phage was used to determine if Lac I over-expression 
could reduce preferential growth of empty vector phage. The sensitivity of F124N lysogens 
were determined by colony forming efficiency and phage release when exposed to a range of 
concentrations of CB1954. 
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 Figure 4.4 Schematic of plasmid vector pET 15b map encoding lac I gene from Novagen 
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Figure 4.5 Schematic of plasmid vector pET 21b map encoding lac I gene from Novagen 
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4.3 RESULTS 
4.3.1 Validation of PCR mutagenesis 
Agarose gel electrophoresis was used to ensure DNA fragments of the correct size were 
amplified.  Bands of the correct size were the major products of each PCR reaction, although 
additional bands were present in the unpurified reactions (see Figure 4.6a). All the additional 
bands were effectively removed by the gel purification (see Figure 4.6b). 
                                         
                                                                                        
  M   1   2   3    4    5   6   7   8   9  10  11 12 13                                   M   1   2   3   4   5   6   7  8   9  10  11 12 13 
 
Figure 4.6 Agarose gel for PCR products from initial right and left end NTR PCR products and 
combined PCR’s 
a) Example of total PCR products from NTR PCR, b) Examples of PCR products after clean up by gel 
extraction. PCR products were run on a 0.7% agarose gel. M = Marker 1 kb plus ladder, Lanes 1-6 
Left End PCR‟s using the alternate templates WT, N71S, T41L N71S, T41N N71S, T41G N71S and 
T41Q N71S respectively (654 bp), Lane 7 Right End (463 bp), Lanes 8-13 combined PCR‟s WT, 
N71S, T41L N71S, T41N N71S, T41G N71S and T41Q N71S respectively (1093 bp) 
 
 
 
 
 
  2036 
   506 
  3054 
   396 
  1018 
  1636 
  a)                                                                                                         b) 
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After the second PCR step to combine left and right end into full length NTR, resulting PCR 
fragments were sequenced to check the diversity of nucleotides at targeted codons. At 
residues not targeted for mutagenesis single strong predominant peaks corresponding with 
expected nucleotides, were observed as demonstrated by K122 (see Figure 4.7). In contrast, at 
targeted nucleotides, there are clear peaks for all four bases (C, G, A, T) at positions 
corresponding to “N” in the mutagenic primer and two bases (C and G) at positions 
corresponding to “S”. In some cases the height of the peaks are similar but it others the T peak 
is substantially higher. This suggests that there is not perfectly equal representation of all the 
variants, nevertheless mutations were clearly present therefore high diversity is expected in 
this library.  
  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Extract from sequencing plot for residues R121-A125 NTR following degenerate 
primer mutagenesis 
As expected either four or two peaks can be seen for each nucleotide of residues R121, F123, F124 
and A125. A single peak for each nucleotide can also clearly be seen for residue K122  
 
 
 A     A    G 
 
      K122 
N     N     S 
 
      R121 
N      N     S 
 
     F123 
N     N     S 
 
     F124 
N      N     S 
 
     A125 
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4.3.2 Preparation of PCR product for inserting in lambda vector 
Following digested with Sfi I PCR fragments encoding libraries of full length mutant NTR 
genes were resolved by agarose gel electrophoresis (see Figure 4.8). 
 
                                             
                                       M      1      2       3      4    5     6 
 
Figure 4.8 Agarose gel of digested PCR products 
PCR products were run on a 0.7% agarose gel. M = Marker 1 kb plus ladder, Lanes 1-6 Sfi I digested 
WT, N71S, T41L N71S, T41N N71S, T41G N71S and T41Q N71S fragments. Two Sfi I sites were cut 
and the bands of expected size were excised from a preparative gel. As indicated on this gel, the 
digestion did not go to completion, and the major 751 bp band containing NTR was purified on a 
further preparative gel, prior to ligation into the lambda vector 
 
 
4.3.3 Optimisation of lambda growth, purification and digestion 
4.3.3.1 Lambda growth  
The production of λJG3J1 vector has previously been problematic both with achieving good 
yield, purification and Sfi I digestion. Phage were grown following standard protocols by 
infecting C600 bacteria in the early stages of culture growth with a low inoculum of phage, 
expecting the phage to go through several cycles of lytic growth as the bacterial culture grew 
up, and expecting to obtain lysis of most remaining bacteria at a high culture density.  
Input undigested fragment 
Fully Sfi I digested NTR 
fragment  
 
1018 
2036 
1636 
  506 
3054 
  396 
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However, although the culture OD600 increased with bacterial growth, the amount of lysis was 
minimal, giving low yields of poor quality phage DNA. Initial experiments increasing the 
phage inoculum did not improve the result. In retrospect, it appears likely that most bacteria in 
the culture lysed early on, and the bacteria that grew were actually lysogenised, and so the 
levels of lambda repressor in the cells would inhibit the lytic cycle. An experiment was 
conducted to test whether lower amounts of phage inoculum would lead to better lysis. 
Approximately 1 x 10
9
 C600 cells were used for each culture.  
                    
Figure 4.9 Growth curves measuring OD600 of E. coli C600 cells with a range of phage titres 
Growth was measured at an OD
600
 from 0 to 390 minutes after infection at 30 minute intervals. Four 
different phage titres were used along with an uninfected control. No phage (Black), 5 x 10
5
 pfu (Red), 
1 x 10
6
 pfu (Blue), 5 x 10
6
 pfu (Green) and 1 x 10
7
 pfu (Pink) 
 
As shown in Figure 4.9 the uninfected culture (black) shows good growth right up to 390 
minutes. After infection with 5 x 10
6
 pfu (green) and 1 x 10
7
 pfu (pink) growth of the cultures 
remained good up to 180 minutes. A small drop in OD600 from 0.8 to 0.4 was observed before 
culture growth started to increase again. After infection with 1x 10
6
 pfu (blue) the culture 
grew well until 240 minutes, following which a large drop in OD600 from 2 to 0.4 was 
observed.  
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After infection with 5 x 10
5
 pfu (red) the culture grew well until 270 minutes where it began 
to plateau before a large drop in OD600 from 2.4 to 0.8. Optimal growth and lysis was 
observed when using 5 x 10
5
 – 1 x 106 pfu of phage to infect the cultures, therefore 
subsequent phage preparations used parallel cultures using these sizes of phage inoculum. 
 
4.3.3.2 Purification of lambda vector 
Two techniques were tested for purifying lambda vector. A method based on PEG 
precipitation of phage from culture supernatant, followed by CsCl density gradient 
centrifugation (Sambrook 1989) and a Qiagen lambda maxi kit method which used ion 
exchange column to purify the PEG precipitated phage. Optimum purification was achieved 
using the PEG and CsCl (see Figure 4.10). 
 
                                                               
                                                                              M      1      2 
Figure 4.10 Agarose gel of purified lambda DNA 
Two purification techniques tested for the purifying of lambda DNA. Lane 1 Qiagen Maxi kit, Lane 2 
PEG and CsCl 
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Poor purification with either degradation of lambda DNA or carryover of bacterial DNA was 
observed when using the Qiagen kit. However a clean single band of phage DNA was 
observed when using PEG and CsCl. 
 
4.3.3.3 Sfi I digestion of lambda vector 
As with chapter 3 initial attempts to generate this large library used λJG3J1 vector. This 
vector contains two Sfi I sites, 21 bp apart downstream of a tac promoter, used for directional 
insertion of mutant NTR gene as an Sfi I fragment (see Figure 3.7). It is essential to achieve 
complete Sfi I digestion, in order to minimise the occurrence of empty vector (original vector) 
phage within the library. Significant problems with digestion were encountered as can be seen 
from Figure 4.11 where partial digestion was observed.  
 
 
 
 
 
 
 
 
                                                           M      1   2    3 
 
Figure 4.11 Agarose gel of Sfi I digested λJG3J1 DNA 
M = Marker 1 kb plus ladder, Lane 1 Undigested λJG3J1 DNA. Lane 2-3 Sfi I digested DNA. Two Sfi I 
sites were cut. As indicated on this gel, the digestion did not go to completion. 
 
Input undigested fragment 
Right and Left ends of lambda DNA 
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Whereas most restriction enzymes can cut efficiently at a single site, Sfi I must bind 
simultaneously to two recognition sequences (GGCCnnnn↓nGGCC) in order for the enzyme 
to cut and the addition of excess enzyme inhibits the reaction (Nobbs et al. 1998, Wentzell et 
al 1998, Embleton et al. 1999, Watson et al.2000 and Embleton et al. 2004).  
 
Optimisation of DNA preparation resulted in improvement in Sfi I digestion, however still 
long digestion times and several rounds of digestion were required. Small pilot libraries using 
these preparations showed that at least 15-20% of the clones lacked NTR insert despite 
improvements in digestion. An example test library PCR result can be seen in Figure 4.12, in 
this case three out of the twenty plaques lacked NTR insert.   
 
                                      
 
Figure 4.12 Agarose gel for PCR products using flanking primers JG2A and JG2B  
Twenty plaques were analysed. The PCR products were run on a 0.7% agarose gel. M = Marker 1 kb 
plus ladder, Lanes 1-10 PCR products. NTR presence was indicated by a band of 1093 bp and empty 
vector by a band of 385 bp 
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  300 
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Two alternative methods were considered to overcome digestion problems, the first was to gel 
purify the correct, fully Sfi I digested fragments. However, lambda DNA is large at 
approximately 40 kb in size; purification of large fragments from a gel was too inefficient for 
this strategy to be used effectively.  
 
An alternative approach was to exploit the unique Pac I restriction enzyme site, included 
between the two Sfi I sites of the vector (see Figure 3.7). Following Sfi I, further digestion 
with Pac I would cut any undigested vector. Alkaline phosphatase treatment would then be 
used to prevent self ligation. Despite Pac I digestion small pilot libraries showed that at least 
5-10% of the clones analysed showed no NTR insert. An example test library PCR result can 
be seen in Figure 4.13, in this case one out of the twenty plaques lacked NTR insert.  
 
                                     
 
Figure 4.13 Agarose gel for PCR products using flanking primers JG2A and JG2B  
Twenty primary plaques were analysed. The PCR products were run on a 0.7% agarose gel. M = 
Marker 1 kb plus ladder, Lanes 1-10 PCR products. NTR presence was indicated by a band of 1093 
bp and empty vector by a band of 385 bp 
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A single round of phage amplification further increased the proportion of the libraries with no 
NTR insert to as much as 30-50%, as shown in Figure 4.14, in this case ten out of the twenty 
plaques lacked NTR insert. 
 
                                     
 
 
Figure 4.14 Agarose gel for PCR products using flanking primers JG2A and JG2B  
Twenty plaques from an amplified test library were analysed. The PCR products were run on a 0.7% 
agarose gel. M = Marker 1 kb plus ladder, Lanes 1-10 PCR products. NTR presence was indicated by 
a band of 1093 bp and empty vector by a band of 385 bp 
 
The ten clones lacking NTR insert from Figure 4.14 were then test digested with Pac I. Four 
of the ten PCR products were digested by the Pac I enzyme (see Figure 4.15). 
 
                                                 
 
Figure 4.15 Agarose gel of Pac I digested empty vector PCR products 
M = Marker 1 kb plus ladder, Lane 1-10 Pac I digested PCR‟s  
1000 
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The remaining six clones which failed to digest were sequenced. Only one of the plaques was 
identical to the original starting vector, the remaining five phage clones had small deletions 
within the region of the Sfi I and Pac I sites as shown in Figure 4.16. 
 
         Original start vector 
 
         ATCTAGGGCCTGCGAGGCCTTAATTAAGGCCTCCCGGGCCTCTAGAGTCG 
         TAGATCCCGGACGCTCCGGAATTAATTCCGGAGGGCCCGGAGATCTCAGC 
         
         Sequenced plaque 
 
         ATCTAGGGCCT::::::::::::::::::::::::::::::CTAGAGTCG 
        TAGATCCCGGA::::::::::::::::::::::::::::::GATCTCAGC 
 
Figure 4.16 Deletion found in 5/6 clones lacking NTR inserts, from library testing the efficiency 
of Pac I digestion 
Individual clones lacking NTR inserts as indicated by PCR with flanking primers, were sequenced 
following Pac I digestion. Red sequence represents Sfi I sites and green represents Pac I site location 
 
 
The lambda DNA ends may have become nibbled during Sfi I digestion allowing blunt end 
ligation. This is especially likely to happen during the prolonged exposure time required for 
adequate digestion, and it may therefore be difficult to further reduce the proportion of phage 
lacking inserts by these approaches. 
 
As mentioned previously, Sfi I enzyme requires two target sequences in order to cut. The two 
Sfi I sites in λJG3J1 vector are separated by 21 bp. As shown by Embleton et al the optimal 
separation for Sfi I sites is 211-1023 bp. The rate becomes increasingly inefficient as the sites 
get closer together. Separations shorter than 100 bp showed very slowest rates. However 
intermediate lengths showed oscillating rates, due to Sfi I reactions yielding helical repeat of 
about 11.5 bp per turn (Wentzell et al 1998).  
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Therefore it was decided to try using a derivative of λJG3J1 with a DNA insert between the 
Sfi I sites. λSV054 contains an inserted NfsA gene, with the sites separated by 784 bp. This 
greater separation of Sfi I sites is predicted to improve the efficiency of Sfi I digestion. 
However, an obvious potential problem would be how to prevent NfsA from re-ligating into 
the vector. Calf alkaline phosphatase treatment will be used after Sfi I digestion to remedy this 
problem. NfsA can also easily be distinguished from NfsB NTR by PCR, so the presence of 
NfsA in the resulting library can easily be monitored. It is also possible to predict that phage 
with NfsA may have more similar growth properties to phage with NfsB genes, than empty 
vector. 
 
This phage was grown and purified using the same method as the λJG3J1 vector. Digestion of 
this vector with Sfi I still required three rounds of digestion but with four hour incubations 
rather than overnight (see Figure 4.17). This should reduce nibbling and was therefore used 
for subsequent library construction. 
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Figure 4.17 Agarose gel of Sfi I digested λSV054 DNA 
M = Marker 1 kb plus ladder, Lane 1 Undigested λSV054 DNA. Lane 2-6 Sfi I digested DNA. Two Sfi I 
sites were cut. As indicated on this gel, the digestion appears to have gone to completion with clear 
distinct bands 
Input undigested fragment 
Right and Left ends of lambda DNA 
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4.3.4 Over-expression of the lac repressor, to reduce background 
NTR expression and reduce growth-advantage of empty vector 
 
Observation on the propagation of lysogens with or without NTR inserts indicated that those 
with NTR genes grew more slowly (Guise et al. unpublished). When analysing phage plaques 
in this study it was also noted that empty vector plaques were larger than NTR-containing 
counterparts also demonstrating this growth advantage.  
 
One of the possible reasons for this growth advantage is the leaky expression of NTR, which 
is slightly detrimental to the bacterial lysogen. NTR expression is under the control of a tac 
promoter, which is a hybrid derived from both trp and lac. Expression from tac is more 
efficient than either promoter alone. The lac repressor Lac I controls expression, by normally 
binding to the lac operator sites and inhibiting transcription. In the presence of inducers such 
as IPTG, the lac repressor dissociates from the DNA, allowing transcription to proceed.  
 
The addition of excess Lac I will hopefully completely shut off NTR expression while 
amplifying the library therefore NTR encoding phage should be able to grow more quickly, 
removing the growth advantage of empty vector. 
 
Two closely related plasmids containing Lac I gene were available, their efficiency for Lac I 
expression and shut off of NTR expression were therefore compared. The two plasmids pET 
15b and pET 21b were transformed into C600 and UT5600 bacterial cell lines (see Figure 4.4-
4.5). Lac I and NTR expression were comparing by western blotting for each bacterial cell 
line (see Figure 4.18). 
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Figure 4.18 Western Blotting of C600 and UT5600 bacterial cells 
a) Western blotting for Lac I expression comparing C600, C600 pET 15B, C600 pET 21B, UT5600, 
UT5600 pET 15B and UT5600 pET 21B cell lines. b) NTR expression comparing empty vector (EV), 
wild type NTR (WT) and wild type NTR that has been induced by IPTG (WT IPTG) in C600, C600 pET 
15B and C600 pET 21B 
 
No Lac I expression was detected in C600 and UT5600 cells alone confirming that 
endogenous expression is low. Both cell lines with plasmid pET 15b showed Lac I expression 
and both cell lines with pET 21b showed even higher expression of Lac I (see Figure 4.18a).  
 
Clear reduction in NfsB NTR expression can be seen in C600 cells with both plasmid pET 15b 
and pET 21b when compared with C600 cells alone (see Figure 4.18b). However the greatest 
reduction in NTR expression can be seen with pET 21b. NTR expression can still be induced 
with IPTG however lower expression was seen with pET 15b and pET 21b plasmids. This 
correlates well with the results seen for Lac I expression. 
 
 
 
 
 
 
 
a) b) 
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To determine whether over-expression of Lac I was able to overcome the preferential growth 
of empty vector phage, a mixed population of 1 x 10
6
 phage, containing 50% NTR and 50% 
empty vector was used to infect C600, C600 pET 15b and C600 pET 21b bacterial cells. This 
method modelled the procedure used for amplification of phage libraries. The original input 
phages were checked by PCR to ensure the correct proportions of NTR and EV were used. 
The resulting PCR bands indicate 50% NTR and 50% EV (see Figure 4.19a). When C600 
cells were used for amplification the proportion of empty vector increased to 90% (see Figure 
4.19b). The expression of pET 15b in the C600 cells had no effect on amplification; the 
proportion of empty vector increased to 90% (see Figure 4.19c). However the expression of 
pET 21b in the C600 cells reduced the preferential growth with only 60% of the phage 
encoding empty vector (see Figure 4.20d). Therefore pET 21b could be advantageous when 
amplifying phage libraries. 
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     a) Control – No Amplification                                                                                             b) C600 cells 
 
                                
 
                                                  15 plaques NTR   50%                                                                                                           3 plaques NTR   10% 
                                                  15 plaques EV      50%                                                                                                          27 plaques EV    90% 
 
      c) C600 15b cells                                                                                                            d) C600 21b cells 
   
                                 
 
                                            3 plaques NTR   10%                                                                                                         12 plaques NTR   40% 
                                          27 plaques EV    90%                                                                                                           18 plaques EV      60% 
 
NTR 
EV 
EV 
Figure 4.19 Testing the ability of Lac I over-expression to reduce preferential amplification of empty vector phage 
Gels showing PCR products from individual plaques comparing input phage with phage amplified in C600, C600 pET 15b and pET 21b cell line. a) 
Input phage (before amplification), b) Liquid culture amplification in C600 cells, c) Liquid culture amplification in C600 pET 15b and d) Liquid culture 
amplification in C600 pET 21b. 1 x 10
6
 phage was used for each with 50% NTR and 50% EV phage used.  NTR presence was indicated by a band of 
1093 bp and empty vector by a band of 385 bp 
NTR 
EV 
EV 
NTR 
EV 
EV 
NTR 
EV 
EV 
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However western blotting showed that high levels of Lac I reduced the amount of NTR 
expression upon induction with IPTG. This could potentially reduce the sensitivity of 
lysogens to CB1954, so an experiment was designed to test this by exposing lysogenic 
cultures to a range of CB1954 concentrations. The sensitivity of the lysogens to the different 
CB1954 concentrations was tested by plating efficiency and the amount of phage release 
measured. The cultures were exposed to CB1954 as a 15 minute pulse. F124N mutant phage 
were used for this experiment comparing UT5600, UT5600 pET 15b and UT5600 pET 21b 
bacterial cells. F124N was used because this mutant produces a clear peak in phage release at 
approximately 100 µM CB1954 allowing any shift to be easily compared (Guise et al. 2007). 
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Figure 4.20 Colony Forming Efficiency for UT5600, UT5600 pET 15b and UT5600 pET 21b 
bacteria and Plaque Forming Units for F124N phage when exposed to a range of 
concentrations of CB1954 
a) Colony forming efficiency at CB1954 concentrations ranging from 0-225 µM CB1954 of F124N in 
UT5600, UT5600 pET 15b and UT5600 pET 21b b) F124N phage release at CB1954 concentrations 
ranging from 0-225 µM CB1954. UT5600 cells alone (blue), UT5600 pET15b (red) and UT5600 
pET21b (green) 
 
 
 
a) b) 
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As shown in Figure 4.20a expression of Lac I had little effect on the dose-response for 
cytotoxicity of CB1954 to the bacterial lysogens. The titres of phage released were reduced by 
approximately 30% and 60% by expression of Lac I from pET15b and pET 21b respectively 
in Figure 4.20b. However there was minimal increase in the concentration of CB1954 giving 
optimum phage release. 
 
4.3.5 Phage production and amplification 
Having optimised the stages of lambda vector production, Sfi I digestion, choice of vector, 
and decided on the use of Lac I, it was possible to proceed on to generate, amplify and 
characterise the large library of NTR mutants. The ligation products were packaged into 
phage particles and plaque titres for each sub-library were determined; the phage yields were 
between 8.1 x 10
6
 – 1.9 x 107 (see Table 4.1). These yields range from 8-14 times greater than 
calculated numbers of possible nucleotide variants, and so the sub-libraries should contain the 
majority of these variants. However the selection process (using CB1954 to enrich for 
mutants better able to activate the prodrug) uses bacterial lysogens and the efficiency of 
generating lysogens is only 1%. In order to maintain the maximum diversity in the lysogens, 
it was necessary to amplify the phage library prior to the generation of lysogens. This was 
done by amplification with liquid culture, giving between 2.7 x 10
10
 – 8.0 x 1010 independent 
phages as shown in Table 4.1.  
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Template Initial phage yield of 
independent clones 
(pfu total) 
Number of possible 
nucleotide variants  
Phage yield after 
amplification  
(pfu total) 
WT 1.2 x 10
7
 1.05 x 10
6
 7.6 x 10
10
 
N71S 1.9 x 10
7
 1.05 x 10
6
 5.2 x 10
10
 
T41L N71S 1.3 x 10
7
 1.05 x 10
6
 8.0 x 10
10
 
T41N N71S 1.4 x 10
7
 1.05 x 10
6
 4.4 x 10
10
 
T41G N71S 8.1 x 10
6
 1.05 x 10
6
 2.7 x 10
10
 
T41Q N71S 9.8 x 10
6
 1.05 x 10
6
 3.2 x 10
10
 
 
Table 4.1 Initial phage yield of independent clones, number of possible nucleotide variants and 
phage yield after amplification by liquid culture 
 
 
PCR was used to check NTR presence, 30 phage plaques from each sub-library were 
analysed. Two sets of primers were used in order to distinguish between NfsA and NfsB NTR 
and empty vector. All the PCR‟s contained NfsB insert; no NfsA or empty vector was seen 
(see Appendix Figure 8.1). 
 
4.3.6 Selection 1 
6.0 x 10
9
 pfu of phage were infected into 1.5 x 10
10
 UT5600 pET 21b cells, using kanamycin 
to select for lysogens. Aliquots of mid log culture were exposed to CB1954 for 15 minutes, 
diluted and pelleted before being resuspended in prodrug free media as described in Materials 
and Methods. Phage released after 1 hour were separated from lysogens by 0.2 µm filtration 
(see Figure 3.9). The library was taken through eight rounds of selection at 10 µM, 25 µM, 50 
µM or 100 µM in parallel (see Figure 4.21). Phage release at each round of selection was 
measured (see Figure 4.22). 
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Figure 4.21 Flow chart showing culture lineages from initial infection through to the eighth 
round of selection 
INITIAL INFECTION 
     0             10             25             50            100 µM CB1954 
  0    10       0    25        0   50       0   100 µM CB1954  
  0    10       0    25        0    50       0   100 µM CB1954  
      0    10       0     25        0   50       0   100 µM CB1954  
1
ST
 ROUND 
2
ND
 ROUND 
3
RD
 ROUND 
4
TH
 ROUND 
5
TH
 ROUND 
6
TH
 ROUND 
7
TH
 ROUND 
8
TH
 ROUND 
   0    10       0     25        0   50       0   100 µM CB1954  
       0    10       0    25        0    50       0   100 µM CB1954  
    0    10       0    25        0    50       0   100 µM CB1954  
     0    10       0    25        0   50       0   100 µM CB1954  
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Figure 4.22 Phage release for rounds 1-7 of selection with 10 µM, 25 µM, 50 µM and 100 µM CB1954 
Background phage release (blue) and CB1954 induced phage release (red) 
170/171 
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Background release of phage was determined by exposing the culture to no CB1954. After 1 
round of selection with CB1954, phage release was as expected with increased release of 
phage induced by increasing concentrations of CB1954. For subsequent rounds of selection, 
the background had to be determined separately for each lineage. Phage release was again 
expected to increase when induced by increasing concentration of CB1954. Theoretically in 
later rounds as selection enriches improved mutants low CB1954 concentrations may induce 
increased phage release.  
 
After 2 rounds of selection higher titres of phage were observed after induction with 25 µM 
than with 10 µM CB1954. However lower phage release was observed after induction with 50 
µM and 100 µM. At 100 µM induction phage release was particularly low and background 
levels appeared to be slightly higher than the induced culture. Varying levels of background 
phage release was observed for each culture. From round 3 onwards no obvious pattern of 
phage release was observed, relative to the CB1954 concentration used for induction.  
 
4.3.6.1 Monitoring population sensitivity of the library under selection 
The effect of selection was also monitored using a lysogen colony forming assay for each 
selection lineage, after three and seven rounds of selection. The unselected library showed 
that almost all of the lysogens were resistant to 200 μM. After three rounds of selection a 
small improvement was seen compared to unselected. Most improvement was seen after 
induction with 10 μM and 25 μM CB1954 (see Figure 4.23a). After seven rounds of selection 
little difference was seen compared to three rounds of selection (see Figure 4.23b). By seven 
rounds of selection better enrichment of this library would be expected.  
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Figure 4.23 Dose Response curves for colony forming assay in UT5600 cells 
a) Three rounds of selection, b) Seven rounds of selection. Unselected (black), 10 µM CB1954 
induction (red), 25 µM CB1954 induction (blue), 50 µM CB1954 induction (green) and 100 µM CB1954 
induction (purple) 
 
 
4.3.6.2 Screening CB1954 sensitivity of individual clones from selected library 
460 individual lysogen colonies were picked from each of the lineages selected with 10 µM 
and 25 µM CB1954. Cultures were grown overnight in 96 well plates and replica plated onto 
plates containing no CB1954 and 35 µM CB1954. All the lambda lysogens showed strong 
growth in the absence of CB1954. All lysogens selected at 10 µM, which gave good growth in 
the absence of CB1954 also grew well at 35 µM (see Figure 4.24). Three lysogens selected at 
25 µM, disappeared at 35 µM and were therefore sensitive to this concentration of CB1954 
(see Figure 4.25). The remaining 457 lysogenic colonies were not sensitive to 35 µM. 
 
The NTR genes from the three lysogens that failed to grow at 35 µM were sequenced. All 
three NTR genes had the same amino acid changes N71S A113 R121V F123N F124V A125C 
K179R referred to as clone 282 for this thesis. IC50 assays were performed for clone 282 (see 
Figure 4.26). WT and N71S have also been shown for comparison. 
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Figure 4.24 Replica plating of individual lysogens after seven rounds of selection using 10 µM 
CB1954 
No CB1954 and 35 µM CB1954 was used for replica plating. The first two lysogens on the top left of 
each plate are controls WT and T41G N71S respectively.  
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Figure 4.25 Replica plating of individual lysogens after seven rounds of selection using 25 µM 
CB1954 
No CB1954 and 35 µM CB1954 was used for replica plating. The first two lysogens on the top left of 
each plate are controls WT and T41G N71S respectively. The red circles indicate where lysogens 
have disappeared 
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Figure 4.26 CB1954 IC50 Assay of selected lysogen N71S A113V R121V F123N F124V A125C 
K179R (clone 282) 
Lysogenic cultures were spread onto plates containing a range of CB1954 concentrations, and the 
number of colonies on each plate counted after overnight growth. The numbers of colonies were 
compared to plates with no prodrug. Clone 282 (orange), N71S (green) and WT (black) 
 
 
4.3.6.3 Sequencing of random clones from selected and unselected library to 
check representation 
 
Due to the limited increase in CB1954 sensitivity of the library it was decided to test random 
clones after selection to check mutant representation. Twenty plaques were screened by PCR 
to detect NTR insert. All twenty plaques were found to have inserted NTR (NfsB) genes. The 
NTR genes for each was then sequenced (see Table 4.2). Fifteen different mutants were 
observed. Eight mutants had single nucleotide deletions resulting in a frame-shift. Deletions 
were observed at residues R121, F123, A125 and M127.  
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The high incidence of frame-shift mutations following selection was surprising. Therefore 
twenty four clones from the unselected library (four from each of the amplified sub-libraries) 
were also sequenced (see Table 4.3). Twenty one of the twenty four gave clear sequences. 
However only nine encoded full length NTR, seven have frame-shift single nucleotide 
deletions, which were seen at residues P110, F123, F124, A125, D126 and M127. Two 
mutants had deletions at more than one residue.  The remaining five mutants had at least one 
stop codon. Furthermore four NTR sequences were seen more than once, this was highly 
unlikely to happen by chance, either each sub-library failed to contain the diversity that was 
expected or only a small proportion of each sub-library was retrieved following amplification. 
Therefore twenty four clones from the unselected library prior to amplification (four from 
each of the un-amplified sub-libraries) were then sequenced (see Table 4.4). Twenty two of 
the twenty four clones encoded full length NTR, with the remaining two having stop codons 
at either R121 or A125. No two NTR sequences were the same, therefore good diversity was 
seen for each initial sub-library and amplification must have only expanded a small proportion 
of each sub-library. 
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Amino Acid substitutions Number of mutants Codon Usage 
T41Q N71S F123V F124A A125S M127 deletion D135G 4 V = GTG A = GCC S = TCG G = GGT (4) 
T41Q N71S R121 deletion F123L F124S A125H 1 L = TTG S = AGC H = CAG 
T41Q N71S A113V R121F F124D A125C G177G 1 V = GTG F = TTC D = GAC C = TGC G = GGC 
T41Q N71S F123 deletion F124G A125 deletion D126R D135G 1 G = GGC R = CGG G = GGT 
T41Q N71S R121V F123V F124T A125Y 1 V = GTC V = GTG T = AAC Y = TAC 
T41N N71S F123V F124A A125S M127 deletion D135G 1 V = GTG A = GCC S = TCG G = GGT 
T41L N71S R121Y F124G A125L 1 Y = TAC G = GGC L = CTG 
E25G T41L N71S A113V R121V F123L F124P 1 G = GGA V = GTG V = GTC L = TTG P = CCG 
T41G N71S 1 - 
N71S R121L F123S F124S A125W V143A  2 L = CTC S = TCC S = TCC W = TGG A = GCT (2) 
N71S R121A F123L F124G A125Q 1 A = GCG L = CTC G = GGC Q = CAG 
A113V R121L F123I F124T A125S 1 V = GTG L = CTC I = ATC T = ACG S = TCG 
R121A F123N F124S A125E K141E 1 A = GCC N = AAC S = AGC E = GAG E = GAA 
R121Y F123 STOP F124Y A125 deletion V191E 1 Y = TAC STOP = TAG Y = TAC E = GAA 
R121C F123I F124S A125F 1 C = TGC I = ATC S = AGC F = TTC 
F124N 1 N = AAC 
 
Table 4.2 Summary of sequenced NTR mutants following eight rounds of selection at 25 µM 
Targeted amino acid substitutions are shown in black, single residue frame-shift deletions in red and non-targeted mutations in blue 
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Amino Acid substitutions Number of mutants Codon Usage 
R121W F123I F124S A125 STOP 2 TGG = W ATC = I AGC = S TAG = STOP 
R121V F123Y F124Y A125Q 1 GCT = V TAC = Y TAC =Y CAG = Q 
SEQUENCE FAILED 1 - 
N71S REST OF SEQUENCE FAILED 2 - 
N71S K87R R121C F123T F124K A125L 1 AGA = R TGC = C TCG = T AAG = K CTG = L  
N71S A113V D118N R121F F123L F124H A125 STOP 1 GTG = V AAT = N TTC = F CTC = L CAC = H TAG = STOP 
T41L N71S P110 - D126 several deletions 1 - 
T41L N71S R121I F123F F124K A125F  1 ATC = I TTC = F AAG = K TCC = F  
T41L N71S R121F F123V F124S A125S W138R 1 TTC = F GTC = V AGC = S TCT = S CGG = R 
T41L N71S R121F F123L F124 STOP A125Y P206L 1 TTC = F TTG = L TAG = STOP TAC = Y CTG = L 
I4T T41N N71S R121D F123N F124 STOP A125S 2 ACT = T GAC = D AAC = N AGC = STOP TCG = S 
T41N N71S 1 - 
T41N N71S R121Y F123V F124H A125C 1 TAC = Y GTC = V CAC = H TGC = C 
T41Q N71S R121R F123V F124A A125S M127 deletion D135G 2 AGG = R GTG = V CCC = A TCG = S G = GGT 
T41Q N71S R121H F123V F124N A125Y 1 CAC = H GTC = V AAC = N TAC = Y 
T41Q N71S R121S F123V F124 - D126 deletion 1 TCG = S GTC = V 
T41G N71S R121I F123A F124 deletion A125 deletion I164T 2 ATC = I GCC = A ACC = T 
T41G N71S R121F F123F F124E A125S 1 TTC = F TTC = F GAG = E TCC = S 
T41G N71S R121I F123 deletion F124R A125 deletion 1 ATC = I CGG = R 
 
 
 
 
 
Table 4.3 Summary of sequenced NTR mutants, with four from each sub-library following liquid culture amplification 
Targeted amino acid substitutions are shown in black, single residue frame-shift deletions in red and non-targeted mutations in blue 
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Amino Acid substitutions Number of mutants Codon Usage 
A113V R121G F124N A125Y 1 GTG = V GGG = G AAC = N TAC = Y 
S5P R121 STOP F123M A125V 1 CCT = P TAG = STOP ATG = M GTG = V 
R121F F124L F124G A125N 1 TTC = F TTG = L GGC = G AAC = N 
R121R F123L F124P A125G 1 CGG = R TTG = L CCC = P GGC = G 
N71S R121F F123S F124T A125C 1 TTC = F AGC = S ACC = T TGC = C 
N71S A113V R121F F123S F124I A125R 1 GTG = V TTC = F TCC = S ATC = I CGC = R 
N71S A113V K119T R121Y F123D F124A A125C 1 GTG = V ACA = T TAC = Y GAC = D GCC = A TGC = C 
N71S A113V F123M F124Y A125Y 1 GTG = V ATG = M TAC = Y TAC = Y 
T41L N71S R121Y F123W F124G A125 STOP 1 TAC = Y TGG = W GGC = G TAG = STOP 
T41L N71S R121M F123C F124M A125L 1 ATG = M TGC = C ATG = M TTG = L 
T41L N71S H80Y R121Y F123M F124R A125S 1 TAC = Y TAC = Y ATG = M CGC = R TCC = S 
T41L N71S R121E F123L F124S A125L 1 GAG = E TTG = L AGC = S CTC = L 
T41N N71S R121V F123I F124S A125F 1 GTC = V ATC = I AGC = S TTC = F 
T41N N71S R121S F123L F124A A125Y 1 TCC = S TTG = L GCG = A TAC = Y 
T41N N71S R121P F123V F124P A125S 1 CCC = P GTG = V CCC = P TCG = S 
M1V T41N N71S R121Y F123T F124E A125C 1  GTG = V GAC = Y ACC = T GAG = E TGC = C GAC = D 
T41Q N71S R121V F123V F124S A125P 1 GTC = V GTG = V TCC = S CCC = P 
T41Q N71S A113V R121C F123L F124G A125S 1 GTG = V TGC = C CTC = L GGC = G TCC = S 
T41Q N71S T109S R121V F124T A125C 1 TCG = S GTG = V ACC = T TGC = C 
Q6R T41Q N71S R121Y F123M F124R A125S 1 CGG = R TAC = Y ATG = M CGC = R TCC = S 
T41G V50A N71S R121G F124G A125A 1 GCT = A GGC = G GGG = G GCG = A 
T41G N71S R121L F123L F124S A125Y 1 TTG = L CTC = L TCC = S TAC = Y 
T41G N71S R121I F123C F124Y A125C 1 ATC = I TGC = C TAC = Y TGC = C 
T41G N71S R121F F123L F124D A125W 1 TTC = F CTG = L GAC = D TCG = W 
Table 4.4 Summary of sequenced NTR mutants, with four from each start sub-library prior to liquid culture amplification 
Targeted amino acid substitutions are shown in black and non-targeted mutations in blue 
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4.3.6.4 Validation of library amplified by plate lysate 
Amplification by liquid culture failed to maintain diversity within the library. An alternative 
approach which has been used previously (Chapter 3) used amplification by plate lysate. 
Phage plaques spread out across the agar plates, ensuring no loss in diversity. 3 x 10
6
 pfu of 
phage stock for each sub-library was amplified using 1 x 10
6
 pfu to infect bacteria spread as a 
lawn in top agar on each of three 10 cm plates. A total of 7 ml of amplified stock was 
retrieved from each sub-library. Plaque yields before and after amplification are shown in 
Table 4.5 
 
Template Initial phage yield of 
independent clones 
(pfu total) 
Number of possible 
nucleotide variants  
Phage yield after 
amplification  
(pfu total) 
WT 7.0 x 10
6
 1.05 x 10
6
 2.7 x 10
9
 
N71S 1.4 x 10
7
 1.05 x 10
6
 1.1 x 10
9
 
T41L N71S 8.0 x 10
6
 1.05 x 10
6
 1.4 x 10
9
 
T41N N71S 9.0 x 10
6
 1.05 x 10
6
 1.3 x 10
9
 
T41G N71S 3.1 x 10
6
 1.05 x 10
6
 3.9 x 10
9
 
T41Q N71S 4.8 x 10
6
 1.05 x 10
6
 1.8 x 10
9
 
 
Table 4.5 Initial phage yield of independent clones, number of possible nucleotide variants and 
phage yield after amplification by plate lysate 
 
Four individual plaques from each amplified sub-library were sequenced (see Table 4.6). 
Twenty out of the twenty four plaques encoded full length NTR. Two had stop codons at 
either R121 or A125 and a further two had frame-shift deletions. Although there were two 
frame-shift deletions this is substantially lower than previously seen, and no duplicate 
sequences were seen. These plate lysate amplification stocks were therefore used for a further 
attempt at library selection. 
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Amino Acid substitutions Number of mutants Codon Usage 
R121A F123L F124Q A125S 1 GCG = A CTC = L CAG = Q TCC = S 
R121L F123L F124R A125 STOP 1 TTG = L CTG = L CGC = R TAG = STOP 
R121I F123 STOP F124T A125Y F199S 1 ATC = I TAG = STOP ACC = T TAC =Y TCT = S 
R121N  F123 - A125 deletions 1 AAC = N 
N71S R121L F123C F124C A125W 1 CTG = L TGC = C TGC = C TGG = W 
N71S K74R R121F F123L F124I A125Q 1 AGA = R TTC = F CTG = L ATC = I CAG = Q 
N71S R121L F123C F124Q A125C 1 CTC = L TGC = C CAA = Q TGT = C 
N71S R121L F123S F124C A125W 1 CTG = L AGC = S TGC = C TGG = W 
T41L N71S R121L F123L F124Y A125 deletion 1 TTG = L TTG = L TAC = Y 
S5P T41L N71S R121V F123V F124N A125C Q142R 2 CCT = P GTC = V GTG = V AAC = N TGC = C CGG = R 
A7V T41L N71S R121T F123L F124R A125S 1 GTC = V ACC = T CTC = L CGG = R TCC = S 
T41N N71S R121L F123C F124T A125C 1 TTG = L TGC = C ACG = T TGC = C 
T41N N71S R121P A125Y 1 TTC = P TAC = Y 
T41N N71S R121I F123L F124L A125W 1 ATC = I TTG = L CTG = L TGG = W 
T41N N71S R121F F123L F124K A125F 1 TTC = F TTG = L AAG = K TTC = F 
T41Q N71S A113V R121L F123L F124N A125H 1 GTG = V TTG = L CTG = L AAC = N CAC = H 
T41Q N71S R121L A125R 1 CTC = L CGG = R 
T41Q N71S R121D F123A F124T A125S 1 GAC = D GCG = A ACC = T TCC = S 
T41Q N71S A113V R121L F123E F124P A125Y M139V 1 GTG = V TTG = L GAG = E CCG = P TAC = Y GTG = V 
T41G N71S R121V F123S F124R A125F 1 GTC = V TCC = S CGG = R TCC = F 
T41G N71S R121P F123P F124H A125Y P209L 1 CCC = P CCC = P CAC = H TAC = Y CTG = L 
T41G N71S A113V R121 STOP F123H F124S A125L 1 GTG = V TAG = STOP CAC = H TCG = S CTG = L 
T41G N71S R121F F123W F124P A125 STOP K181R 1 TTC = F TGG = W CCC = P TAG = STOP AGA = R 
Table 4.6 Summary of sequenced NTR mutants, with four from each sub-library amplified by plate lysate 
Targeted amino acid substitutions are shown in black, single residue frame-shift deletions in red and non-targeted mutations in blue 
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4.3.7 Selection 2 
6.0 x 10
9
 pfu of phage were infected into 1.5 x 10
10
 UT5600 cells to generate lysogens for 
selection (containing 1.0 x 10
9
 pfu of phage from each sub-library). Selection followed as 
Figure 3.9. The library was taken through twenty rounds of selection at 25 µM, 50 µM, 75 
µM or 100 µM in parallel. Phage release at each round of selection was measured (see Figure 
4.27). 
  
As previously in this chapter background release of phage was determined by exposing the 
culture to no CB1954. After 1 round of selection with CB1954, phage release was as expected 
with increased release of phage induced by increasing concentrations of CB1954 up to 75 
µM. This wasn‟t observed with 100 µM CB1954 which gave the lowest release of phage. For 
subsequent rounds of selection, background phage release was determined separately for each 
lineage. Phage release was expected to increase when induced by increasing concentration of 
CB1954.  
 
After 2 rounds of selection higher titres of phage were observed after induction with 25 µM 
and 50 µM. However lower phage release was observed for 75 and 100 µM. For each 
CB1954 concentration greater phage release was observed relative to background. Varying 
levels of background phage release was observed for each culture. 
 
From round 3 onwards no obvious pattern of phage release was observed, relative to the 
CB1954 concentration used for induction.  
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Figure 4.27 Phage release after 1-20 rounds of selection with 0 µM, 25 µM, 50 µM, 75 µM and 100 µM CB1954 
Red columns indicate background phage release and blue columns indicate CB1954 induced phage release 
184/185 
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4.3.7.1 Monitoring population sensitivity of the library under selection 
The effect of selection was also monitored using a lysogen colony forming assay for each 
selection lineage, after three, seven, fourteen and twenty-one rounds of selection. The 
unselected library showed that almost all the lysogens were resistant to 200 µM CB1954. 
After three rounds of selection a small improvement was seen compared to the unselected 
library. Most improvement was seen with lysogens selected with 75 μM however 70% of the 
lysogens were still resistant to 200 μM CB1954 (see Figure 4.28a). After seven rounds of 
selection little difference was seen relative to three rounds (see Figure 4.28b). By fourteen 
rounds 60% of the lysogens selected with 75 μM were still resistant to 200 μM (see Figure 
4.28c). No further improvement was seen after twenty-one rounds (see Figure 4.28d). Further 
selection is unlikely to improve the library further. 
 
4.3.7.2 Screening CB1954 sensitivity of individual clones from selected library 
230 individual lysogen colonies were picked from each of the lineages selected with 25 µM, 
50 µM, 75 µM and 100 µM CB1954. Cultures were grown overnight in 96 well plates and 
replica plated onto agar plates containing no CB1954, 5 µM, 12 µM and 25 µM CB1954. All 
lambda lysogens showed strong growth in the absence of CB1954. None of the clones 
demonstrated any susceptibility to CB1954 within this range (see Appendix Figures 8.2-8.5).  
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Figure 4.28 Dose Response curves for colony forming assay in UT5600 cells 
a) Three rounds of selection, b) Seven rounds of selection, c) Fourteen rounds of selection, d) Twenty-one rounds of selection. Unselected (black), 25 µM 
CB1954 induction (red), 50 µM CB1954 induction (blue), 75 µM CB1954 induction (green) and 100 µM CB1954 induction (purple) 
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4.4 DISCUSSION  
This chapter aimed at determining whether six residues around the active site were able to 
improve the efficiency of CB1954 activation. Mutant generation involved PCR using a 
degenerate primer, incorporating NNS at four out of five adjacent residues. Prior to cloning, 
the incorporated sequence diversity was checked by sequencing the PCR product. A good 
diversity of mutations were seen at each residue. However considerable difficulties were 
encountered at several steps in the generation of the library. 
 
4.4.1 Phage lambda vector  
4.4.1.1 Lambda growth  
Initially phage λJG3J1 vector was grown following standard protocols by infecting C600 
bacteria in the early stages of culture growth with a low innoculum of phage. The phages were 
expecting to go through several cycles of lytic growth, while the bacterial culture multiplied. 
By high culture density it was hoped that a large proportion of the bacteria would be lysed by 
the phage. However the amount of lysis was minimal, giving low yields of poor quality phage 
DNA. This was remedied by reducing the amount of lambda added to the culture, allowing 
the bacteria more time to multiply before being lysed. The optimum quantities of phage to 
bacterial cells were determined with 1 x 10
9
 C600 cells being infected with 5 x 10
5
 – 1 x 106 
pfu of phage.  
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4.4.1.2 Purification of lambda vector 
Two techniques were tested for the purification of the lambda vector. Firstly a Qiagen lambda 
maxi kit method, which used ion exchange column to purify the PEG precipitated phage and 
secondly a more successful PEG precipitation and CsCl density gradient centrifugation 
method (Sambrook 1989). A clean single band of phage DNA was observed when using PEG 
and CsCl. 
 
4.4.1.3 Sfi I digestion of lambda vector 
The lambda vector was cut using Sfi I enzyme. It was essential to achieve complete Sfi I 
digestion, in order to minimise the amount of empty vector (original vector) phage carrying 
over into the library. However problems with partial digestion were encountered. This led to 
the use of two alternative methods as an attempt to overcome digestion problems: the first 
was to gel purify the correct, fully Sfi I digested fragments, and secondly to exploit the unique 
Pac I restriction enzyme site, included between the two Sfi I sites of the vector. However 
neither of these methods totally prevented carryover of empty vector.  
 
4.4.1.4 Alternative vector 
An alternative vector λSV054 that is a derivative of λJG3J1, which contains a DNA insert 
(NfsA gene) between the Sfi I sites was grown and digested, in the hope that it would Sfi I 
digest more efficiently than λJG3J1. Greater separation of Sfi I sites did improve the 
efficiency of Sfi I digestion, allowing libraries with no empty vector to be constructed.  
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4.4.1.5 Lac I expression 
The effect of over-expression of Lac I repressor was examined, for the prevention of 
background leaky NTR expression. Two pET vectors expressing Lac I were compared in 
several bacterial cell lines. Western blot analysis showed that pET 21b was most efficient at 
reducing NTR expression and that IPTG was still able to induce NTR expression. Further 
experiments showed that over-expression of Lac I was able to reduce preferential growth of 
empty vector, without having a major effect on the dose-response with CB1954.  
 
4.4.2 Selection 
Two attempts at selection were undertaken with eight and twenty-one rounds performed. 
After every round of selection phage release was measured, initially increased release of 
phage was seen after induction by increasing concentrations of CB1954. However as selection 
proceeded no obvious phage release patterns were observed.  
 
4.4.2.1 Population sensitivity 
Population sensitivity was analysed by examining lysogen colony forming efficiency; this 
showed very little improvement relative to the starting library. Individual clones were 
screened for their sensitivity to CB1954. Only three clones showed any sensitivity; all three 
had the following amino acid changes N71S A113 R121V F123N F124V A125C K179R. 
IC50 assays showed that this clone has an IC50 of 20 µM. It is very unlikely that this mutant 
was the only good mutant in the starting library. The library should at least have contained 
several of the previously known good mutants such as T41L N71S, T41G N71S and T41Q 
N71S F124T.  
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Construction for this library was different from that in Guise et al 2007. Guise et al used 
multiple PCR reactions with several degenerate primers, before joining fragments together 
with flanking primers. However in this library a single large and intricate degenerate primer 
was used, making miss-priming and deletions in the mutagenic region more likely. In an 
attempt to prevent primer errors SH033A and SH033B were specially purified. Sequencing 
appeared to indicate that these primers had worked well with clear sequencing seen within 
mutagenic regions; however a large number of deletion frame shift mutation were seen when 
analysing individual clones. All these frame shift deletions were observed in primer regions. 
 
Selection is not entirely clean, with some spontaneous phage release. If the frequency of 
beneficial mutants was low it is possible that the recovered phage were largely random. 
However it was expected that after multiple cycles of selection, the relative abundance of 
good mutants would increase. It is possible that uncontrolled spontaneous phage release 
interfered with the selection process.  
 
The library generated in this chapter consisted of maximum diversity of 6.3 x 10
6
 possible 
nucleotide combinations relative to 6.8 x 10
5
 possible combinations for Guise et al. 2007. It is 
possible that this library was too large for successful selection. In hind sight it may have been 
wiser to have performed selection separately for each sub-library, with each having a 
maximum diversity of 1.05 x 10
6
. This was not possible for this thesis due to time constraints, 
but should be considered for future work when dealing with very large libraries. 
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CHAPTER 5: KINETIC STUDIES OF WT AND 
MUTANT NTR 
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5.1 INTRODUCTION  
Nitroreductase is a flavoenzyme with tightly bound FMN cofactor. The enzyme‟s action is by 
a substituted, “ping-pong”, mechanism, where the enzyme bound FMN is first reduced by 
NAD(P)H to FMNH2 and the NAD(P)
+
 product dissociates. A number of different substrates 
can then bind to the enzyme and be reduced by FMNH2. NTR is highly soluble and stable and 
can easily be over expressed and purified from bacteria (Anlezark et al. 1992 and Lovering et 
al. 2001). Steady state kinetic assays have determined the Michaelis constants of WT NTR 
with a range of substrates (Anlezark et al. 1992, Race et al. 2003 and Zenno et al. 1996b). 
Several NTR mutants have also been kinetically analysed (Jaberipour 2005, Race et al. 2007 
and Jarrom 2008). 
 
During this study, a number of improved NTR mutants have been generated and tested in 
bacterial cells, see Chapters 3 and 4. The aim of the work in this chapter was to purify and 
kinetically characterise the two double mutants T41G N71S and T41L F70A and the multiple 
mutant N71S A113V R121V F123N F124V A125C K179R (clone 282). It should be noted 
mutant T41L F70A was generated by Mansooreh Jaberipour (Jaberipour 2005). This mutant 
showed promise in tissue culture assays and therefore kinetic characterisation was considered 
useful. The three mutants were compared to WT NTR, the single mutant F124N, the double 
mutant T41L N71S and the triple mutant T41Q N71S F124T which had previously been 
characterised. Kinetic parameters were determined with CB1954, nitrofurazone and 
menadione as substrates. 
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5.2 MATERIAL AND METHODS 
5.2.1 NTR expression 
5.2.1.1 Plasmid construction 
λ lysogens encoding desired NTR mutants were streaked onto LB plates containing a fresh 
lawn of E. coli UT5600. The resulting lysis area was picked and used to provide a template 
for a PCR reaction, using Kod polymerase with primers JG2A and JG2B (see Section 2.2.1) 
to generate NTR PCR fragments. PCR products were resolved by agarose gel electrophoresis 
to confirm that DNA fragments of the correct size had been amplified, and purified using 
Roche High Pure PCR Product Purification Kit (Roche Applied Sciences, Germany). 
 
A plasmid vector pET 24c was digested with Nde I and Bam HI and the appropriate size 
fragment was extracted using Qiagen QIA-Quick Gel Extraction Kit (Qiagen, West Sussex). 
The NTR PCR products were sequentially digested with Nde I and Bam HI before ligation 
with the digested pET 24c (0.2 pico moles of PCR insert with 200 ng plasmid vector) and 
transformed into competent E. coli XL-2 blue cells. Individual colonies were picked and 
grown in 10 ml of LB Broth containing kanamycin. Mini Prep plasmid purification was 
performed on the bacterial cultures and the resulting plasmids were digested with Nde I, Eco 
RV and Bgl II and analysed by agarose gel electrophoresis (see section 2.2.14). Plasmids with 
correct digestion patterns were taken on to large-scale 300 ml cultures. Bulk Prep purification 
was performed on the bacterial cultures (see section 2.2.15) and aliquots of the resulting 
plasmid preps were again digested with Nde I, Eco RV and Bgl II. Plasmids with correct 
digestion patterns were linearised with Hind III and the inserted NTR gene sequenced with 
primers PS1013A and PS1013B (see section 2.2.1).  
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                                                                                                                          Figure 5.1 Schematic diagram of plasmid pET 24c vector 
Plasmid pET 24c is a high level vector that contains a bacteriophage T7 promoter and terminator, allowing large amounts of protein to be generated. 
This plasmid was designed for the expression of open reading frames from multiple cloning sites, in this case insertion of NTR between Nde I and 
Bam HI sites 
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5.2.1.2 Bacterial growth and protein Induction 
1 µl (200 ng) of undigested plasmid DNA construct pET 24c encoding mutant NTR was 
transformed into E. coli BL21 λDE3. These cells allow over-expression of mutant NTR as the 
λDE3 encodes T7 RNA Polymerase (RNAP). A single colony was picked for each mutant and 
grown at 37 
o
C overnight in 50 ml LB Broth containing kanamycin as a starter culture. 10 ml 
of this initial culture was used to inoculate 1 litre of LB kanamycin and left to shake at 37 
o
C 
until an OD600 of approximately 0.6 was reached. Absorbance readings were taken on an 
Eppendorf Biophotometer. Expression of NTR was induced by the addition of IPTG to a final 
concentration of 1 mM. Subsequently, the cells were grown for a further 4 hours and 
harvested by centrifugation at 8000x g for 20 minutes. Pelleted cells were frozen at -20 
o
C to 
facilitate cell wall weakening and aid lysis. 
 
5.2.2 Preparation of crude extract 
The cells and all cell suspensions were incubated on ice during the preparation of the extract. 
4 ml of lysis buffer (20 mM sodium phosphate pH 7.0, 10 µg/ml DNase I, 10 µg/ml RNase A, 
10 µg/ml PMSF and 20 µM FMN) was added per gram of cells. The cells were gently 
resuspended using a rubber teat on the end of a glass rod, and were broken open by sonication 
for approximately 2.5 minutes using 4 cycles of 20 seconds pulse, 20 seconds pause. The 
lysed cells were then centrifuged at 8000x g for 20 minutes (MSE Europa) and the 
supernatant collected. Ammonium sulphate was added to the supernatant to a final 
concentration of 0.5 M. A distinct gold colour was observed. This was followed by a further 
centrifugation step at 8000x g for 20 minutes (MSE Europa). The resultant gold supernatant 
was then filtered through a 0.45 µm filter. 
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5.2.3 Purification of crude extract 
5.2.3.1 Phenyl sepharose column (Hydrophobic interaction column) 
Phenyl sepharose columns bind NTR at high ionic strength allowing the removal of the 
majority of contaminating proteins before elution from the column at low ionic strength. The 
phenyl sepharose column (50 ml in volume) was pre-equilibrated with 20 mM sodium 
phosphate (pH 7.0), 0.5 M ammonium sulphate and 50 µM FMN. The cell extract (~51 ml 
from 1 litre) was applied onto the column at room temperature and washed with the same 
buffer containing 10 µg/ml of PMSF (flow rate of ~31.2 ml/hr). The absorbance of each 
fraction was measured at 280 nm (this monitors the protein content). Once the absorbance of 
the fractions approached zero, the bound protein was eluted with 10 mM Tris (pH 7.0), 50 µM 
FMN and 10 µg/ml PMSF.  Fractions containing NTR were identified by absorbance (280 
nm) and activity (550 nm). Peak fractions containing NTR were pooled. 
 
5.2.3.2 Q-sepharose column (Ion Exchange column) 
Q-sepharose is an ion exchange column that uses a linear NaCl gradient.  The Q-Sepharose 
column (50 ml in volume) was pre-equilibrated with 20 mM Tris HCl (pH 7.0), 50 µM FMN 
and 10 µg/ml PMSF. The pooled fractions from the Phenyl Sepharose column were diluted 
with the above buffer (final volume of ~75 ml) to reduce the conductivity to 4.5. The sample 
was loaded onto the column (flow rate of ~36 ml/hr). The column was eluted with a gradient 
of 0.1 M NaCl buffer to 0.3 M NaCl buffer 80 ml and 15 minute fractions collected. 
Absorbance at 280 nm and activity at 550 nm were measured for each fraction as well as the 
conductivity.  
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Conductivity of gradient buffers at 4 
o
C: 
0.1 M NaCl / 20 mM Tris/20 µM FMN/ PMSF = 4.5 
0.5 M NaCl / 20 mM Tris/20 µM FMN/ PMSF = 12 
1 M NaCl / 20 mM Tris/20 µM FMN/ PMSF = 32 
 
5.2.4 Concentration of NTR protein 
NTR pools were concentrated using an Amicon series 8000 50 ml or 3 ml capacity stirred 
ultrafiltration cell (Millipore, UK). YM10 membrane was used and each protein was 
concentrated to a final concentration of approximately 2.5 mg/ml. 
 
5.2.5 Determination of protein concentration 
NTR protein concentrations were estimated from the absorbance at 280 nm using an 
extinction coefficient of 43,000 M
-1
 cm
-1
 (Race et al. 2005), which was determined by 
calculation of amino acid composition and flavin content, or by Bradford Assay using UV 
absorbance at 595 nm. Standard curves were prepared from a BSA stock 1 mg/ml using a 
range from 0-10 µg. (Bradford 1976). 
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5.2.6 SDS PAGE  
Gels were prepared using Biorad apparatus (Biorad, Hemel Hempstead), see section 2.4.2. 
Samples were diluted 1:1 with Laemmli loading buffer (4% SDS, 20% glycerol, 10% β-
mercaptoethanol, 0.0004% bromophenol blue and 0.125 M Tris HCl) and run alongside 
Biorad Broad range molecular weight markers to verify molecular weights (Laemmli 1970). 
The gels were run at 100 volts for approximately 2 hours. SDS Page gels were stained in 
Coomassie Blue R-250 (2.5 g in 1L 50% Methanol, 10% Glacial Acetic Acid) for 2 hours and 
then destained overnight (in 10% Glacial Acetic Acid, 40% Methanol and 50% Water) to 
remove excess stain. Several changes of destain were required. The fully destained gels were 
dried between sheets of cellulose for 2 hours using a gel dryer. 
 
5.2.7 NTR activity and specific activity 
The activity of NTR was determined using assays with 100 µM NADH (in 10 mM Tris pH 
8.0) and 200 µM Menadione (in DMSO) as enzyme substrates in the presence of 100 µM 
cytochrome c and 10 mM Tris HCl buffer (pH 7.0). The reaction was initiated by the addition 
of a small volume of purified NTR and activity determined by measuring reduction of 
cytochrome c at 550 nm (on Kontron Uvikon 923 spectrophotometer) for 3 minutes at 25 
o
C. 
Each 2e
-
 electron reduction of Menadione leads to two single-electron reductions of 
cytochrome c. 
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The specific activity of NTR was calculated using the cytochrome c extinction coefficient of 
27,000 M
-1
 cm
-1
. 
 
                                                                                                                                                    
      
                                                                                                                                                                      
5.2.8 Preparation of dialysis tubing 
All dialysis tubing was prepared by boiling for 10 minutes in a litre of water containing 0.1 
mM EDTA, 0.1% v/v β-mercaptoethanol and 10-20 mg of sodium bicarbonate. Boiled tubing 
was rinsed with sterile water and stored at 4 
o
C. 
 
5.2.9 Kinetic assays 
Initial velocity studies of WT and mutant NTR were performed using a series of 
spectrophotometric assays (using Kontron Uvikon 923 spectrophotometer) for substrates 
CB1954, nitrofurazone and menadione, using NADH as cofactor. The menadione assay was 
coupled with 100 µM cytochrome c. This allows menadione to be recycled preventing 
substrate inhibition.  
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Changes Monitored 
 
Substrate λ reaction 
nm 
ε at λ reaction 
M
-1
 cm
-1
 
λ [substrate] 
nm 
ε at λ [substrate] 
M
-1
 cm
-1 
2 and 4 hydroxylamine formation CB1954 420 1,200 327 12,000 
Nitrofurazone reduction Nitrofurazone 440 880 400 
420 
12,960 
5,590 
Cytochrome C reduction Menadione 550 27,000 340 
363 
251 
2,480 
15,100 
17,400 
 
       
            
  
 
 
Table 5.1 Spectrophotometric changes monitored during enzyme kinetics studies and extinction coefficient used at respective 
wavelengths 
Two different λ values are shown for each substrate. These show the wavelength for the substrate and the product(s) of the reaction 
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Table 5.1 shows the wavelengths used for the reduction of substrates and the extinction 
coefficients for determining substrate concentrations and for calculation of rates. Reactions 
were carried out using 0.5 and 1 cm path length cuvettes. Different path lengths were used to 
reduce background absorbance when high substrate concentrations were required. All 
reactions were performed in 10 mM Tris HCl pH 7.0, 5% DMSO at a constant temperature of 
25 
o
C using a circulating water bath. It has been reported that DMSO concentrations of more 
than 5% (total volume) can inhibit NTR reactions (Anlezark et al. 1992) Reactions were 
initiated by the addition of 2-4 µl (1-50 nM) of ice cold enzyme. All substrates used were 
dissolved in 90% DMSO, 10% 100 mM Tris pH 7.0.   
 
Rates of reaction were measured in duplicate over a range of substrate concentrations, ranging 
from 0.5-5 times Km or as high as substrate concentration permitted by solubility. Direct linear 
plots were used to estimate initial Km of NTR mutants to design experiments. 
 
Rates were measured varying one substrate concentration [A] while keeping the other 
substrate concentration constant. For example varying NADH while keeping CB1954 
constant. The vi (initial rate) and [A] were then fitted to a simple single-substrate Menten 
equation where [E] is the enzyme concentration (see Equation 5.1). 
 
[A]
[A]
[E] 

mAapp
catappi
K
kv
  Equation 5.1 
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The parameter to fit this equation estimates the kcatapp (the number of cycles a single enzyme 
molecule undergoes per unit of time), and the KmAapp (the concentration of substrate A at 
which the initial rate is half of its possible maximum). 
 
When looking at a “ping pong” mechanism however, these values are dependent on the 
concentration and kinetic parameters of the fixed substrate B (see Equations 5.2 and 5.3). 
 
    
]B[
]B[


mB
mA
mAapp
K
K
K      Equation 5.2     and      
]B[
]B[


mB
cat
catapp
K
k
k      Equation 5.3 
 
This is why they are described as apparent kcat and Km (Kcatapp and Kmapp). However for this 
mechanism, kcat/Km remains constant at various concentrations of substrate B (Engel 1981). 
 
When apparent kcat or Km cannot be correctly estimated the kcat/Km can be determined by 
fitting to a modified Equation 5.4  
 
]A[
]A[
]E[












mA
cat
cat
catappi
K
k
k
kv
 Equation 5.4 
 
When several plots have been determined at a range of substrate concentrations, it is possible 
to obtain the overall kinetic parameters by means of a global fit which describes the full “ping 
pong” reaction (see Equation 5.5). 
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[A][B][A][B]
[A][B]
]E[   KK
kv
mBmA
cati

      Equation 5.5 
 
Again it is possible to estimate the kcat/Km of each substrate independently by fitting kcat/Km as 
an independent parameter (see Equation 5.6).  
 
[A][B][A][B]
[A][B]
]E[
 
K
k
k
 
K
k
k
kv
mB
cat
cat
mA
cat
cat
cati






















     Equation 5.6 
 
5.2.10 Determining kinetic parameters 
Sigma Plot 11 software package (SPSS, UK) was used to analyse all steady-state kinetic data 
using non-linear regression to fit to Michaelis Menten equation. Fitted data was analysed 
statistically by calculating t test and P values for each regression curve, t equals the ratio of 
the regression coefficient to its standard error, indicating how much the rate of the reaction 
depends on the Km or kcat. A large t value indicates that the data fits the equation and that the 
rate of reaction can be predicted from the parameters. The P value is the probability that the 
parameters fit the curve by chance, the smaller the P value the less likely it occurred by 
chance. Ideally P values should be < 0.05, which indicates a reliable fit to the experimental 
data.  
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5.2.11 Nuclear Magnetic Resonance 
One-dimensional NMR spectra were collected at 500.18 MHz at 298K using a Bruker 500 
spectrometer with a TXI cryoprobe. Typically 128 scans were collected with 32k data points, 
a sweep width of 12 ppm, and a relaxation delay of 1.5 seconds between scans. The H2O and 
DMSO signals were reduced using excitation sculpting (Hwang and Shaka 1995). 
  
NAD(P)H (1 mM final concentration) and CB1954 (0.5 mM final concentration, in 10% final 
DMSO) were mixed in 10 mM sodium phosphate buffer, pH 7.0, containing 10% D2O. 
Approximately 0.1 µM of each enzyme was then added and the one-dimensional NMR 
spectrum taken within 5-10 minutes. 
 
5.3 RESULTS 
5.3.1 NTR expression 
5.3.1.1 Plasmid construction 
The genes of NTR mutants were recloned from λ lysogens into pET 24c using PCR 
amplification. PCR products were resolved by agarose gel electrophoresis to ensure DNA 
fragments of the correct size were amplified (see Figure 5.2). Bands of the correct size were 
the major products of each PCR reaction and were gel purified. 
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         M     1     2      3 
 
 
Figure 5.2 Agarose gel of PCR fragments for plasmid construction using primers JG2A and 
JG2B  
Total PCR products amplified from λ phage. PCR products were run on 0.7% agarose gel. M = Marker 
1 kb plus ladder, Lanes 1-3 NTR fragments T41G N71S, T41L F70A and 282 respectively. A single 
fragment of approximately 1000 bp observed for each PCR corresponding to full length gene 
 
 
The purified PCR products were digested with Nde I and Bam HI before being ligated with 
Nde I and Bam HI digested pET 24c plasmid vector and transformed. Plasmids were isolated 
from individual colonies, and the resulting plasmid DNA digested with Nde I, Eco RV and 
Bgl II to check whether the correct plasmids were isolated. Digestion products were resolved 
by agarose gel electrophoresis (see Figure 5.3).  
 
Plasmids with correct digestion patterns were digested with Hind III and sequenced with 
primers PS1013A and PS1013B to ensure the correct NTR gene was cloned. 
12000 
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100 
700 
1000 
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gene  
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Figure 5.3 Restriction enzyme digests of plasmid bulk preparation DNA  
Plasmid digests run on 0.7% agarose gel. M = Marker 1kb plus ladder, Lanes 1-3 pSHT41GN71S24c, Lanes 4-6 pSHT41LF70A24c, Lanes 7-9 
pSH28224c. Each set of three showed Eco RV, Bgl II and Nde I digests from left to right. The table on the right shows expected band sizes for each 
enzyme digestion. The schematic diagram shows the fully constructed plasmid with Eco RV, Bgl II and Nde I restriction sites labelled. Correct 
digestion patterns were observed for all four plasmids 
 
Eco RV Bgl II Nde I 
4686 5470 5967 
1281 497  
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5.3.2 Purification of T41G N71S NTR  
5.3.2.1 Phenyl sepharose Column (Hydrophobic column) 
T41G N71S was expressed in BL21 λDE3 cells and crude extracted prepared before being 
purified on a Phenyl sepharose column. After loading and elution from the column 
absorbance measurements, activity assays and SDS PAGE gels showed that fractions 34, 35 
and 36 contained active NTR with greatest purity (see Figure 5.4). Further NTR was found 
between fractions 26-33 and 37. It seems that the protein started to lose bonding to the 
column prior to elution with low NaCl buffer. Two pools were generated: fractions 34-36 and 
fractions 26-33 and 37. Both pools were concentrated before taking forward to Q-sepharose 
columns. 
 
5.3.2.2 Q-sepharose Column (Ion Exchange column) 
Pool one (fractions 34-36) was loaded onto a Q-sepharose column and eluted using a NaCl 
gradient. In this case the protein failed to bind to the column.  The protein (fractions 4-13) 
was loaded onto a second column and was eluted between fractions 19-25. See Figure 5.5 for 
absorbance, activity assays, conductivity and SDS PAGE gels.  
 
Pool two (fractions 26-33 and 37) was loaded on onto a Q-sepharose column and eluted using 
a NaCl gradient. Conductivity, absorbance, activity assays and SDS PAGE gels were run. The 
protein bound tightly to the column and eluted between fractions 13-17 (see Figure 5.6).  
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                   Figure 5.4 Summary of phenyl sepharose column purification T41G N71S 
The blue line represents absorbance at 280 nm and the pink line is the activity of each fraction at 550 nm based on activity assays. Each section is 
labelled with the column buffer, with the vertical dotted line representing the point of buffer change. SDS PAGE gel 1 shows the crude extract put onto 
the column in lane 1 and peak fractions 34-36 in lanes 2-4. Gel 2 shows fractions 26-32 in lanes 1-6 
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Figure 5.5 Summary of Q-sepharose column purification T41G N71S pool 1 
The blue line represents absorbance at 280 nm and the pink line is the activity of each fraction at 550 nm based on activity assays. The green line 
shows the conductivity of each fraction. SDS PAGE gel 1 shows Q-sepharose pool (fractions 4-13 from first Q-sepharose column), concentrated pool, 
diluted pool and fractions 6 and 18-22 and gel 2 shows fractions 23-25 
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 Figure 5.6 Summary of Q-sepharose column purification T41G N71S pool 2 
The blue line represents absorbance at 280 nm and the pink line is the activity of each fraction at 550 nm based on activity assays. The green line shows 
the conductivity of each fraction. SDS PAGE gel 1 showing phenyl sepharose pool (26-33 and 37), dialysed pool and concentrated pool and gel 2 shows 
fractions 12-20 
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5.3.3 Purification of T41L F70A NTR  
5.3.3.1 Phenyl sepharose Column (Hydrophobic column) 
The same method of purification was used for T41L F70A. However absorbance 
measurements, activity assays and SDS PAGE gels showed that fractions 10-30 contain a 
large amount of active NTR protein. This indicates that most of the protein didn‟t bind to the 
column and washed straight through. A further peak was seen at fractions 38-41 where any 
tightly bound protein was eluted, as shown in Figure 5.7. The protein which didn‟t bind to the 
column was very clean and was therefore pooled, concentrated and stored for later analysis. 
Fractions 38, 39, 40 and 41 were pooled and concentrated before taking forward to Q-
sepharose column. 
 
5.3.3.2 Q-Sepharose Column (Ion Exchange column) 
T41L F70A (fractions 38-41) was loaded onto Q-sepharose column and eluted the same as 
T41G N71S. The protein bound to the column and eluted between fractions 16-22 (see Figure 
5.8).  
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Figure 5.7 Summary of phenyl sepharose column purification T41L F70A  
The blue line represents absorbance at 280 nm and the pink is the activity of each fraction at 550 nm based on activity assays. Each section is 
labelled with the column buffer, with the vertical dotted line representing the point of buffer change. SDS PAGE gel 1 shows the crude extract put 
onto column in lane 1 and fractions 13, 15, 17, 19, 21, 23 and 25 in lanes 2-8. Gel 2 showing fractions 27, 29, 31, 33, 35, 36, 37 and 42 in lanes 1-8 
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Figure 5.8 Summary of Q-sepharose column purification T41L F70A 
The blue line represents absorbance at 280 nm and the pink line activity of each fraction at 550 nm based on activity assays. The green line shows the 
conductivity of each fraction. The SDS PAGE gel shows diluted onto Q-Sepharose (Phe Seph fractions 38-41) in lane 1 and fractions 16-22 from Q-
Sepharose column lanes 2-8 
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5.3.4 Purification of N71S A113V R121V F123N F124V A125C K179R 
(282) NTR 
 
5.3.4.1 Phenyl sepharose Column (Hydrophobic column) 
The same method of purification was used for N71S A113V R121V F123N F124V A125C 
K179R. However absorbance measurements were very high for fractions 3-10, indicating 
most of the protein didn‟t bind to the column and washed straight through along with any 
impurities. Fractions 3-14 were pooled and concentrated before loading onto a second phenyl 
sepharose column under different conditions. The second column was pre-equilibrated with 
20 mM Sodium Phosphate (pH 7.0), 1 M ammonium sulphate and 50 µM FMN. The protein 
was loaded onto the column and washed with 1 M ammonium sulphate, before being eluted 
first with 0.75 M ammonium sulphate, then 0.5 M ammonium sulphate and finally with Tris 
(pH 7.0). Fractions containing NTR were identified by absorbance and activity assays. SDS 
PAGE gels were used to examine the purity of NTR containing fractions (see Figure 5.9). 
Fractions 39-56 were pooled for loading on Q-Sepharose column. 
 
5.3.4.2 Q-Sepharose Column (Ion Exchange column) 
Clone 282 (fractions 39-56) was loaded onto the Q-sepharose column and eluted the same as 
T41G N71S and T41L F70A. The protein bound to the column and eluted between fractions 
21-31 (see Figure 5.10). 
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Figure 5.9 Summary of phenyl sepharose column 2 purification 282  
The blue line represents absorbance at 280 nm and the pink is the activity of each fraction at 550 nm based on activity assays. Each section is 
labelled with the column buffer, with the vertical dotted line representing the point of buffer change. SDS PAGE gel 1 shows fractions 44-52 in lanes 
1-9. Gel 2 showing fractions 53-61 in lanes 1-9  
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Figure 5.10 Summary of Q-Sepharose column purification 282 
The blue line represents absorbance at 280 nm and the pink line activity of each fraction at 550 nm based activity assays. The green line shows the 
conductivity of each fraction. SDS PAGE gel shows concentrated onto Q-Sepharose (Phe Seph fractions 39-56) in lane 1 and fractions 1, 19-22 lanes 
2-6 and gel 2 fractions 23-31 lanes 1-9 
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5.3.5 Pool and concentration of NTR enzyme stocks 
Based on specific activity four pools for T41G N71S, three pools for T41L F70A and three 
pools for 282 were created. Each pool was dialysed overnight and concentrated (see Table 
5.2). UV Spectra (ratio 454/272 nm) was measured for each pool to determine the ratio of 
bound and free FMN, see Figure 5.11 for an example of NTR UV spectrum. 
 
Enzyme Pool Volume  
(ml) 
UV spectra  
(454/272 nm) 
Bradford  
(µg/µl) 
Specific activity  
(s
-1
) 
T41G N71S Q2 Major 1 0.32 2.1 0.1 
Q2 Minor 1 0.35 1.8 0.1 
Q3 3.5 0.30 2.4 3.7 
Phe 1 0.34 1.1 0.1 
T41L F70A  Q 3 0.3 2.3 9.9 
P Major 3 0.25 2.2 9.8 
P Minor 3 0.28 6.8 7.3 
282 Q1 4.2 0.24 2.8 1.1 
Q2 2.5 0.22 4.5 1.0 
Q3 2.5 0.20 4.0 0.5 
 
 
 
                  
 
Figure 5.11 UV Spectra  
UV spectra of NTR protein containing bound FMN. The ratio of 454/272 nm should be around 0.30 to 
indicate that most of the FMN present is bound to the enzyme with little free enzyme 
Table 5.2 Final pools for T41G N71S, T41L F70A and 282 
Comprising enzyme, pool, volume (ml), UV spectra (454/272 nm), bradford assay (µg/µl) determining 
the enzyme concentration of each pool and the specific activity of each enzyme pool based on 
bradford assay. Highlighted in red are the pools to be used for kinetic assays 
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Bradford assays were performed for WT, F124N, T41L F70A, T41L N71S, T41G N71S, 
T41Q N71S F124T and clone 282 to determine protein concentration. This data was used to 
determine the specific activity (see Table 5.3).  
 
Enzyme Bradford 
(µg/µl) 
Specific activity 
(µmol min
-1
) 
WT 2.4 2.1 
F124N 6.8 3.2 
T41L F70A 2.3 9.9 
T41L N71S 2.4 4.8 
T41G N71S 16.7 3.7 
T41Q N71S F124T 12.9 5.2 
282 2.5 1.1 
 
 
 
30 µg of each enzyme was run on an SDS PAGE gel. This shows the enzyme purity. Enzyme 
T41L N71S shows fewer impurities than the other enzymes. However good purity was seen 
for all the enzymes (see Figure 5.12). 
  
 
                                  
 
Figure 5.12 Purified enzymes for kinetic studies 
This gel shows the purity of each enzyme with 30 µg of NTR protein loaded. Lanes 1 -7 show WT, 
F124N, T41L F70A, T41L N71S, T41G N71S, T41Q N71S F124T and 282 respectively 
NTR 
Table 5.3 Bradford assay results for purified enzymes 
Bradford assays were used to determine µg/µl protein contents for each purified enzymes and the 
specific activity 
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5.3.6 Steady-state kinetic assays and substrate specificity 
Steady-state kinetic assays were used to determine the kinetic parameters of mutant NTR 
relative to WT. WT and three of the mutants (T41L N71S, F124N and T41Q N71S F124T) 
had previously been studied. These were studied by a single assay with each substrate. The 
three new mutants T41G N71S, T41L F70A and clone 282 were analysed by 8 assays with 
CB1954 and nitrofurazone substrates and a single menadione assay. For CB1954 global 
kinetic parameters were determined for the three new mutants. Previous assays were shown 
for comparative purposes.  
 
5.3.6.1 CB1954 Kinetics 
Steady-state rates for the reduction of CB1954 were determined at fixed concentrations of 
NADH, varying the concentration of CB1954 (see Section 1.4.3.2). These were fitted to 
Equation 5.1 to give apparent Km and kcat values for NADH at each CB1954 concentration 
(see Figures 5.13, 5.15 and 5.17). Rates were also determined at varying concentrations of 
NADH with fixed concentrations of CB1954. These were also fitted to Equation 5.1 to give 
apparent Km and kcat values for CB1954 at each NADH concentration (see Figures 5.14, 5.16 
and 5.18). All the curves fitted Michaelis-Menten hyperbolae. The apparent kcat and Km CB1954 
increased with increasing NADH concentration and the apparent kcat and Km NADH also 
increased with increasing CB1954 concentration, as expected for ping pong Menten kinetics. 
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As with WT NTR and previously purified mutants, the kcat/Km CB1954 and kcat/Km NADH ratios 
remained constant at each concentration for T41G N71S, T41L F70A and 282 (see Tables 5.4, 
5.5 and 5.6). These results indicate that the nitroreduction of CB1954 follows a “ping pong” 
mechanism as stated in literature (Anlezark et al. 1992 and Zenno et al. 1996b) and discussed 
further in Section 1.4.3.  
 
WT, F124N, T41L N71S and T41Q N71S F124T were studied by a single CB1954 assay as 
these NTR enzymes have already been extensively studied (Jarrom 2008, Jaberipour 2005). 
The assays were undertaken for comparative purposes. Each enzyme was studied at 500 µM 
NADH with a range of CB1954 concentrations. Results were fitted to Equation 5.1 and the 
rate of reaction shown graphically (see Figure 5.19). The rates for T41G N71S, T41L F70A 
and 282 at the same concentration of NADH have also been added to this graph. This allows 
all the enzymes to be compared together. The kinetic parameters Km, kcat and kcat/Km were 
determined for each enzyme (see Table 5.7). Again T41G N71S, T41L F70A and 282-HAve 
also been added for comparison.  
 
Previous data for these enzymes have been compared with the ones obtained in this study. 
Table 5.8 shows data for WT, F124N, T41L N71S and T41Q N71S F124T (Jarrom 2008). 
Figure 5.20 shows this comparison in graphical form for each enzyme. A small difference was 
seen for each enzyme, but most values are within error of fit. 
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Finally all data from T41G N71S, T41L F70A and 282 have been fitted to Equation 5.5 to 
give global kinetic parameters for CB1954 and NADH (see Figure 5.21, 5.22, 5.23 and Table 
5.9). This allows the determination of the Km and kcat values, for each substrate. For 
comparison previous global kinetics data for WT, F124N, T41L N71S and T41Q N71S 
F124T have been shown in Table 5.10. 
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Figure 5.13 Plots of rate of reduction of CB1954 by T41G N71S, versus CB1954 concentration 
100 µM NADH (red), 250 µM NADH (black) and 500 µM NADH (green). Lines were fitted to Equation 
5.1 
Figure 5.14 Plots of rate of reduction of CB1954 by T41G N71S, versus NADH concentration 
400 µM CB1954 (red) and 800 µM CB1954 (black). Lines were fitted to Equation 5.1 
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(A) 
 
[NADH] 
(µM) 
[CB1954] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-1750 400 39 ± 2 18.2 <0.0001 470 ± 66 7.1 <0.0001 0.084 ±0.008 10.9 <0.0001 
0-2500 800 42 ± 1 37 <0.0001 312 ± 30 10.3 <0.0001 0.135 ± 0.010 13.3 <0.0001 
 
 (B) 
 
 
 
[CB1954] 
(µM) 
[NADH] 
(µM) 
kcat app CB1954 
(s
-1
) 
t test P Km app CB1954 
(µM) 
t test P kcat/KM CB1954 
(µM s
-1
)
 
t test P 
0-1000 100 13 ± 0.3 39.3 <0.0001 34 ± 4 8.8 <0.0001 0.374 ± 0.036 10.3 <0.0001 
0-800 250 22 ±0.7 31.6 <0.0001 67 ± 8 8.1 <0.0001 0.322 ± 0.032 10.2 <0.0001 
0-800 500 44 ± 1 31.2 <0.0001 97 ± 11 8.9 <0.0001 0.457 ± 0.039 11.8 <0.0001 
Table 5.4 Kinetic Parameters of the reduction of CB1954 by T41G N71S 
(A) CB1954 concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed CB1954 
concentrations. Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and 
P values for each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction 
depends on the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. 
The P value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values 
should be <0.05, which indicates a reliable fit to the experimental data 
 
 225 
                        
 
 
                        
 
 
Figure 5.15 Plots of rate of reduction of CB1954 by T41L F70A, versus CB1954 concentration 
60 µM NADH (red), 100 µM NADH (black) and 500 µM NADH (green). Lines were fitted to Equation 
5.1 
Figure 5.16 Plots of rate of reduction of CB1954 by T41L F70A, versus NADH concentration 
400 µM CB1954 (red) and 900 µM CB1954 (black). Lines were fitted to Equation 5.1 
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[CB1954] 
(µM) 
[NADH] 
(µM) 
kcat app CB1954 
(s
-1
) 
t test P Km app CB1954 
(µM) 
t test P kcat/Km CB1954 
(µM s
-1
)
 
t test P 
0-900 60 31 ± 2 14.3 <0.0001 295 ± 51 5.8 <0.0001 0.106 ± 0.012 9.1 <0.0001 
0-1300 100 35 ± 2 16.1 <0.0001 234 ± 47 5.0 0.0001 0.148 ± 0.022 6.7 <0.0001 
0-2500 500 60 ± 3 21.3 <0.0001 584 ±84 7.0 <0.0001 0.103 ± 0.012 9.8 <0.0001 
 
(A) 
 
 
[NADH] 
(µM) 
[CB1954] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-1150 400 18 ± 0.4 38.7 <0.0001 24 ± 3 7.2 <0.0001 0.699 ± 0.085 8.2 <0.0001 
0-2000 900 43 ± 1 34.3 <0.0001 79 ± 11 7.2 <0.0001 0.542 ± 0.065 8.3 <0.0001 
 
(B) 
 
 
 
Table 5.5 Kinetic Parameters of the reduction of CB1954 by T41L F70A 
(A) CB1954 concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed CB1954 
concentrations. Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and 
P values for each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction 
depends on the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. 
The P value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values 
should be <0.05, which indicates a reliable fit to the experimental data 
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Figure 5.17 Plots of rate of reduction of CB1954 by 282, versus CB1954 concentration  
250 µM NADH (red), 500 µM NADH (black) and 1000 µM NADH (green). Lines were fitted to 
Equation 5.1 
Figure 5.18 Plots of rate of reduction of CB1954 by clone 282, versus NADH concentration  
400 µM CB1954 (red) and 800 µM CB1954 (black). Lines were fitted to Equation 5.1 
 228 
 
[CB1954] 
(µM) 
[NADH] 
(µM) 
kcat app CB1954 
(s
-1
) 
t test P Km app CB1954 
(µM) 
t test P kcat/Km CB1954 
(µM s
-1
)
 
t test P 
0-1500 250 4 ± 0.2 24.9 <0.0001 232 ± 28 8.3 <0.0001 0.016 ± 0.001 11.5 <0.0001 
0-3000 500 10 ± 0.7 23.3 <0.0001 575 ± 109 8.9 <0.0001 0.017 ± 0.001 13.7 <0.0001 
0-3000 1000 19 ± 0.6 30.3 <0.0001 688 ± 67 10.2 <0.0001 0.028 ± 0.002 14.4 <0.0001 
 
(A) 
 
 
[NADH] 
(µM) 
[CB1954] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-1000 400 11 ± 0.4 28.3 <0.0001 92 ± 12 7.6 <0.0001 0.165 ± 0.012 9.6 <0.0001 
0-1000 800 17 ± 0.5 33.5 <0.0001 127 ±14 9.3 <0.0001 0.136 ± 0.011 12.1 <0.0001 
 
(B) 
 
Table 5.6 Kinetic Parameters of the reduction of CB1954 by 282 
(A) CB1954 concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed CB1954 
concentrations. Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and 
P values for each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction 
depends on the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. 
The P value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values 
should be <0.05, which indicates a reliable fit to the experimental data 
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Figure 5.19 Plots of rate of reduction of CB1954, versus CB1954 concentration at 500 µM NADH 
WT (black), F124N (cyan), T41L N71S (purple), T41Q N71S F124T (pink), T41G N71S (red), T41L 
F70A (blue) and 282 (green) 
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NTR 
 
kcat app CB1954 
(s
-1
) 
t test P Km app CB1954 
(µM) 
t test P kcat/Km CB1954 
(µM s
-1
) 
t test P 
Wild Type N.D - - N.D - - 0.009 ± 0.0006 15 <0.0001 
F124N 106 ±12 9 <0.0001 3917 ± 703 6 <0.0001 0.027 ± 0.002 15 <0.0001 
T41L N71S 118 ± 6 23 <0.0001 188 ± 33 7 <0.0001 0.628 ± 0.072 9 <0.0001 
T41Q N71S F124T 161 ± 3 55 <0.0001 578 ± 30 20 <0.0001 0.277 ± 0.010 29 <0.0001 
T41G N71S 44 ± 1 31 <0.0001 97 ± 11 9 <0.0001 0.457 ± 0.039 12 <0.0001 
T41L F70A 60 ± 3 21 <0.0001 584 ± 84 7 <0.0001 0.103 ± 0.012  10 <0.0001 
282 10 ± 1 23 <0.0001 975 ± 109 9 <0.0001 0.010 ± 0.001 14 <0.0001 
 
 
 
 
NTR 
 
kcat app CB1954 
(s
-1
) 
t test P Km app CB1954 
(µM) 
t test P kcat/KM CB1954 
(µM s
-1
) 
t test P 
Wild Type N.D - - N.D - - 0.006 ± 0.0004  18 <0.0001 
F124N 85 ± 2 55 <0.0001 3000 ± 100 27 <0.0001 0.029 ± 0.001 52 <0.0001 
T41L N71S 112 ± 3 40 <0.0001 160 ± 20 8 <0.0001 0.700 ± 0.070 10 <0.0001 
T41Q N71S F124T 159 ± 4 38 <0.0001 520 ± 40  <0.0001 0.310 ± 0.020 19 <0.0001 
 
 
Table 5.7 Kinetic Parameters of WT and six NfsB mutants for the reduction of CB1954 at a constant NADH concentration of 500 µM 
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values for 
each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends on the 
Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P value is the 
probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values should be <0.05, 
which indicates a reliable fit to the experimental data. N.D stands for not determined. It is not possible to determine the kcat apparent and Km apparent for 
WT at this concentration. New data highlighted in red 
Table 5.8 Kinetic Parameters of WT and three NfsB mutants for the reduction of CB1954 at a constant NADH concentration of 500 µM 
Data from previous studies (Jarrom 2008), which have been included for comparison purposes. N.D stands for not determined 
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                      (a)                       (b)  
                       (c)                       (d)
Figure 5.20 Plots of rate of reduction of CB1954, versus CB1954 concentration at 500 µM NADH 
Graphical representation with the red lines showing previous data (Jarrom 2008) and the blue lines this study. (a) WT (b) F124N (c) T41L N71S and (d) 
T41Q N71S F124T 
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Figure 5.21 Global 3D plot of rate of CB1954 reduction at different NADH and CB1954 
concentrations for T41G N71S 
Data fitted to Equation 5.5 
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Figure 5.22 Global 3D plot of rate of CB1954 reduction at different NADH and CB1954 
concentrations for T41L F70A 
Data fitted to Equation 5.5 
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Figure 5.23 Global 3D plot of rate of CB1954 reduction at different NADH and CB1954 
concentrations for 282 
Data fitted to Equation 5.5 
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 WT F124N T41L N71S T41Q N71S F124T 
kcat  s
-1
 140 ± 12 95 ± 7 135 ± 9 181 ± 7 
Km CB1954  µM 17000 ± 5000 3100 ± 500 150 ± 38 570 ± 45 
kcat/Km CB1954  µM s
-1
 0.0072 ± 0.0002 0.031 ± 0.03 0.9 ± 0.1 0.32 ± 0.02 
Km NADH  µM 30 ± 16 55 ± 7 180 ± 33 140 ± 12 
kcat/Km NADH  µM s
-1
 0.83 ± 0.01 1.7 ± 0.2 0.7 ± 0.1 1.33 ± 0.08 
Reference Jarrom, 2008 Jaberipour, 2005 Jarrom, 2008 Jarrom, 2008 
 
 
 T41G N71S t test P T41L F70A t test P 282 t test P 
kcat  s
-1
 46 ± 3 18.6 <0.0001 86 ± 5 18.8 <0.0001 20 ± 2 9.2 <0.0001 
Km CB1954  µM 88 ± 18 4.7 <0.0001 750 ± 91 8.7 <0.0001 619 ± 135 4.6 <0.0001 
kcat/Km CB1954  µM s
-1
 0.52 ± 0.1 5.4 <0.0001 0.11 ± 0.01 14.4 <0.0001 0.018 ± 0.01 6.6 <0.0001 
Km NADH  µM 305 ± 38 8.2 <0.0001 125 ± 13 9.7 <0.0001 183 ± 60 3.0 0.0029 
kcat/Km NADH  µM s
-1
 0.15 ± 0.01 11.6 <0.0001 0.69 ± 0.05 13.1 <0.0001 0.11 ± 0.03 3.9 0.0002 
Table 5.9 Global kinetics parameters for the reduction of CB1954 
Data for T41G N71S, T41L F70A and 282 were fitted to Equation 5.5 and analysed statistically by calculating t test and P values for each 
regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends on 
the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The 
P value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P 
values should be <0.05, which indicates a reliable fit to the experimental data 
 
Table 5.10 Global kinetics parameters for the reduction of CB1954  
WT, F124N, T41L N71S and T41Q N71S F124T NTR from previous studies 
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5.3.6.2 Nitrofurazone Kinetics  
Similar experiments were done for the reduction of nitrofurazone (see Section 1.4.3.2). 
Figures 5.24, 5.26 and 5.28 give apparent Km and kcat values for NFZ with fixed 
concentrations of NADH and Figures 5.25, 5.27 and 5.29 gives apparent Km and kcat values 
for NADH with fixed concentrations of NFZ. Kinetic Parameters for these enzymes can be 
seen in Tables 5.11, 5.12 and 5.13. As seen with CB1954 the apparent kcat and Km NFZ 
increased with increasing NADH concentration and the apparent kcat and Km NADH also 
increased with increasing NFZ concentration.  
 
WT, F124N, T41L N71S and T41Q N71S F124T have been studied by a single NFZ assay for 
comparative purposes. Each enzyme was studied using 200 µM NADH with a range of NFZ 
concentrations as can be seen in Figure 5.30. Kinetic parameters showing Km, kcat and kcat/Km 
values were determined for each enzyme (see Table 5.14). Previous NFZ data for these 
enzymes have been compared to that obtained in this study (see Table 5.15 and Figure 5.31). 
Small differences were seen for WT and T41L N71S enzymes; these values are within error 
of fit. However, F124N and T41Q N71S F124T enzymes showed bigger differences. The Km 
values for these two enzymes were double that previously determined; however the kcat values 
were similar to previous data. 
 
Global parameters for nitrofurazone were attempted however the data did not fit well and 
were not statistically consistent, data not shown. 
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Figure 5.24 Plots of rate of reduction of nitrofurazone by T41G N71S, versus NFZ 
concentration 
200 µM NADH (red), 500 µM NADH (black) and 1000 µM NADH (green). Lines were fitted to 
Equation 5.1 
Figure 5.25 Plots of rate of reduction of nitrofurazone by T41G N71S, versus NADH 
concentration 
500 µM NFZ (red) and 1000 µM NFZ (black). Lines were fitted to Equation 5.1 
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[NFZ] 
(µM) 
[NADH] 
(µM) 
kcat app NFZ 
(s
-1
) 
t test P Km app NFZ 
(µM) 
t test P kcat/Km NFZ 
(µM s
-1
)
 
t test P 
0-1000 200 12 ± 1 18.7 <0.0001 110 ± 24 4.5 0.0003 0.113 ± 0.020 5.7 <0.0001 
0-1700 500 15 ± 1 20.7 <0.0001 132 ± 30 4.3 0.0005 0.116 ± 0.023 5.2 <0.0001 
0-1700 1000 41 ± 3 16.1 <0.0001 438 ± 80 5.5 <0.0001 0.095 ± 0.012 7.9 <0.0001 
 
(A) 
 
 
[NADH] 
(µM) 
[NFZ] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-2000 500 13 ± 0.4 32.6 <0.0001 280 ± 32 8.8 <0.0001 0.048 ± 0.004 11.3 <0.0001 
0-2000 1000 28 ± 1 30.0 <0.0001 503 ± 49 10.3 <0.0001 0.056 ± 0.004 14.9 <0.0001 
 
(B)  
Table 5.11 Kinetic Parameters of the reduction of nitrofurazone by T41G N71S 
(A) NFZ concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed NFZ concentrations. 
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values for each 
regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends on the Km and 
kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P value is the 
probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values should be <0.05, 
which indicates a reliable fit to the experimental data 
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Figure 5.26 Plots of rate of reduction of nitrofurazone by T41L F70A, versus NFZ 
concentration  
40 µM NADH (red), 60 µM NADH (black) and 200 µM NADH (green). Lines were fitted to Equation 
5.1 
Figure 5.27 Plots of rate of reduction of nitrofurazone by T41L F70A, versus NADH 
concentration  
500 µM NFZ (red) and 1000 µM NFZ (black). Lines were fitted to Equation 5.1 
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[NFZ] 
(µM) 
[NADH] 
(µM) 
kcat app NFZ 
(s
-1
) 
t test P Km app NFZ 
(µM) 
t test P kcat/Km NFZ 
(µM s
-1
)
 
t test P 
0-1650 40 48 ± 4 13.7 <0.0001 347 ± 88 3.9 0.0020 0.138 ± 0.026 5.3 0.0002 
0-2200 60 86 ± 5 16.5 <0.0001 953 ± 138 6.9 <0.0001 0.090 ± 0.008 11.4 <0.0001 
0-2000 200 90 ± 3 31.9 <0.0001 481 ± 46 10.5 <0.0001 0.186 ± 0.013 14.9 <0.0001 
 
(A) 
 
 
[NADH] 
(µM) 
[NFZ] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-2000 500 33 ± 0.4 79.7 <0.0001 41 ± 4 11.1 <0.0001 0.810 ± 0.067 12.0 <0.0001 
0-2000 1000 46 ± 1 37.8 <0.0001 90 ± 13 6.9 <0.0001 0.517 ± 0.0065 7.9 <0.0001 
 
(B) 
 
 
 
 
Table 5.12 Kinetic Parameters of the reduction of nitrofurazone by T41L F70A 
(A) NFZ concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed NFZ concentrations. 
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values for each 
regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends on the Km and 
kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P value is the 
probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values should be <0.05, 
which indicates a reliable fit to the experimental data 
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Figure 5.28 Plots of rate of reduction of nitrofurazone by 282, versus NFZ concentration  
100 µM NADH (red) and 200 µM NADH (black). Lines were fitted to Equation 5.1 
Figure 5.29 Plots of rate of reduction of nitrofurazone by 282, versus NADH concentration 
500 µM NFZ. Lines were fitted to Equation 5.1 
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[NFZ] 
(µM) 
[NADH] 
(µM) 
kcat app NFZ 
(s
-1
) 
t test P Km app NFZ 
(µM) 
t test P kcat/Km NFZ 
(µM s
-1
)
 
t test P 
0-1700 100 5 ± 0.2 22.8 <0.0001 217 ± 37 5.8 <0.0001 0.021 ± 0.003 7.3 <0.0001 
0-1700 200 6 ± 0.4 14.8 <0.0001 216 ± 57 3.8 0.0017 0.029 ± 0.006 4.7 0.0002 
 
(A) 
 
 
[NADH] 
(µM) 
[NFZ] 
(µM) 
kcat app NADH 
(s
-1
) 
t test P Km app NADH 
(µM) 
t test P kcat/Km NADH 
(µM s
-1
)
 
t test P 
0-2000 500 5 ± 0.3 19.2 <0.0001 136 ± 34 4.0 0.0008 0.039 ± 0.008 4.8 0.0002 
 
(B) 
Table 5.13 Kinetic Parameters of the reduction of nitrofurazone by 282  
(A) NFZ concentration is varied at a range of fixed NADH concentrations (B) NADH concentration is varied at a range of fixed NFZ concentrations. 
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values for 
each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends on the Km 
and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P value is the 
probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values should be <0.05, 
which indicates a reliable fit to the experimental data 
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Figure 5.30 Plots of rate of reduction of nitrofurazone, versus NFZ concentration at 200 µM 
NADH  
WT (black), F124N (cyan), T41L N71S (purple), T41Q N71S F124T (pink), T41G N71S (red), T41L 
F70A (blue) and 282 (green) 
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NTR 
 
kcat app NFZ 
(s
-1
) 
t test P Km app NFZ 
(µM) 
t test P kcat/Km NFZ 
(µM s
-1
) 
t test P 
Wild Type 76 ± 4 17.3 <0.0001 1105 ± 134 8.2 <0.0001 0.068 ± 0.005 15 <0.0001 
F124N 30 ± 4 11.4 <0.0001 609 ± 171 4.7 0.0002 0.049 ± 0.006 7.7 <0.0001 
T41L N71S 36 ± 1 28.7 <0.0001 120 ± 17 7.2 <0.0001 0.302 ± 0.034 9.0 <0.0001 
T41Q N71S F124T 28 ± 2 28.7 <0.0001 718 ± 141 8.6 <0.0001 0.038 ± 0.002 16.3 <0.0001 
T41G N71S 12 ± 1 18.7 <0.0001 110 ± 24 4.5 0.0003 0.113 ± 0.020 5.7 <0.0001 
T41L F70A 90 ± 3 31.9 <0.0001 481 ± 46 10.5 <0.0001 0.186 ± 0.013 14.9 <0.0001 
282 6 ± 0.4 14.8 <0.0001 216 ± 57 3.8 0.0017 0.029 ± 0.006 4.7 0.0002 
 
 
 
 
NTR 
 
kcat app NFZ 
(s
-1
) 
t test P Km app NFZ 
(µM) 
t test P kcat/Km NFZ 
(µM s
-1
)
 
t test P 
Wild Type 80 ± 2 36 <0.0001 1280 ± 70 19 <0.0001 0.063 ± 0.002 38 <0.0001 
F124N 27 ± 2 13 <0.0001 350 ± 60 5.7 <0.0001 0.077 ± 0.008 9.4 <0.0001 
T41L N71S 37 ± 1 27 <0.0001 120 ± 10 10 <0.0001 0.300 ± 0.020 15 <0.0001 
T41Q N71S F124T 23 ± 2 15 <0.0001 320 ± 50 6.8 <0.0001 0.070 ± 0.006 12 <0.0001 
 
 
Table 5.14 Kinetic Parameters of WT and six NfsB mutants for the reduction of nitrofurazone at a constant NADH concentration of 200 µM  
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values 
for each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends 
on the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P 
value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values 
should be <0.05, which indicates a reliable fit to the experimental data. New data highlighted in red 
Table 5.15 Kinetic Parameters of WT and three NfsB mutants for the reduction of nitrofurazone at a constant NADH concentration of 200 
µM 
Data from previous studies (Jarrom 2008), which have been included for comparison purposes 
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                          (a)                       (b)  
                          (c)                       (d)
Figure 5.31 Plots of rate of reduction of nitrofurazone, versus NFZ concentration at 200 µM NADH  
Graphical representation with the red lines showing previous data (Jarrom 2008) and the blue lines this study. (a) WT (b) F124N (c) T41L N71S and (d) 
T41Q N71S F124T 
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5.3.6.3 Menadione Kinetics 
In addition to the reduction of nitroaromatic compounds NTR can reduce quinones to the 
corresponding quinols (see Section 1.4.3.1). Steady-state rates for the reduction of menadione 
were determined at a single fixed concentration of 500 µM NADH, varying the concentration 
of menadione for WT and all six mutants. This reaction was coupled with 100 µM 
cytochrome c. These were fitted to Equation 5.1 and a graph showing the rate of reaction 
constructed (see Figure 5.32). Kinetic parameters showing apparent Km, kcat and kcat/Km were 
determined for each enzyme (see Table 5.16).  
 
Previous menadione data for WT, F124N, T41L N71S and T41Q N71S F124T enzymes have 
been compared to that obtained in this study (see Table 5.17 and Figure 5.33). A small 
difference was seen for each enzyme; however the kcat/Km for each was similar to previous 
data. 
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Figure 5.32 Plots of rate of reduction of menadione, versus menadione concentration at 500 µM 
NADH 
WT (black), F124N (cyan), T41L N71S (purple), T41Q N71S F124T (pink), T41G N71S (red), T41L 
F70A (blue) and 282 (green). (a) Shows T41Q N71S F124T, WT and 282 (b) Shows detail T41L F70A, 
T41L N71S and T41G N71S 
      (a) 
     (b) 
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NTR 
 
kcat app MENADIONE 
(s
-1
) 
t test P Km app MENADIONE 
(µM)  
t test P kcat/Km MENADIONE 
(µM s
-1
) 
t test P 
Wild Type 96 ± 3 28.8 <0.0001 231 ± 21 10.9 <0.0001 0.42 ± 0.03 16.6 <0.0001 
F124N 50 ± 2 29.1 <0.0001 14 ± 2 6.3 <0.0001 3.57 ± 0.49 7.3 <0.0001 
T41L N71S 57 ± 2 36.8 <0.0001 9 ± 1 15.3 <0.0001 6.23 ± 0.26 24.4 <0.0001 
T41Q N71S F124T 117 ± 1 83.5 <0.0001 12 ± 1 19.0 <0.0001 9.75 ± 0.30 22.4 <0.0001 
T41G N71S 18 ± 1 20.1 <0.0001 5 ± 1 6.8 <0.0001 3.43 ± 0.36 9.5 <0.0001 
T41L F70A 170 ± 5 34.9 <0.0001 25 ± 1 12.1 <0.0001 6.80 ± 0.50 17.2 <0.0001 
282 16 ± 0.4 45.4 <0.0001 8 ± 2 5.7 <0.0001 1.97 ± 0.32 6.1 <0.0001 
 
 
 
 
NTR 
 
kcat app MENADIONE 
(s
-1
) 
t test P Km app MENADIONE 
(µM) 
t test P kcat/Km MENADIONE 
(µM s
-1
) 
t test P 
Wild Type 80 ± 3 31 <0.0001 150 ± 15 9.8 <0.0001 0.58 ± 0.04 13 <0.0001 
F124N 58 + 4 14 <0.0001 24 ± 6 3.9 0.005 2.8 ± 0.5 4.9 0.001 
T41L N71S 53 ±  5 11.2 <0.0001 8 ± 2 3.6 0.0046 6.4 ± 1.2 5.3 0.0002 
T41Q N71S F124T 107 ± 5 23 <0.0001 7 ± 1 5.4 0.0005 15 ± 2 6.3 0.0001 
 
 
Table 5.16 Kinetic Parameters of WT and six NfsB mutants for the reduction of menadione at a constant NADH concentration of 500 µM  
Parameters for data were fitted to Equation 5.1 for a single substrate Menten equation and analysed statistically by calculating t test and P values 
for each regression curve, t equals the ratio of the regression coefficient to its standard error, indicating how much the rate of the reaction depends 
on the Km and kcat. A large t value indicates that the data fits the equation and that the rate of reaction can be predicted from the parameters. The P 
value is the probability that the parameters fit the curve by chance, the smaller the P value the less likely it occurred by chance. Ideally P values 
should be <0.05, which indicates a reliable fit to the experimental data. New data highlighted in red 
Table 5.17 Kinetic Parameters of WT and three NfsB mutants for the reduction of menadione at a constant NADH concentration of 500 µM 
Data from previous studies (Jarrom 2008 and Anchal unpublished), which have been included for comparison purposes  
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                                (a)                       (b)  
                                 (c                       (d)
Figure 5.33 Plots of rate of reduction of menadione, versus menadione concentration at 500 µM NADH 
Graphical representation with the red lines showing previous data (Jarrom 2008) and the blue lines this study.  (a) WT (b) F124N (c) T41L N71S and (d) 
T41Q N71S F124T 
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5.3.7 Analysis and quantification of product ratios for the reduction     
of CB1954  
 
WT NfsB enzyme reduces the prodrug CB1954 at both the 2-hydroxylamine and 4- 
hydroxylamine in equal ratios. The 4-hydroxylamine (4-HA) is highly cytotoxic being a 
difunctional alkylating agent (Anlezark et al. 1992). Whereas the 2-hydroxylamine (2-HA) is 
a less toxic monofunctional alkylating agent which allows greater spread of the active product 
known as the “bystander effect” (Helsby et al. 2004).  It has previously been determined that 
most NfsB mutants produce a 50:50 ratio of the 2-HA and 4-HA, with the exception of 
mutants with a T41 mutation to Leucine. Both the mutant T41L and T41L N71S only produce 
the 4-HA. 
 
Nuclear magnetic resonance spectroscopy (NMR) was used to analyse the product ratio for 
T41G N71S, T41L F70A and clone 282 NTR activation of CB1954. WT NfsB, T41L N71S 
and NfsA were also analysed for comparison purposes. 
 
T41G N71S produces both the 4-HA and 2-HA with a slight preference for the 4-HA. Both 
T41L F70A and clone 282 dominantly produce the 4-HA. In the case of 282 a small amount 
of 2-HA is produced (see Figure 5.34). 
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CB1954
CB1954 + NADH
WT NfsB
2 HA 4 HA
(a)
 
2-HA                  4-HA 
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    Figure 5.34 NMR spectra for the reduction of CB1954  
(a) Control: CB1954 alone, CB1954 + NADH and CB1954 + NADH + WT NfsB, (b) Previous enzymes: 
WT NfsB, WT NfsA and T41L N71S, (c) New enzymes: N71S A113V R121V F123N F124V A125C 
K179R (282), T41L F70A and T41G N71S. NAD(P)H (1 mM final concentration) and CB1954 (0.5 mM 
final concentration, in 10% final DMSO) were mixed in 10 mM sodium phosphate buffer, pH 7.0, 
containing 10% D2O. Approximately 0.1 µM of each enzyme was then added and spectrum taken within 
5-10 minutes. NADH was used for all enzymes except WT NfsA which used NADPH. This work was 
carried out by Dr Eva Hyde using purified enzymes purified in this study 
251/252 
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  2-HA                              4-HA 
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5.4 DISCUSSION 
5.4.1 Column purification 
Three NTR mutants T41G N71S, T41L F70A and clone 282 were purified by column 
chromatography. Firstly using a hydrophobic column (phenyl sepharose), which selectively 
binds hydrophobic proteins. Most of the T41G N71S NTR bound to the column at 0.5M 
ammonium sulphate. However most of the T41L F70A NTR slipped off the column and all of 
the 282 NTR washed straight through the column at 0.5M ammonium sulphate but bound to 
the column at 1M ammonium sulphate. This indicates that T41L F70A is less hydrophobic 
than T41G N71S and 282 is less hydrophobic than both T41G N71S and T41L F70A. In the 
case of T41L F70A there is a substitution of phenylalanine 70 to alanine and for 282 there 
were substitutions of phenylalanine 123 and 124 to asparagines and valine respectively.  
 
The second column used was an ion-exchange column (Q-Sepharose column). T41L F70A, 
T41G N71S and 282 were further purified with a single Q-Sepharose column. All proteins 
bound tightly and eluted with a 0.1M NaCl/0.5M NaCl gradient (pH 7.0).  
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5.4.2 Kinetic Assays 
The ideal NTR mutant would have an increased kcat to allow faster conversion of prodrug, 
coupled with a reduced Km CB1954 lowering the physiological concentrations required for 
efficient turnover. This would allow administration of a lower dose of the prodrug. The Km 
NADH values are also important, research shows that the physiological concentration of NADH 
is in the millimolar range (Garofalo et al. 1988). For WT NfsB millimolar concentrations 
mean that NADH is not rate limiting. However some of the best mutants have led to large 
increases in the Km NADH. Ideally the mutant would also have an increased specificity for 
CB1954, with improved enzyme activity for CB1954, but reduced activity for other NTR 
substrates eg: nitrofurazone and menadione.  
 
5.4.2.1 CB1954 
The initial Km and kcat was determined for F124N, T41L N71S, T41G N71S, T41L F70A, 
T41Q N71S F124T and 282 at 500 µM NADH. However because CB1954 is a poor substrate 
for WT NTR, it was not possible to determine the Km and kcat for the WT reaction.  To 
determine these values a high substrate concentration would be required. Substrate 
concentrations that high are not achievable, as CB1954 is only soluble to 4 mM in Tris buffer.  
 
The reduction of CB1954 by WT, F124N, T41L N71S and T41Q N71S F124T NTR were 
then compared to previous data (see Figure 5.24 and Tables 5.9-5.10). Small differences 
within error were seen for each enzyme. Overall previous and current data are consistent with 
each other. 
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However the kcat/Km can reliably be determined for WT, as this parameter can be determined 
even if the substrate saturation is not achieved. The kcat/Km of all the mutants were better than 
WT enzyme, showing that T41L N71S (~70-fold increase) was kinetically the best at 
reducing CB1954, followed by T41G N71S (~50-fold increase), T41Q N71S F124T (~30-fold 
increase), T41L F70A (~10-fold increase), F124N (~3-fold increase) and 282 (~1-fold 
increase).  
 
Finally global kinetic parameters were determined for T41G N71S, T41L F70A and 282. This 
allows the determination of Km and kcat values, for one substrate if the enzyme was saturated 
with the second substrate. T41G N71S has a kcat ~3-fold lower than WT, however the Km was 
~200-fold lower. Only a small reduction in kcat compared to a huge reduction in Km means 
that the kcat/Km CB1954 for T41G N71S is ~80-fold higher than WT. Alternatively T41L F70A 
has a kcat and Km ~1.5-fold and ~25-fold lower, giving a kcat/Km ~15-fold higher than WT. 
Finally 282 has a kcat and Km ~7-fold and ~250-fold lower, giving a kcat/Km ~2.5-fold higher. 
Therefore all the mutants had a reduced Km but they also all had reduced kcat values.  
 
5.4.2.2 Nitrofurazone 
Initial Km and kcat parameters were determined for T41G N71S, T41L F70A and 282 for the 
reduction of nitrofurazone. These were compared to WT enzyme. T41G N71S has a kcat ~6.3-
fold lower than WT and Km ~10-fold lower. T41L F70A has a kcat ~1.2-fold higher than WT 
and Km ~2.3-fold lower and 282 has a kcat ~12.7-fold lower than WT and Km ~5.1-fold lower.  
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Two of these mutants had an increase in specificity constant for nitrofurazone. In particular 
mutant T41L F70A showed a high specificity constant for nitrofurazone with a reduction in 
Km and increase in kcat. By contrast mutant 282 showed a decrease in specificity constant with 
a large drop in kcat and only a small drop in Km. Thus three of the mutant NTR‟s were better at 
reducing nitrofurazone than WT enzyme. T41L N71S (~4.4-fold increase) was kinetically the 
best, followed by T41L F70A (~2.7-fold increase) and T41G N71S (~1.7-fold increase). 
F124N (~1.4-fold decrease), T41Q N71S F124T (~1.8-fold decrease) and 282 (~2.3-fold 
decrease) were kinetically worse than WT NTR.  
 
The reduction of nitrofurazone by WT, F124N, T41L N71S and T41Q N71S F124T was 
compared to previous data (see Figure 5.35 and Tables 5.16-5.17). Small differences within 
error were seen for WT and T41L N71S enzyme. However F124N and T41Q N71S F124T 
showed bigger differences. In both of these cases the kcat is similar but the Km is 
approximately double what was previously found, having a big effect on the kcat/Km. My data 
puts both T41Q N71S F124T and F124N as less sensitive to nitrofurazone but previous data 
has them as more sensitive than WT. The fact two of the enzymes give similar results 
indicates that consistent results are possible. However the big differences for the other two 
enzymes is still a little worrying. It is difficult to determine why such differences in data were 
seen. Different preparations of enzyme were used however if there had been contamination of 
some sort CB1954 results would also have also been different. 
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5.4.2.3 Menadione 
Km and kcat parameters were also determined for T41G N71S, T41L F70A and 282 for the 
reduction of menadione at 500 µM NADH. These were compared to WT enzyme. T41G 
N71S has a kcat ~5.3-fold lower than WT and Km ~46.2-fold lower. T41L F70A has a kcat 
~1.8-fold higher than WT and Km ~9.2-fold lower and 282 has a kcat ~6-fold lower than WT 
and Km ~28.9-fold lower. All three of these mutants had an increase in specificity constant for 
menadione. In particular mutant T41L F70A showed high specificity constant for menadione 
with a reduction in Km and increase in kcat.  
 
The kcat/Km measurements were again used to determine the fold increase in activity of each 
mutant relative to WT NTR. T41Q N71S F124T (~23.2-fold increase) was kinetically the 
best, followed by T41L F70A (~16.2-fold increase), T41L N71S (~14.8-fold increase), 
F124N (~8.5-fold increase), T41G N71S (~8.2-fold increase) and 282 (~2.3-fold increase).  
 
The reduction of menadione by WT, F124N, T41L N71S and T41Q N71S F124T NTR was 
compared to previous data (see Figure 5.37 and Tables 5.18-5.19). Small differences were 
seen for all enzymes, but the kcat/Km remained similar to that determined previously. 
 
 
 
 
 
 
 258 
5.4.3 Product ratios for the reduction of CB1954 
T41L F70A enzyme produced mostly the 4-HA, with negligible amounts of the 2-HA. This 
was expected. However N71S A113V R121V F123N F124V A125C K179R enzyme also 
produced mainly the 4-HA. This has only previously been seen for T41L mutants (Race et al. 
2007 and Jarrom et al. 2009). This enzyme shows no mutation at position T41. Therefore it is 
feasible that the mutation of either A113, R121, F123, A125 or K179 or a combination of 
these also leads to a shift towards the 4-HA derivative. Enzyme T41G N71S produced both 
the 2-HA and 4-HA, with possibly a slight preference for the 4-HA.  
  
Looking at activity based on kcat/Km, T41L N71S is kinetically the best mutant at reducing 
CB1954. Of the three mutants purified in this study, T41G N71S was kinetically the best 
mutant at reducing CB1954. This mutant showed clear improvement for CB1954 with a 
reduction in Km, showing the tightest CB1954 data of all the mutants. However the NADH 
kinetic data for T41G N71S was poor with a large increase in Km. This large increase in Km 
could potentially make NADH rate limiting when in an in vivo setting. 
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CHAPTER 6: COMPARISON OF WT AND MUTANT 
NTR IN HUMAN CELLS 
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6.1 INTRODUCTION  
VDEPT is a cancer gene therapy strategy which requires enzyme delivery by a viral vector. In 
the past, replication deficient adenoviruses and retroviruses have been used to express NTR in 
human tumour cells (Bridgewater et al. 1995, Green et al. 1997, McNeish et al. 1998, 
Weedon et al. 2000). As previously stated CB1954 is a poor substrate for NTR, however 
improving the catalytic efficiency of the system may produce therapeutic benefits. WT NTR 
and several improved mutants have previously been tested in human tumour cells lines (Grove 
et al. 2003, Jaberipour 2005 and Guise et al. 2007). Many of the mutants identified as 
improved in bacterial assays showed comparable improvement in human cells, however there 
have been exceptions. In particular NTR mutants N71S F124K and N71S F124N were poor in 
human cells due to poor expression. 
 
During this study a number of improved NTR mutants have been isolated and tested in 
bacterial cells (Chapter 3 and 4 this study) and kinetic parameters determined in vitro 
(Chapter 5 this study). The main aim of this chapter is to assess the therapeutic potential of 
four improved mutants in human ovarian carcinoma cells (SKOV-3). Adenoviruses that 
express the four most promising NTR mutants T41G N71S, T41N N71S, N71S A125T and 
N71S A113V R121V F123N F124V A125C K179R (282) were constructed and compared 
with previous adenoviruses WT, T41L N71S and T41Q N71S F124T. These four new mutant 
NTRs were chosen based on their ability to sensitise bacterial cells to CB1954. 
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6.2 MATERIAL AND METHODS 
6.2.1 NTR expression 
6.2.1.1 Plasmid construction 
λ lysogens encoding desired NTR mutants were streaked onto LB plates containing a fresh 
lawn of E. coli UT5600. The resulting lysis area was picked and used to provide a template 
for a PCR reaction, using Kod polymerase with primers JG138A and JG138B (see section 
2.2.1) to generate NTR PCR fragments. JG138A introduces the Kozak sequence (CCACC) 
immediately preceding the ATG start codon of the NTR coding sequence (Kozak 1987) and 
JG138B spans the end of the coding region. PCR products were resolved by agarose gel 
electrophoresis to confirm DNA fragments of the correct size were amplified and purified 
using Roche High Pure PCR Product Purification Kit (Roche Applied Sciences, Germany).  
 
A plasmid vector pPS1326B1 was digest with Hpa I and the appropriate size fragment was 
gel extracted using Qiagen QIA-Quick Gel Extraction Kit (Qiagen, West Sussex). The 
plasmid vector pPS1326B1 contains adenovirus type 5 genome sequence from the left end to 
Xba I site at 10589 bp of the genome, with the E1 region from 360 bp to 3525 bp deleted and 
replaced with CMV enhancer and promoter, and sequences from human β globin and 
complement C2 genes, which contain an intron and poly A site transcription termination 
signals, respectively. This plasmid was designed for the expression of open reading frames 
inserted into an Hpa I site downstream of the CMV promoter. Figure 6.1 shows a schematic 
of pPS1326B1 plasmid vector. 
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Figure 6.1 Schematic diagram of plasmid pPS1326B1 left end vector.  
Plasmid pPS1326B1 contains adenovirus type 5 genome sequence from the left end to Xba I site at 10589 bp of genome, with an E1 deletion 
from 360 bp – 3525 bp. The deleted region has been replaced with a CMV enhancer and promoter, with sequences from human β globin and 
complement C2 genes, containing an intron and poly A transcription termination signal. 
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PCR products were ligated with the Hpa I digested pPS1326B1 (0.5 pico moles of PCR insert 
with 200 ng plasmid vector) and transformed into competent E. coli XL-2 blue cells. 
Individual colonies were picked and grown in 10 ml of LB Broth containing ampicillin. Mini 
Prep plasmid purification was performed on the bacterial cultures and the resulting plasmid 
preps were digested with Nco I, Eco RV and Bgl II and analysed by agarose gel 
electrophoresis. Plasmids with correct digestion patterns were taken on to large-scale cultures 
(1 µl of undigested Mini-Prep Plasmid DNA was re-transformed into E. coli XL-2 blue cells. 
A single colony was picked for each mutant NTR and grown in 300 ml of LB Broth 
containing ampicillin). Bulk Prep purification was performed on the bacterial cultures, and the 
resulting plasmid preps were again digested with Nco I, Eco RV and Bgl II. 
                                                                                                                 
Plasmids with correct digestion patterns were linearised with Xba I and the inserted NTR gene 
sequenced with primers PS1013A and PS1013B.  
 
6.2.2 Generation of adenovirus vectors in HEK 293 cells 
The adenoviruses were generated by co-transfection of DNA from plasmids carrying “left 
end” and “right end” of the adenoviral vector into HEK 293 cells. HEK 293 cells are derived 
from human embryonic kidney cells, which have been transformed with adenovirus DNA. 
They contain the E1 region of the adenovirus genome, which allows them to support the 
replication of E1-deleted adenovirus vectors (Graham et al. 1977). The resulting full length 
genome was therefore generated by homologous recombination (see Figure 6.2 and 6.3).  
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Figure 6.2 Schematic diagrams of plasmids pPS1105A4 and pPS1223F3 
Plasmid pPS1105A4 contains Adenovirus left end with EGFP from CMV promoter and plasmid pPS1223F3 contains Ad5 sequence from the start 
of pIX to the right end, with E3 deletion  
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Figure 6.3 Homologous recombination of pSH T41G N71S, pSH T41N N71S, pSH N71S A125T, 
pSH 282, pSH EGFP with pPS1223F3, to produce non-replicating adenovirus 
The plasmids pSH T41G N71S, pSH T41N N71S, pSH N71S A125T, pSH 282 (encoding mutant 
NTR),  pSH EGFP (encoding green fluorescent protein) and pPS1223F3 were linearised and bacterial 
sequence separated by restriction digestion with Xba I/Swa I and Cla I/Swa I respectively. These 
plasmids were co-transfected into HEK 293 cells with FuGENE. Following homologous recombination 
within cells, adenoviruses encoding mutant NTR were produced 
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10 µg of the “left end” plasmid encoding mutant NTR (pSHT41GN71S, pSHT41NN71S, 
pSHN71SA125T or pSH282) and 10 µg of plasmid pPS1105A4 “left end” (encoding EGFP) 
were digested with Xba I and 50 µg of plasmid pPS1223F3 “right end” was digested with Cla 
I to linearise the DNA. These were cleaned by phenol/chloroform extraction and ethanol 
precipitation before digestion with Swa I allowing the removal of bacterial genome from the 
plasmids. The plasmids were again cleaned by phenol/chloroform extraction and ethanol 
precipitation and resuspended in 50 µl and 250 µl sterile T10E1 respectively.  
 
10 µl FuGENE 6 transfection reagent was added to 206.5 µl DMEM (serum free) media. This 
mix was vortexed for 1 second and incubated for 5 minutes at room temperature. The two 
digested plasmids containing inserted DNA (5.0 µg left end, 1.7 µg right end) were mixed 
with the FuGENE/DMEM mixture and incubated for 30-60 minutes. The mixture was then 
pipetted gently onto 90% confluent HEK 293 cells growing in a 25 cm
2
 tissue flask, and 
incubated while rocking occasionally for 5 hours in a 37 
o
C incubator. After 5 hours, 5 ml of 
2% FBS DMEM plus 2 mM glutamine and pen/strep was added.  
 
The following plasmid combinations were transfected, to generate the indicated viruses:  
pSH T41G N71S left end with pPS1223F3 right end = vSH T41G N71S 
pSH T41N N71S left end with pPS1223F3 right end = vSH T41N N71S 
pSH N71S A125T left end with pPS1223F3 right end = vSH N71S A125T 
pSH 282 left end with pPS1223F3 right end = vSH 282 
pPS1105A4 left end with pPS1223F3 right end = vSH EGFP 
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A control of pPS1105A4 “left end” plasmid alone was also transfected. After 3-5 days 
reporter gene expression was checked for the control and vSH EGFP by fluorescence 
microscopy. Figure 6.4a shows background EGFP expression from the control and Figure 
6.4b shows viral EGFP gene expression. Clear spread of virus can be seen. 
 
           a)                                                                                    b)                                                            
                    
 
Figure 6.4 Photograph showing EGFP expression from control and EGFP virus using FuGENE 
transfection in HEK 293 cells 
a) Control showing a small amount of background expression, b) EGFP viral gene expression 5 days 
after transfection. Clear viral spread can be seen 
 
6.2.3 Adenoviral rescue 
When most of the cells showed cytopathic effect, the cultures were harvested by tapping side 
of flask and or flushing with a Pasteur pipette. The sample was then centrifuged at 1,000 rpm 
for 5 minutes at 4 
o
C to pellet cells (Beckman GS-6R bench top centrifuge). Media was 
removed to leave approximately 1.5 ml. Virus particles were released from cells by three 
cycles of alternating freezing (in liquid nitrogen) and thawing (in 37 
o
C water bath). The 
sample was then centrifuged at 4,000 rpm for 10 minutes at 4 
o
C (Beckman GS-6R bench top 
centrifuge) to bring down the cell debris. The virus-containing supernatant was transferred to 
a new container and stored at -80 
o
C. 
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6.2.4 Expansion of adenovirus stocks 
For virus titration  a 75 cm
2
 flask of confluent HEK 293 cells was trypsinised and suspended 
in 20 ml DMEM containing 10% FBS, 2 mM Glutamine and 20 mM HEPES. HEK 293 cells 
were counted using a Hycor KOVA Glasstic® Slide 10 Haemocytometer, and 5 x 10
5
 cells 
were added to each well of three six well plates and made up to a total volume of 1 ml with 
DMEM. Three virus dilutions were used for each virus with 2 µl, 10 µl and 100 µl of virus 
prep added to 1 ml of DMEM. These virus dilutions were added to the cells and mixed 
thoroughly by swirling, before incubation at 37 
o
C until clear cytopathic effect was seen. The 
cells were then harvested and pelleted by centrifugation at 1,000 rpm for 5 minutes and 
resuspended in 1.5 ml of medium. A cleared virus lysate was made from freeze-thawed cells 
as above in section 6.2.3. The culture with clear CPE after 3-5 days was designated as P1 
stock.  
 
To propagate viral stocks three 75 cm
2
 flasks of sub-confluent HEK 293 cells were infected 
with 1 µl, 4 µl and 10 µl of the P1 virus and incubated at 37 
o
C for 2-5 days until cytopathic 
effect was seen. The cells with most CPE were then harvested and pelleted by centrifugation 
at 4,000 rpm for 10 minutes at 4 
o
C and resuspended in 1 ml of medium. A cleared lysate was 
made from freeze-thawed cells as above in section 6.2.3 and designated as P2 stock.  
 
Finally twenty 150 cm
2
 flasks of sub-confluent HEK 293 cells were infected with 1 µl of the 
P2 stock.  The resulting 10 ml of harvested cells were freeze thawed as above in section 6.2.3. 
A 1/100 volume of N-butanol was added before mixing thoroughly by inversion and left on 
ice for 1 hour, after which the mixture was centrifuged in a Beckman GS-6R centrifuge for 10 
minutes at 2,000 rpm.  
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A caesium chloride gradient was prepared by firstly adding 2 ml of ρ=1.32 g/ml CsCl (32 g 
CsCl, 6.8 ml 0.5 M Tris pH 7.9, 61.2 ml sterile distilled water) to a 15 ml Beckman 
polycarbonate tube, followed by underlaying with 3 ml of ρ=1.45 g/ml CsCl (20.5 g CsCl, 2.9 
ml 0.5 M Tris pH 7.9, 25.8 ml sterile distilled water). On top of this, 2 ml of 40% glycerol (40 
g glycerol, 2 ml 0.5 M Tris pH 7.9, 0.5 ml 0.2 M EDTA, sterile distilled water to 100 ml) was 
slowly added, followed by the supernatant from the N-butanol/virus lysate centrifugation. The 
tubes were then topped up with medium to just below the brim. Balanced tubes were placed in 
an SW40 rotor in a Beckman Coulter Optima™ LE-80K ultracentrifuge and spun at 25,000 
rpm for two hours. A clear white band of adenovirus could be seen and was removed by 
piercing the tube with a 21 gauge needle. Dialysis of the virus suspension to remove 
contaminating CsCl was then performed by inserting virus into Slidealyser (Pierce, PO Box 
117, Rockford, IL, 61105) 5 ml dialysis cassettes. The virus was dialysed three times against 
PBS/10% glycerol. Virus was finally removed from the cassette and aliquoted into Sartstedt O 
ring sealed 1 ml tubes for storage at -85 C. 
 
6.2.5 Adenoviral DNA purification 
Adenoviral DNA was extracted from banded preparations for each virus using Qiagen 
QIAamp DNA Mini Kit (Qiagen House, Fleming Way, Crawley, West Sussex). 200 µl of 
virus was used for each extraction, and extraction followed the manufacturer‟s instructions. 
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6.2.6 Virus titre determination 
6.2.6.1 Virus Particle concentration  
20 µl of dialysed virus stock was mixed with 20 µl SDS (0.1%) and heat inactivated by 
incubation at 56 C for 30 minutes. The resulting virus lysate was serially diluted and the 
concentration of DNA determined using DNA binding reagent PicoGreen (Molecular Probes, 
Eugene, USA) (Murakami and McCaman 1999). The DNA concentration can then be 
converted to virus particles using the conversion factor: 
 
                                       1 µg DNA = 2.74 x 10
10
 virus particles 
 
6.2.6.2 Plaque Assays 
For plaque assays, the cell line HER 911 was used. These are human embryonic retina cells 
transfected with a fragment of Ad5 DNA spanning the E1 region (Fallaux et al. 1998). These 
support replication of E1-deleted adenovirus vectors in the same way as HEK 293 cells, but 
give a more uniform monolayer, making it easier to see viral plaques.  
 
24 hours before infection, one 150 cm
2
 flask of 90% confluent HER 911 cells was split into 
twenty 6 cm
2
 tissue culture dishes. Serial, ten fold dilutions of virus were made in DMEM 
medium with 2% FBS down to 10
-10
. 100 µl of each virus dilution ranging from 10
-3
 to 10
-9
 
was added, in duplicate, to each 6 cm
2
 dish of 911 cells. The dishes were incubated for 90 
minutes with gentle agitation every 15 minutes to ensure cells did not dry and to allow gentle 
mixing. 
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After removal of virus, 4 ml of a 1:1 mixture of liquified 1.4% agar noble, and complete 2x 
DME medium (100 ml of 2x DME medium, 4 ml FBS,  2 ml 200 mM glutamine, 1 ml 0.5 M 
NaHCO3, 1 ml 1 M MgCl2 and 2 ml penicillin / streptomycin) were added gently.  These 
solutions had been pre warmed to 37 C. The agar was allowed to set at room temperature 
before incubation at 37 C in 5% CO2. The cells were fed at day 4, day 7 and day 10 with 2 
ml further 1:1 mixture of complete 2x DME medium and agar noble. Plaques were usually 
counted between days 10-12 until no further plaques appear. The value for the plaque forming 
units per ml of virus (pfu/ml) was calculated using the following formula:  
 
pfu / ml = number of plaques per dilution factor  
                 0.1                         
                              
6.2.6.3 Rapid titration of infectious virus (Adeno-X rapid titre kit) 
As an alternative to plaque assays, adeno-X rapid titre kit (Clontech Laboratories Inc, 1290 
Terra Bella Avenue, Mountain View, CA 94043) was used for the quantification of adenoviral 
stocks. This allows quick determination in approximately 48 hours taking advantage of the 
production of viral hexon protein. HEK 293 cells were used for infection, after 24 hours these 
were fixed and stained with hexon antibody. Methods followed manufacturer‟s instructions 
with the exception that virus was plated out first followed by HEK 293 cells; whereas the 
original protocol plated the cells first. The order was changed to allow greater mixing and to 
ensure even spread of virus and cells. Sixteen fields of brown/black positive cells were 
counted per well. For each virus duplicate wells were used for each virus concentration. 
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The mean numbers of brown/black positive cells or infectious units were determined as 
followed: 
 
          (ifu / ml) = (positive cells / field) x (fields / well) x (number of ml virus dilution) 
                                                      (volume virus ml) x (dilution factor) 
 
Dilution factor = 10
-7
 
Volume = 100 µl (0.1 ml) 
5x objective 
10x Eye Piece lense  
4 mm field diameter 
12.5 mm
2 
field area 
= 16 Fields/well on a 24 well plate based on area being 2.0 cm
2 
 
Figure 6.5 shows photographic examples of the brown/black positive cells examined for this 
study. 
 
                     
Figure 6.5 Photographs showing brown/black positive cells 
The individual spots were counted and the mean number per field determined 
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6.2.7 Sensitisation of SKOV3 cells to CB1954 using adenovirus 
expressing NTR 
 
Human ovarian carcinoma SKOV3 cells were used for prodrug sensitivity assays. Cells were 
trypsinised and resuspended in culture media and allowed to recover for 1 hour in suspension 
at 37 
o
C with intermittent mixing to prevent clumping. 1.33 x 10
6 
cells were infected with 
each adenovirus (expressing NTR) at 300, 100, 30, 10 and 0 infectious virus particles per cell 
(based on Adeno-X hexon staining) on day zero. The suspension was incubated at 37 
o
C for 
90 minutes with gentle intermittent mixing before plating 1.5 x10
4
 cells (150 µl) per well into 
96 well plates. The plates were then incubated at 37 
o
C. The medium was aspirated on day 
two and prodrug CB1954 was added in 150 µl medium to each well. Triplicates of each 
CB1954 concentration were used ranging from 0-300 µM. See Figure 6.6 for 96 well plate 
layout. 
 
                                                             10                       30                       100                     300    iv/cell           
                                   
Figure 6.6 Plate layout for MTT Assay using Adenovirus encoding NTR 
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The prodrug was removed after 16 hours of incubation at 37 
o
C and replaced with 150 µl 
fresh medium. On day five, medium was removed and replaced with 150 µl fresh culture 
medium containing 0.5 mg/ml MTT, diluted fresh from a 5 mg/ml stock solution in PBS. 
Plates were incubated for three hours at 37 °C before the MTT solution was aspirated from 
the wells. Plates were dried for 30 minutes at room temperature before the addition of 150 µl 
DMSO to each well. Plates were left overnight to allow crystals to fully dissolve before 
reading the Absorbance at 490 nm using a Wallac Victor 1420 plate reader (Perkin Elmer, 
Monza, Italy).           
 
6.2.8 Protein harvesting from virus infected tissue culture cells 
In parallel to the sensitisation assay 5.1 x 10
5
 SKOV3 cells were infected and plated in tissue 
culture dishes (6 cm) and incubated at 37 
o
C for 48 hours. The media was removed from the 
plates and washed twice with PBS. The cells were then scraped with a cell scraper into 1 ml 
of PBS and transferred to a screw topped 15 ml Sartstedt tube. The tubes were centrifuged at 
1,500 rpm to pellet cells. The PBS was removed and 150 µl Urea (8M) was added, the pellet 
was dispersed by vortexing. The cells were incubated on ice for 10 minutes, before vortexing 
and transfer to a 1.5 ml microfuge tube. These cell lysates were stored at -20 
o
C until required. 
Protein concentrations were measured using bradford assay (see section 2.4.1). 
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6.2.9 SDS PAGE Gel Electrophoresis 
Cell lysates were diluted 1:1 with 50 mM Laemmli loading buffer (4% SDS, 20% glycerol, 
10% β-mercaptoethanol, 0.0004% bromophenol blue and 0.125 M Tris HCl) containing 1 M 
DTT before heating to 95 
o
C for 5 minutes and run on a 12% SDS PAGE gel as described in 
section 2.4.2. PageRuler™ Plus Prestained Protein Ladder (Fermentas, UK) was also run to 
verify molecular weights. Gels were run at 120 volts for approximately 2 hours (Laemmli 
1970). 
 
6.2.10 Western Blotting 
Separated proteins were transferred to nitrocellulose membranes (see section 2.4.3). NTR and 
β-tubulin as a loading control were detected using primary and secondary antibodies listed in 
table 6.1. The secondary antibodies were peroxide conjugated and the bands were visualised 
using immobilon western detection reagents. 
 
Protein Primary Antibody Secondary Antibody 
Nitroreductase NTR sheep Anti sheep made in donkey 
β-tubulin β-tubulin mouse Anti mouse made in sheep 
 
Table 6.1 Primary and secondary antibodies used for western blotting 
 
 
6.2.11 Sensitisation of SKOV3 cells to CB1954 using purified 
enzymes 
 
Cells were seeded on day one at 1 x 10
4
 cells per well in 96 well flat bottomed plates at a total 
volume of 150 µl. The cells were allowed to adhere overnight. The medium was aspirated 
from the plates on day two. Purified enzymes (see chapter 5 for purification of enzymes) were 
diluted with a range from 0-3000 nM final concentration in culture medium.  
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Each enzyme‟s concentration was tested in triplicate in a total volume of 50 µl. CB1954 
prodrug at a final concentration of 10 µM and 50 µM was added with 0.1 µM FMN and either 
100 µM or 200 µM NADH/NADPH in a volume of 100 µl. See Figure 6.7 for 96 well plate 
layout. Columns 1-6 indicate final enzyme concentrations from 0-3000 nM and columns 7-12 
indicate final enzyme concentrations from 0-1000 nM.  
 
                                         NADH 100        NADPH 100       NADH 200      NADPH 200    µM 
                          
Figure 6.7 Plate layout used for MTT Assay using purified enzymes 
 
 
The medium containing enzyme and substrate was removed after 4 hours of incubation at 37 
o
C and replaced with 150 µl fresh medium. On day five, medium was removed and replaced 
with 150 µl fresh culture medium containing 0.5 mg/ml MTT, diluted fresh from a 5 mg/ml 
stock solution. Plates were incubated for three hours at 37 °C before the MTT solution was 
aspirated from the wells. Plates were dried for 30 minutes at room temperature before the 
addition of 150 µl DMSO to each well. Plates were left overnight to allow crystals to fully 
dissolve before reading the Absorbance at 490 nm using a Wallac Victor 1420 plate reader. 
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6.3 RESULTS 
6.3.1 NTR expression 
6.3.1.1 Plasmid construction 
PCR products were resolved by agarose gel electrophoresis to confirm DNA fragments of the 
correct size were amplified (see Figure 6.8). Bands of the correct size were the major products 
of each PCR reaction and were gel purified. 
 
                                                                             
                                                                                   M   1    2    3    4 
Figure 6.8 Agarose gel of PCR fragments for plasmid construction using primers JG138A and 
JG138B 
Total PCR products amplified from NTR. PCR products were run on 0.7% agarose gel. M = Marker 1 
kb plus ladder, Lanes 1-4 NTR fragments T41G N71S, T41N N71S, N71S A125T and 282 
respectively. A single fragment of approximately 700 bp observed for each PCR  
 
 
The purified PCR products were ligated with pPS1326B1 plasmid vector and transformed. 
Plasmid preps were generated from individual colonies and the resulting plasmid DNA 
digested with Nco I, Eco RV and Bgl II to ensure the correct plasmids were isolated. 
Digestion products were resolved by agarose gel electrophoresis (see Figure 6.9). 
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Figure 6.9 Restriction enzyme digests of plasmid bulk preparation DNA  
Plasmid digests were run on 0.7% agarose gel. M = Marker 1kb plus ladder (Invitrogen, UK), Lanes 1-4 pSH282, Lanes 5-8 pSHT41GN71S, Lanes 9-
12 pSHT41NN71S and Lanes 13-16 pSHN71SA125T. Each set of four showed undigested, Nco I, Eco RV and Bgl II digests from left to right. The table 
on the right shows expected band sizes for each enzyme digestion. The schematic diagram shows the fully constructed plasmid with Nco I, Eco RV and 
Bgl II restriction sites labelled. Correct digestion patterns were observed for all four plasmids.  
 
Nco I Eco RV Bgl II 
5036 7559 6892 
2038 5397 5638 
1765  426 
1670   
1240   
857   
330   
 
 
M 1    2 3 4 5    6  7 8 9 10   11  12   13  14  15  16  
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Plasmids with correct digestion patterns were digested with Xba I and sequenced with primers 
PS1013A and PS1013B to ensure the NTRs they encode were correct. 
 
6.3.2 Generation of adenovirus vectors in HEK 293 cells 
Co-transfection was used to generate five viruses, vSH T41G N71S, vSH T41N N71S, vSH 
282, vSH N71S A125T, and vSH EGFP. Each virus was rescued, propagated and caesium 
chloride-banded (as described in Section 6.2.4). DNA was extracted from each banded virus, 
digestion patterns were checked by Hind III digestion. Predicted fragment sizes and agarose 
gel results can be seen in Figure 6.10.  
 
                                                                                              
 
Figure 6.10 Restriction enzyme digests of viral DNA 
Each virus was digested with Hind III and run on 0.7% agarose gel. Bands of the correct size were 
observed for virus preparations 1, 2 and 4. Virus preparation 3 has a stronger band at ~4600bp and 
absent bands at 3945bp and 674bp. The darker band at ~4600 bp correlates with the band expected 
at 4597 bp and a further band at ~ 4619 bp, which could result from loss of the Hind III site between 
the adjacent 3945 bp and 674 bp fragments. M = Marker 1kb plus ladder (Invitrogen, UK) Lanes 1 vSH 
282, Lanes 2 vSH T41G N71S, Lane 3 vSH T41N N71S and Lanes 4 vSH N71S A125T 
Hind III 
8010 
5324 
4597 
3945 
2937 
2273 
2081 
1534 
1198 
1005 
674 
75 
19 
 
5000 
    1000 
  12000 
    2000 
    1650 
    1000 
  500 
   M       1      2      3       4    
= 4619 
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Figure 6.11 Schematic diagrams of recombination between plasmids pPS1326B1 NTR (T41G N71S, N71S A125T, T41N N71S and 282) and 
pPS1223F3 
Co-transfection of pPS1326B1 NTR (T41G N71S, N71S A125T, T41N N71S and 282) “right end” virus with pPS1223F3 “left end” virus. A: Indicates the 
two linearised plasmids, showing the region of overlap for recombination. B: Full length NTR virus. Hind III sites have been marked, which were used for 
test digestion to ensure correct viruses generation 
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Figure 6.11 shows schematic diagrams of the two plasmids used for co-transfection and the 
fully constructed virus with Hind III sites highlighted. 
 
The restriction pattern for vSH T41N N71S shows absence of bands, 3945 bp and 674 bp. 
These two fragments are adjacent in the viral DNA indicating a missing Hind III site shortly 
after the inserted NTR gene, and would generate a fragment of 4619 bp if joined. The 
increased intensity of the band at ~ 4619 bp probably results from comigration of this 4619 bp 
band, and the predicted 4597 bp fragment. The vSH T41G N71S, vSH N71S A125T and vSH 
282 showed expected digestion patterns. The DNA for each virus was sequenced; the correct 
NTR sequence was seen for each with no additional base changes, additions or deletions. A 
single base substitution was shown within the Hind III site just downstream of NTR for vSH 
T41N N71S. This was in a non-coding region, therefore not expected to influence function, 
therefore it was decided that this virus could be used.  
 
6.3.3 Virus validation 
To allow comparison of generated adenoviruses, the titre of each virus needed to be 
determined. Three methods were used to determine virus concentrations, initially by virus 
particle number. This give a good indication of the amount of viral DNA present, however not 
all virus particles can infect cells and therefore this is not an ideal method for determining a 
viruses titre. Plaque Assays were performed for each virus and the particle to infectivity ratios 
determined. These ratios are a little high (see Table 6.2).  
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Table 6.2 Particles per ml, Plaque forming units (pfu) per ml from plaque assay and Particle to 
infectivity (P:I) ratio for each virus 
 
 It has previously been found that viruses encoding some mutant NTRs can be impaired in 
their growth and fail to produce good plaques (Jaberipour 2005). It is believed that NTR can 
be toxic, killing some cell early in the infectious cycle, thus inhibiting plaque formation. In 
this situation the plaque assay may underestimate the number of viruses able to infect a target 
cell and express the inserted gene. A reliable method that will not be affected by NTR toxicity 
was required. Adeno-X rapid titer kit was used to determine infectious units per ml. This 
method is based on hexon protein staining 48 hours after infection of a HEK 293 monolayer, 
when virus is in its first infection cycle, thus, unlike the plaque assay, cell to cell spread of 
virus is not required. A further advantage to this method is that more “events” are counted 
than a plaque assay, therefore expect greater accuracy. Tighter particle to infectivity ratios 
were determined using this kit, with Ifu/ml values being higher than Pfu/ml, as expected, and 
this is probably a better reflection of the number of virus particles that can enter a cell to 
express NTR (See Table 6.3). 
 
 
 
 
 
 
 
 
Virus Particles/ml pfu/ml Particle to infectivity 
(P:I) ratio 
vWT 6.5 x 10
12
 8.1 x 10
10
 80.3 
vT41L  N71S 7.3 x 10
12
 8.9 x 10
9
 820.2 
vT41Q N71S F124T 5.8 x 10
11
 7.2 x 10
8
 805.6 
vSH T41G N71S 4.6 x 10
12
 6.0 x 10
10
 76.7 
vSH T41N N71S 1.1 x 10
12
 7.0 x 10
9
 157.1 
vSH N71S A124T 2.3 x 10
12
 3.0 x 10
10
 76.7 
vSH 282 2.0 x 10
12
 6.1 x 10
10
 32.8 
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Table 6.3 Particles per ml, Infectious units (ifu) per ml based on Adeno-X titre and Particle to 
infectivity (P:I) ratio for each virus 
 
 
6.3.4 MTT prodrug Sensitivity Assay  
The efficiency of adenoviruses expressing WT and mutant NTR‟s at sensitising human 
tumour cell line SKOV3 to CB1954 were compared by prodrug sensitivity assays. SKOV3 
cells were infected with each virus at various MOI‟s (based on adeno-X titre) and the cell 
survival was assessed by MTT Assay. Figure 6.12 shows survival curves for each individual 
virus at various MOI‟s and Figure 6.13 shows survival curves for all viruses at specific 
MOI‟s.
Virus Particles/ml ifu/ml Particle to infectivity 
(P:I) ratio 
vWT 6.5 x 10
12
 1.10 x 10
11
 59.1 
vT41L  N71S 7.3 x 10
12
 2.66 x 10
11
 27.4 
vT41Q N71S F124T 5.8 x 10
11
 1.36 x 10
10
 42.7 
vSH T41G N71S 4.6 x 10
12
 2.06 x 10
11
 22.3 
vSH T41N N71S 1.1 x 10
12
 3.53 x 10
11
 3.1 
vSH N71S A124T 2.3 x 10
12
 5.59 x 10
11
 4.1 
vSH 282 2.0 x 10
12
 1.75 x 10
11
 11.4 
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   E: vSH T41N N71S 
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 F: vSH N71S A125T 
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Figure 6.12 Survival curves for adenoviruses expressing WT and mutant NTR’s A: vWT, B: vT41L N71S, C: vT41Q N71S F124T, D: vSH T41G 
N71S,  E: vSH T41N N71S, F: vSH N71S A125T and G: vSH 282 at MOI 0 (grey), 10 (red), 30 (black), 100 (green), 300 (blue) based on ifu/cell 
The percentage cell survival was determined by MTT, normalised to cell survival with no prodrug. Error bars shown are standard errors of the mean 
based on measurement of three replicate wells within the same experiment 
284/285 
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Figure 6.13 Survival curves for adenoviruses expressing WT and mutant NTR’s vWT (black), vT41L N71S (purple) and vT41Q N71S F124T (pink), vSH 
T41G N71S (red), vSH T41N N71S (brown), vSH N71S A125T (orange), vSH 282 (green) 
The different plots show cells exposed to different MOI A: 10 ifu/cell, B: 30 ifu/cell, C: 100 ifu/cell and D: 300 ifu/cell. The percentage cell survival was 
determined by MTT, normalised to cell survival with no prodrug. Error bars shown are standard errors of the mean based on measurement of three replicate 
wells within the same experiment 
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Percentage cell survival for each enzyme was determined and survival curves constructed 
using four different MOI‟s of 10, 30, 100 and 300 ifu/cell (see Figures 6.13). As expected 
very little killing was seen when no virus was used (grey) and all the viruses showed the least 
killing at 10 ifu/cell (red) and the most at 300 ifu/cell (blue).  
 
Survival curves for each MOI (ifu/cell) can be seen in Figure 6.13. At the highest MOI 300 
ifu/cell vT41Q N71S F124T showed greatest killing, ~9-fold improvement relative to WT. 
This was closely followed by vT41L N71S, ~8-fold better, then vT41N N71S ~1-fold better. 
vT41G N71S showed similar sensitisation as WT enzyme. Finally vN71S A125T and v282 
were ~10-fold and ~60-fold less sensitive than WT. However at a lower MOI of 30 ifu/cell 
vT41Q N71S F124T and vT41L N71S have similar sensitisation and vT41G N71S is less 
sensitive to WT enzyme. 
 
6.3.4.1 NTR expression levels  
One of the major contributing factors to the degree of cell sensitisation to CB1954 is the level 
of NTR expression. Previous viruses have sometimes shown differences in expression levels. 
Either the NTR degrades more quickly or is expressed at a lower level. To quantify the 
amount of NTR being expressed by each virus western blotting was used as previously 
described. To confirm even loading of cell lysate, the blots were also probed for the protein β-
tubulin (Westermann and Weber 2003). The western blots of these samples (MOI 10 ifu/cell) 
probed with antibodies against both NTR and β-tubulin is shown in Figure 6.14.                      
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Figure 6.14 Western blots of cell lysates  
M: Marker, 1: vSH T41G N71S, 2: vSH T41N N71S, 3: vSH N71S A125T, 4: vSH 282, 5: vT41L N71S, 
6: vT41Q N71S F124T, 7: vWT, 8: Control no virus, at MOI 10 ifu/cell and exposure for 1 minute 
 
The intensity of the NTR band showed a considerable variation between samples. There was 
much less variation in the β-tubulin band, and the two didn‟t correlate, rather the β-tubulin 
showed greater intensity in the samples with less NTR detected. Therefore this result shows 
that the viruses expressing WT, T41L N71S and T41Q N71S F124T produce more NTR in 
infected cells than those expressing T41G N71S and T41N N71S, while N71S A125T and 
282 appear to be particularly poorly expressed.  
 
In order to compare the viruses further, western blot analysis was performed at four different 
MOI‟s 10, 30, 100 and 300 ifu/cell. This makes it possible to identify which MOI‟s of the 
different viruses give the most closely matched levels of NTR expression. This allows 
comparison of NTR expression levels, giving a crude overview. Western blots for this 
showing both NTR and β-tubulin can be seen in Figure 6.15. 
 
       
 
  
          β-tubulin 
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Figure 6.15 Western blots of cell lysates 
vT41G N71S, vT41N N71S, vN71S A125T, v282, vT41L N71S, vT41Q N71S F124T, and vWT at MOI 10, 30, 100, 300 based on ifu/cell  
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 Comparison of these blots indicates that 10 ifu/cell for vWT, vT41L N71S and vT41Q N71S 
F124T express approximately the same amount of NTR as 100 ifu/cell for vT41G N71S and 
vT41N N71S and 300 ifu/cell for v282 and vN71S A125T. Figure 6.16 shows survival curves 
for each individual virus at the MOI (ifu/cell) that best approaches normalisation of NTR 
expression for each virus, using existing data. 
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Figure 6.16 Survival curves for adenoviruses expressing WT and mutant NTR’s  
vWT 10 ifu/cell (black), vT41L N71S 10 ifu/cell (purple) and vT41Q N71S F124T 10 ifu/cell (pink), 
vT41G N71S 100 ifu/cell (red), vT41N N71S 100 ifu/cell (brown), vN71S A125T 300 ifu/cell (orange), 
v282 300 ifu/cell (green) and control no virus (grey). The percentage cell survival was determined by 
MTT, normalised to cell survival with no prodrug. Error bars shown are standard errors of the mean 
based on measurement of three replicate wells within the same experiment 
 
 
Cell survival curves were constructed based on MOI‟s (ifu/cell) that showed best 
normalisation of NTR expression in this case vT41Q N71S F124T, vT41L N71S and vT41N 
N71S showed similar sensitisation with ~9-fold improvement over WT enzyme. vT41G N71S 
was also better than WT with ~2-fold improvement observed. However vN71S A125T and 
v282 remain less sensitive than WT at ~1-fold and ~5-fold respectively.   
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6.3.5 Sensitisation of SKOV3 cells to CB1954 using purified 
enzymes 
 
An alternative way of comparing NTR mutants with WT is to use purified enzymes of known 
concentration. The benefit of this is the ability to compare appropriately matched, controlled 
enzyme concentrations. WT, F124N, T41L N71S and T41Q N71S F124T have been 
previously purified and T41G N71S, T41L F70A and 282 were purified for this study (see 
Chapter 5). F124N and T41L F70A viruses were not used previously however purified 
enzyme was available so they were included.  
 
The abilities of purified WT and mutant NTR to sensitise human tumour cell line SKOV3 to 
CB1954 were compared. SKOV3 cells were plated out and NTR protein dilutions were added 
along with 0.1 µM FMN, appropriate concentrations of either NADH or NADPH and 
appropriate concentrations of CB1954. Cell survival was assessed by MTT Assay. Figures 
6.17 shows survival curves for each NTR and Figure 6.18 show survival curves at each 
reaction condition. 
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 A: T41L F70A   B: 282 
 C: T41Q N71S F124T 
  D: WT 
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E: F124N F: T41L N71S 
G: T41G N71S 
Figure 6.17 Survival curves for WT and mutant enzymes A: T41L F70A, B: 282, C: T41Q N71S F124T, D: WT, E: F124N, F: T41L N71S and G: T41G 
N71S using 100 µM NADH 10 µM CB1954 (red), 100 µM NADPH 10 µM CB1954 (black), 200 µM NADH 50 µM CB1954 (green), 200 µM NADPH 50 µM 
CB1954 (blue) 
Percentage cell survival was determined by MTT, normalised to cell survival with no prodrug. Error bars shown are standard errors of the mean based on 
measurement of three replicate wells within the same experiment 
29 /293 
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Figure 6.18 Survival curves for WT (black), F124N (cyan), T41L N71S (purple), T41Q N71S F124T (pink), T41G N71S (red), T41L F70A (blue) and 282 
(green) enzymes 
A: 100 µM NADH 10 µM CB1954, B: 100 µM NADPH 10 µM CB1954 C: 200 µM NADH 50 µM CB1954 and D: 200 µM NADPH 50 µM CB1954. Percentage 
cell survival was determined by MTT Assay. Error bars shown are standard errors of the mean based on measurement of three replicate wells within the 
same experiment 
A: 100 µM NADH + 10 µM CB1954 
B: 100 µM NADPH + 10 µM CB1954 
C: 200 µM NADH + 50 µM CB1954 
D: 200 µM NADPH + 50 µM CB1954 
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Percentage cell survival for each enzyme was determined and survival curves constructed 
using NADH and NADPH as cofactor (see Figures 6.17). All enzymes were better with 
NADH than with NADPH, with ~5-fold difference for WT and T41Q N71S F124T. Two of 
the mutant enzymes T41L F70A and F124N showed less difference with ~2-fold difference. 
The remaining two enzymes showed greater than WT preference for NADH over NADPH 
with T41L N71S and T41G N71S showing ~18-fold difference.  
 
Survival curves for each condition can be seen in Figure 6.18. For both 100 µM and 200 µM 
NADH T41Q N71S F124T was the best at sensitising SKOV3 cells to CB1954 being ~ 9-fold 
better than WT NTR. All the other mutants except 282 were better than WT with T41G N71S, 
T41L N71S and T41L F70A showing similar values at ~2.6-fold better and F124N being 
~1.4-fold improved. However with 200 µM NADPH T41L F70A was best (~7-fold) followed 
by T41Q N71S F124T (~5-fold), then F124N (~4.5-fold) and when looking at 100 µM 
NADPH it is less clear which enzymes worked best with WT, T41L F70A, F124N and T41Q 
N71S F124T showing similar results. 
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6.4 DISCUSSION 
6.4.1 Adenovirus 
Four replication defective adenoviruses expressing NTR were generated (vSH T41G N71S, 
vSH T41N N71S, vSH N71S A125T and vSH 282). Prodrug sensitivity assays for CB1954 
were performed for each as well as several previous viruses (expressing WT, T41L N71S and 
T41Q N71S F124T) in SKOV3 cells. 
 
Initial results showed that T41Q N71S F124T was the best mutant at sensitising SKOV3 cells 
to the prodrug CB1954 followed by T41L N71S. This was consistent with previous tissue 
culture results (Guise et al. 2007 and Jaberipour 2005). At 300 ifu/cell T41N N71S was better 
than WT but at 10 ifu/cell WT appears better. This may show that WT has a better bystander 
effect than T41N N71S. None of the three other new mutants were better than WT NTR. This 
contradicts bacterial and kinetics data which showed that T41G N71S should be similar to 
T41L N71S and 282 marginally better than WT. Protein expression of NTR showed different 
expression levels for the viruses making it difficult to compare the different mutants. Using 
previous data, but comparing the dose-response curves at the MOI that gave most closely 
matched levels of NTR expression allowed better comparison of mutant NTR‟s relative to 
WT. In this case T41Q N71S F124T, T41L N71S and T41N N71S appeared to have similar 
sensitisation in SKOV3 cells followed by T41G N71S. N71S A125T and 282 remained less 
sensitive than WT NTR.    
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6.4.2 Purified Enzyme 
An alternative way of comparing NTR mutants with WT in tissue culture cells is to use 
purified enzymes of known concentration. When using the cofactor NADH, T41Q N71S 
F124T was found to be the best mutant at sensitising SKOV3 cells to the prodrug CB1954, 
closely followed by T41G N71S, T41L F70A and T41L N71S which showed similar 
sensitisation to each other. This was followed by F124N the best single mutant. However 
when using the cofactor NADPH, very different results were observed. In this case T41L 
F70A gave greatest sensitisation followed by T41Q N71S F124T, F124N and then WT. 
Several of the best NTR mutants (T41G N71S and T41L N71S) using the cofactor NADH, 
were less sensitive than WT using NADPH as cofactor. The NTR mutant 282 was poor with 
both NADH and NADPH being less sensitive than WT in both cases.  
 
Human cells contain varying amounts of NADH and NADPH. Combined NAD
+
 and NADH 
levels are reported typically to be ~10-fold higher than NADP
+
 and NADPH (Garofalo et al. 
1988). Therefore mutants that work well with and favour NADH as a cofactor, such as T41Q 
N71S F124T, T41G N71S and T41L N71S should work particularly well in human cells. 
T41Q N71S F124T, T41G N71S and T41L N71S showed good sensitisation in SKOV 3 cells. 
However, considering only the reduced cofactors, Pollak et al found NADH levels in 
HEK293 cells were just 1-2 times that of NADPH (Pollak et al. 2007). The similar 
sensitisation of SKOV 3 cells to CB1954 by virus expressing either T41Q N71S F124T or 
T41L F70A is consistent with both reduced cofactors being available to NTR expressed in the 
cell. 
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When using NADH as cofactor the order of sensitisation to CB1954 reassuringly follow a 
similar pattern to that determined kinetically (using NADH as cofactor) with the exception of 
mutants T41Q N71S F124T and 282. Kinetic parameters for mutant 282 were slightly better 
than WT with a 1.8-fold increase in sensitivity; however in all tissue culture experiments WT 
was more efficient at sensitising cells to CB1954. Mutant T41Q N71S F124T was kinetically 
the third best mutant behind T41L N71S and T41G N71S. However, in a tissue culture 
setting, using both virus and purified enzyme, T41Q N71S F124T worked more efficiently 
being the best mutant at sensitising SKOV 3 cells to CB1954.  
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CHAPTER 7: DISCUSSION 
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7.1 VDEPT  
Virus-directed enzyme prodrug therapy (VDEPT) is an emerging strategy against cancer, 
using a virus to administer a gene encoding an activating enzyme to tumour cells (McNeish et 
al. 1997). Phase I/II clinical trials, using NfsB NTR enzyme and the prodrug CB1954 have 
been completed here in Birmingham, using a replication defective adenovirus CTL102 for 
delivery (Palmer et al. 2004, Patel et al. 2009). No patients were cured, but a reduction in 
PSA implies a delay in tumour burden and progression. Kinetic analysis of NTR has shown 
that CB1954 is a poor substrate with a kcat ~ 140 s
-1
 and a Km CB1954 ~ 17200 µM (Jarrom et al. 
2009). Therefore low enzymatic efficiency plus low gene transfection efficiencies are likely to 
have limited the effectiveness of the therapy. Improvement to the system would be highly 
beneficial, with the aim to take refinements into future clinical trials. 
 
It was proposed that engineering NfsB NTR enzyme to better catalyse CB1954 could greatly 
improve the efficacy of this system.  
 
7.2 ENGINEERING NTR ENZYME 
A series of improved NfsB NTR mutants have previously been generated based on the crystal 
structure (Lovering et al. 2001). Initially residues round the active site were targeted (Grove 
et al. 2003). F124N showed modest improvement with a kcat/Km 5-fold greater than WT NTR 
(Jarrom et al. 2008). A second generation combining beneficial mutants were generated with 
T41L N71S and T41L F70A being the most improved, with the kcat/Km for T41L N71S being 
100-fold greater (Jaberipour et al. 2010). A direct positive selection system (Guise et al. 
2007) has allowed further improvements; with T41Q N71S F124T having a kcat/Km that is 50-
fold greater than WT NTR (Jarrom et al. 2008). 
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7.2.1 Generating new mutants 
This system was taken forward in this study to generate further improved NTR mutants. 
Firstly three small libraries were generated with mutations around the active site at adjacent 
positions S40/T41 ± N71S and E165/G166 ± N71S and the single position K14. From these 
libraries three double NTR mutants of interest were determined T41G N71S, T41N N71S and 
N71S A125T giving improved sensitivity to CB1954 in bacterial cells.  
 
These three libraries have improved our knowledge of the contribution of active site residues 
of NTR to the efficacy of CB1954 activation. Only a few isolated mutants contained a 
mutation at position S40. Single mutations at this residue resulting in alanine, glycine or 
threonine all led to NTRs with improved CB1954 activation (Grove et al. 2003). All the 
mutations isolated at S40 were threonine and these appeared to be tolerated mutations. This 
indicates that amino acid changes at both S40 and T41 do not work well together. It is likely 
changes at both these residues may sterically hinder each other. No mutants were isolated 
with amino acid changes at residues E165 and or G166. Previous work indicated that all 
single amino acid substitutions at these residues were detrimental to CB1954 activation 
(Grove et al. 2003). This work indicates that no combination of substitutions at these two sites 
can allow efficient CB1954 activation. No amino acid changes were seen at residue K14, 
indicating that all amino acid substitutions were detrimental to CB1954 activation.  
 
Using this understanding a large library was constructed with mutations at up to six residues 
around the active site. This large library contained a maximum diversity of 6.3 x 10
6
 possible 
nucleotide sequences. One mutant N71S A113 R121V F123N F124V A125C K179R (282) 
analysed showed improvement over WT. 
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7.2.1.1 Kinetic Analysis of mutant NTR 
T41L F70A from a previous study (Jaberipour et al. 2010) and two of the promising mutants 
T41G N71S and clone 282 were purified and kinetically characterised and compared with WT 
and other previously purified mutant NfsB NTR enzymes. Km and kcat were calculated for 
CB1954, nitrofurazone and menadione and the specificity constant kcat/Km has been used to 
compare the activity of each enzyme.  
 
Looking at enzyme activity T41L N71S was the best mutant at reducing CB1954. When 
looking at the three mutants purified in this study T41G N71S was the best mutant at reducing 
CB1954 being the second best mutant analysed just slightly behind T41L N71S. 
 
7.2.1.1.1 Substrate specificity of NTR mutants 
Although activity for CB1954 is important a good enzyme should also demonstrate good 
selectivity for CB1954 compared to other substrates. In order to calculate specificity each 
mutant was tested with nitrofurazone and menadione. The hope is that an improvement in 
CB1954 reducing activity is not reciprocated in the other substrates, to reduce substrate 
competition in human cells. The specificity constant for CB1954 has been compared with the 
specificity constants for nitrofurazone and menadione, allowing ratios for each enzyme and 
substrate combination to be calculated (see Table 7.1). 
 
 
 
 
 303 
kcat/Km µM
-1
 s
-1 
 
 
 WT F124N T41L N71S T41G N71S T41L F70A T41Q N71S 
F124T 
282 
CB1954 0.009  0.027  0.628  0.457  0.103  0.277  0.010  
NFZ 0.068  0.049  0.302  0.113  0.186  0.038  0.038  
MENADIONE 0.42  3.57  6.23  3.43  6.80  9.75  1.97  
 
 
(kcat/Km)/(kcat/Km) 
 
 WT F124N T41L N71S T41G N71S T41L F70A T41Q N71S 
F124T 
282 
CB1954:NFZ 0.13 0.55 2.08 4.04 0.55 7.29 0.26 
CB1954:MENADIONE 0.016 0.013 0.048 0.032 0.027 0.004 0.019 
Table 7.1 Specificity constants and ratios of specificity constants comparing CB1954 with Nitrofurazone and Menadione 
WT, F124N, T41L N71S, T41G N71S, T41L F70A, T41Q N71S F124T 
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The higher the kcat/Km value the greater the likelihood that the reaction will be catalysed. 
Therefore specificity constant ratios can be used to determine which reaction is most likely to 
proceed. When comparing CB1954 and NFZ mutants T41Q N71S F124T, T41G N71S and 
T41L N71S showed greater specificity for CB1954 with a value greater than 1. All the 
mutants showed improvement over WT. My best mutant T41G N71S showed ~30-fold 
improvement relative to WT (see Table 7.1).  
 
When comparing CB1954 and Menadione all the enzymes showed greater specificity for 
Menadione with values less than 1. However T41L N71S, T41G N71S, T41L F70A and 282 
showed improvement over WT being between 1- and 3-fold better (see Table 7.1). 
 
This specificity data indicate that T41Q N71S F124T, T41L N71S and T41G N71S are the 
most promising nitroreductases. T41L N71S and T41G N71S are particularly promising as 
they both show an increase in CB1954:NFZ and CB1954:MENADIONE specificity 
constants.  
 
7.2.1.1.2 CB1954 product ratios 
CB1954 reduction products were determined for the three new enzymes. T41L F70A and 
clone 282 produced mostly the 4-hydroxylamine (4-HA), with a small amount of 2-
hydroxylamine (2-HA) being produced by the latter. T41G N71S however produced 
approximately equal amounts of the 4-HA and 2-HA products.  
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Several previous mutants have also shown a shift towards the production of 4-HA. All of 
these enzymes had a T41L mutation (Race et al. 2007 and Jarrom et al. 2009). It was 
therefore a little surprising that clone 282 also favours the 4-HA as this enzyme doesn‟t have 
a substitution at residue T41. It is feasible that the mutation of A113, R121, F123, A125 or 
K179 or a combination has lead to this shift. It is unclear why leucine at T41 affects the ratio 
of products. Glycine and glutamine at this position both produce equal ratios of 2-HA and 4-
HA.  
 
7.2.1.2 Sensitisation of SKOV3 cells to CB1954 
7.2.1.2.1 Adenovirus 
Four adenoviral vectors expressing the NTR mutants T41G N71S, T41N N71S, N71S A125T 
and clone 282 were generated and their therapeutic potential tested in SKOV3 cells relative to 
previous mutants and WT enzyme. vT41Q N71S F124T was best at sensitising SKOV3 cells 
to CB1954 followed by vT41L N71S. Contrary to bacterial and kinetics data, vT41G N71S 
and v282 confer less sensitivity to CB1954 than vWT. However NTR expression levels make 
a major contribution to the degree of sensitisation. Western blotting showed considerable 
variation between the viruses with vWT, vT41L N71S and vT41Q N71S F124T producing 
much higher levels of NTR. Western blotting at four different MOI‟s was used in order to 
identify which MOI of each virus most closely matched NTR expression. Survival curves for 
vWT, vT41L N71S and vT41Q N71S F124T at 10 ifu/cell were compared with 100 ifu/cell 
for vT41G N71S and vT41N N71S and 300 ifu/cell for v282 and vN71S A125T. These 
demonstrated the best normalisation of NTR possible with these viruses using current data. 
vT41Q N71S F124T, vT41L N71S and vT41N N71S showed similar sensitisation with ~9-
fold improvement and vT41G N71S was ~2-fold improved relative to WT. 
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7.2.1.2.2 Purified Enzyme 
Purified enzymes were also used to sensitise SKOV3 cells to CB1954 using both NADH and 
NADPH as cofactor. When using NADH as cofactor mutant T41Q N71S F124T gave greatest 
sensitisation of SKOV3 cells to CB1954. This was followed by T41G N71S, T41L F70A and 
then T41L N71S. By contrast for NADPH, T41L F70A gave greatest sensitisation. Two of the 
best NTR mutants (T41G N71S and T41L N71S) provided less sensitisation than WT.   
 
7.2.1.3 Comparison of in vitro and in vivo performance 
Kinetic activity of mutant enzymes T41Q N71S F124T, F124N and clone 282 show a direct 
relationship with their ability to sensitise bacterial cells to CB1954. However a direct 
relationship cannot be seen for T41L N71S and T41G N71S (see Table 7.2). In both these 
cases a greater fold increase in sensitivity was seen kinetically compared to bacterial cells.  
 
There are several factors which will have an effect on cell sensitisation. CB1954 in the cell 
will have to compete with endogenous substrates and inhibitors for nitroreductase. Although 
T41L N71S and T41G N71S showed improvement for CB1954 compared to NFZ and 
Menadione we do not know what substrates and inhibitors are present within human cells and 
at what concentrations. It should be noted that crystal structure work has shown that nicotinic 
acid, acetate and dicoumarol can bind to the NTR active site, as crystals containing these 
compounds have been resolved (Lovering et al. 2001 and Johansson et al. 2003). 
 
 
 
 307 
NTR must interact with at least one substrate in human and bacterial cells as growth 
inhibition due to NTR toxicity has been observed in both. In human cells it is harder to 
generate stable cell clones expressing NTR compared to EGFP; it has not been possible to 
rescue some NTR mutant viruses. When doing plaque assays smaller plaques are produced by 
NTR expressing viruses and λ bacteriophage. 
 
All kinetic parameters were determined with NADH as cofactor; however both NADH and 
NADPH are available in cells.  Human cells contain varying amounts of NADH and NADPH. 
Combined NAD
+
 and NADH levels are reported typically to be ~ 10 fold higher than NADP
+
 
and NADPH (Garofalo et al. 1988). However when considering only the reduced cofactors 
used for CB1954 reduction, NADH levels in HEK293 cells were just 1-2 times that of 
NADPH (Pollak et al. 2007).  
 
Tissue culture studies in this thesis have shown that both T41L N71S and T41G N71S have a 
big preference for NADH, whereas some of the other nitroreductases show less of a 
preference.  
 
T41G N71S has a high Km NADH of ~305 µM. This is 9.7-fold higher than WT NTR and 
between 1.7-5.5-fold higher than the other NTR mutants. Therefore the amount of NADH in 
the cell may be low enough for NADH to be rate limiting for T41G N71S. NADH is probably 
what limits this enzyme‟s overall success in human cells. 
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 In vitro Kinetics In vivo E. coli bacterial cells In vivo SKOV3 human cells 
Enzyme kcat/Km CB1954 
µM s
-1
 
Fold improvement IC50 CB1954 
µM 
Fold improvement IC50 CB1954 
µM 
Fold improvement 
WT 0.0072 1 143 1 7 1 
T41L N71S 0.90 125 14 10 0.8 9 
T41G N71S 0.52 72 8 18 4 2 
T41Q N71S F124T 0.32 44 4 36 0.8 9 
F124N 0.031 4.3 25 6 - - 
282 0.018 2.5 18 8 60 NO IMPROVEMENT 
Table 7.2 Comparison of in vitro and in vivo efficacy of NfsB mutants with the prodrug CB1954 
Enhancement values are the fold improvement relative to WT NfsB 
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Finally, different NTRs have different bystander effects, the ability of the toxic product to 
spread to surrounding cells. WT NfsB and most of the mutants produce a 50:50 ratio of the 2-
HA and 4-HA products for CB1954 reduction. The 4-HA is known to be more toxic being a 
difunctional DNA alkylating agent. However the less toxic 2-HA monofunctional alkylating 
agent has recently been stated as having a greater contribution to the bystander effect (Helsby 
et al. 2004). The mutant T41L N71S produces only the 4-hydroxylamine product. Therefore 
T41L N71S could plausibly have a lesser bystander effect, with a reduction in spread of the 
toxic product and less killing of surrounding tumour cells. T41G N71S however produces 
both the 2-HA and 4-HA and therefore should have a good bystander effect.  
 
It was more difficult to compare kinetic activity with sensitising SKOV 3 cells to CB1954. In 
all cases the improvement in cell sensitisation was a lot lower than predicted by kinetic 
activity. However clone 282 was less sensitive than WT in SKOV 3 cells, which is 
contradictory to both bacterial E. coli cells and kinetic assays. However clone 282 only 
produces the 4-HA product; therefore it is likely that the bystander effect for this enzyme 
would be poor. In tissue culture much of the killing relies on the spread of the activated 
prodrug to surrounding cells. So NTRs with good bystander effects will be better in tissue 
culture assays. This was also the case with T41L N71S. This enzyme was kinetically the best. 
However, T41Q N71S F124T was better at sensitising SKOV3 cells. As with clone 282 
enzyme T41L N71S only produces the 4-HA product. This shows that enzymes that produce 
both the 2-HA and 4-HA are favourable for VDEPT as they produce the highly cytotoxic 
derivative but also have a good bystander effect killing large portions of surrounding cells. It 
is not currently possible to target every cancerous cell so a good bystander effect would be 
essential for a cure. 
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When analysing all data from this thesis, T41Q N71S F124T NfsB enzyme appears to be the 
best enzyme for use in a CB1954/NTR VDEPT strategy. Although it was not the best enzyme 
kinetically it was consistently best in human cancer cell lines. However the T41Q N71S 
F124T virus had at least 8 fold lower titres, when compared to other NTR viruses. The 
particle to infectivity ratio for the T41Q N71S F124T virus was very high when looking at 
both plaque forming units and infectious units (see Figures 6.2 and 6.3). A GMP clinical 
grade viral stock with a high particle to infectivity ratio would need to be manufactured for 
any clinical trial using these viruses. For T41Q N71S F124T this would be very difficult and 
expensive to produce making this NTR enzyme too costly. 
  
There are three remaining NTR mutants T41G N71S, T41N N71S and F124N, which have 
shown potential. T41G N71S is somewhat limited by its poor NADH kinetics but still showed 
2-fold improvement over WT in SKOV3 cells. However T41N N71S was 3.8-fold better than 
T41G N71S and 7.8-fold than WT. Further work to determine kinetic parameters and ratio of 
products would need to be determined for this enzyme before it could be considered, but 
T41N N71S NTR has potential as a prodrug-activating enzyme for VDEPT with CB1954. 
 
There are several alternative ways to improve an enzyme prodrug system, to use an alternative 
enzyme or prodrug and to improve the viral vector and delivery method. Each of these will be 
discussed further. 
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7.3 ALTERNATIVE ENZYMES 
Several alternative enzymes have been examined with CB1954. Escherichia coli enzyme 
NfsA has been cloned and characterised by our group. NfsA is considered as the major 
nitroreductase with good nitrofurazone metabolism (Whiteway et al. 1998). The activity of 
NfsA with CB1954 was examined and was found to have a 25 fold higher activity than WT 
NfsB (Vass et al. 2009). An adenovirus expressing NfsA in SKOV3 human cells showed 3.5-, 
6.3- and 8.1-fold lower IC50 values than an adenovirus expressing NfsB NTR. However this 
enzyme has a strong preference for NADPH which may limit its efficiency in human cells. 
Several of the NfsB mutants T41Q N71S F124T, T41L N71S, T41G N71S and T41L F70A 
showed greater sensitivity than NfsA.  
 
The nitrobenzene nitroreductase enzyme NbzA from Pseudomonas pseudoalcaligenes has also 
been proposed as an alternative enzyme. This enzyme shares moderate sequence homology 
with E. coli nitroreductase NfsA and is able to reduce nitrobenzene to hydroxylaminobenzene. 
This enzyme has low affinity for nitrofurazone relative to other nitroreductases at 1763 µM. 
NbzA enzyme was found to have a much lower Km CB1954 than NfsB at 11.7 µM. However 
kinetic data was determined by HPLC which is less reliable than steady state kinetics. There 
is no published in vivo data for NbzA (Berne et al. 2006).  
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A further nitroreductase enzyme YwrO from Bacillus amyloliquefaciens which is unrelated to 
NfsB but shares some sequence homology with mammalian NQO1 has been considered with 
CB1954. This enzyme only produces the 4-HA product and favours NADPH as cofactor. 
Kinetic parameters for CB1954 showed that both the kcat and Km are similar to those for NfsB 
NTR with a kcat 618 µM and Km 8.2 µM (Anlezark et al. 2002). However as with some of the 
NfsB mutants, kinetic data was not transferable to in vitro tissue culture assays. Purified YwrO 
enzyme required more CB1954 to kill V79 cells relative to NfsB enzyme. This is most 
probably due to a poor bystander effect, due to failure to produce 2-HA product, and 
preference for NADPH which reduces the amount of available cofactor. 
 
A further E. coli enzyme YieF a chromate reductase has shown CB1954 reducing activity. 
Initially YieF mutants were screened to identify genes that encoded enzymes with superior 
chromate reductase activity. However it wasn‟t until later that several enzymes with improved 
chromate reductase activity where found to also possess superior prodrug-reducing activity. 
One of these YieF mutants has been compared to NfsA. Purified enzymes were used to 
compare the enzymes in HeLa cells. YieF was found to be a 5-fold improvement relative to 
NfsA (Barak et al. 2006). A more recent published paper has attempted to determine kinetic 
parameters for this enzyme using stop flow kinetics, however YieF failed to give detectable 
levels of activity with CB1954 (Prosser et al. 2010).   
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Prosser and colleagues used SOS chromotest (use of genetically modified E. coli encoding β-
gal gene, the β-gal gene becomes activated by the SOS response upon DNA damage) to 
survey eleven E. coli CB1954 NTR candidates. This has allowed independent confirmation 
that NfsA is an effective CB1954 activating enzyme and has identified two other previously 
unreported enzymes with CB1954 reductase activity AzoR and NemA (Prosser et al. 2010). 
Stop flow kinetic data has shown that NfsA was 10-fold more active with CB1954 than NfsB, 
which was in turn approximately 2-fold more active than NemA and 60-fold more active than 
AzoR. IC50 assays showed NfsA (331 µM) then NfsB (490 µM) were best at sensitising E. coli 
SOS-R1 cells to CB1954. These were closely followed by NemA (502 µM).  
 
Further examination would be required before NbzA, YieF, YwrO, NemA and AzoR could be 
considered as an alternative to NfsB; however it is unlikely these enzymes will be better than 
NfsB mutant enzymes. 
 
7.4 ALTERNATIVE PRODRUGS 
Two other classes of compounds have been used as prodrugs for NTR: dinitrobenzamide 
mustards (DNBM) and nitroaromatic phosphoramide mustards. 
 
DNBM are analogues of CB1954 which have nitrogen mustard instead of an aziridine ring. 
The most well known is SN23862 which was originally designed to be activated in hypoxic 
tumour cells (Palmer et al. 1992 and Palmer et al. 1994). SN23862 was later tested with NTR, 
producing only a 2-HA product (see Figure 7.1a) (Anlezark et al. 1995). A range of further 
DNBM prodrugs have been generated by Wilson and colleagues. The prodrug SN24927 was 
found to have superior therapeutic activity to CB1954 (see Figure 7.1b) (Wilson et al. 2002). 
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Figure 7.1 Dinitrobenzamide mustard prodrugs 
a) SN23862, b) SN24927, c) SN26209, d) SN27686 and e) PR-104 
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In collaboration with the Wilson group several DNBM prodrugs have been tested with both 
NfsA and NfsB. SN24927 and SN26209 were found to be better than CB1954 (see Figure 7.1b 
and 7.1c). All the prodrugs tested were found to be better with NfsA than with NfsB (Vass et 
al. 2009). A further prodrug has been designed, SN27686, which also shows more dose 
potency and selectivity than CB1954 and also provide a superior bystander effect (see Figure 
7.1d) (Singleton et al. 2007).  
 
However, first generation DNBMs have poor aqueous solubility which limited in vivo 
application and prompted the development of DNBM phosphate esters, such as PR-104 which 
act as a „pre-prodrug‟. Systemic phosphatase activity generates the corresponding alcohols 
(prodrug PR-104A), which are then able to be reduced by hypoxic reductases or NfsB (see 
Figure 7.1e) (Patterson et al. 2007). PR-104 recently entered a Phase I clinical trial which 
showed that the prodrug was well tolerated (Jameson et al. 2010). PR-104 is now entering a 
Phase II clinical trial.  
 
The most well known phosphoramide mustard, cyclophosphamide has been successfully used 
as an anticancer agent for many years. A number of nitroaromatic phosphoramide prodrugs 
have been designed to allow activation of the phosphoramide mustard by NTR. The best of 
these, LH7, contains a simple nitrobenzene ring, connected to the phosphoramide mustard 
moiety, allowing NTR reduction to release phosphoramide mustard (see Figure 7.2a). Hu and 
colleagues have shown that LH7 is a better substrate for NTR than CB1954, with an IC50 
about 10-fold lower, and a greater differential toxicity between control and NTR expressing 
cells (Hu et al. 2003). 
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Figure 7.2 Phosphoramide mustard prodrugs 
a) LH7, b) LH14, c) LH17, d) LH25 and e) LH26 
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In collaboration with the Hu group a large number of LH7 analogue phosphoramide prodrugs 
have been test with NfsB. Most were less sensitive than LH7 and CB1954. LH7 still remained 
most sensitive closely followed by LH17 then LH14 (see Figure 7.2b and 7.2c) (Vass 2007). 
A further set of prodrugs engineered to have good bystander effects have been tested with 
NfsB. None of these were better than LH7 and CB1954. However LH25 and LH26 were only 
marginally worse than CB1954 with NfsB (see Figure 7.2d and 7.2e) (Vass 2007).  
 
Therefore SN27686, SN26209 and LH7 could prove good alternative to CB1954 when using 
NfsB NTR.  
 
7.5 ALTERNATIVE SYSTEMS 
The most clinically advanced enzyme/prodrug combinations for VDEPT are herpes simplex 
virus thymidine kinase (TK) for activation of the prodrug ganciclovir (GCV) and cytosine 
deaminase (CD) for conversion of 5-fluorocytosine to the antineoplastic agent 5-fluorouracil 
(Dachs et al. 2005 and Dachs et al. 2009).   
 
HSV-TK with ganciclovir (GCV) is the only GDEPT combination to have reached phase III 
human trials. Patients with glioblastoma were treated with an HSV-TK-expressing replication 
defective retrovirus followed by GCV and radiotherapy (Rainov et al. 2000). However this 
treatment failed to improve patient survival. A subsequent phase II trial utilising a replication 
defective adenovirus for delivery of HSV-TK into patients has shown some success. The 
adenoviral vector was injected into the wound bed after glioma resection. A clinically and 
statistically significant increase in median survival over standard therapy was observed. 
(Immonen et al. 2004).  
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Adenovirally delivered HSV-TK has been granted Orphan Drug Status by the European 
Committee for Orphan Medicinal Products under the name of Cerepro. Their most recent 
Phase III clinical trial showed promising results (Arktherapeutics website 
www.arktherapeutics.com/CEREPRO September 2010).   
 
HSV-TK mutants and ganciclovir (GCV) derivatives have been developed in an attempt to 
reduce toxicity, owing to HSV-TK having a higher affinity for its natural substrate thymidine 
(Field et al. 1983, Balzarini et al. 1993 and Munir et al. 1994). Ten thymidine kinase variants 
were selected from a random mutagenesis library consisting of over 1 million thymidine 
kinases. All ten showed increased activity to both GCV and ACV (Black et al. 1996). Further 
remodelling has further improved substrate specificity for GCV, giving improved prodrug-
mediated tumour cell killing (Black et al. 2001 and Wiewrodt et al. 2003). It should be noted 
that these improvements to HSV-TK have resulted from a reduction in binding to thymidine 
(the natural substrate) rather than an improvement in activity with the prodrug. Therefore any 
improvement made stems from a reduction in substrate competition in contrast to 
improvements made by my group, which have improved the activity with the prodrug 
CB1954. 
 
Cytosine deaminase (CD) and 5-fluorocytosine (5-FC) in combination has been tested in 
several Phase I clinical trials (Huber et al. 1993 and Padha et al. 1999). Initial work used 
bacterial CD cloned from E. coli, which has been shown in a number of in vitro studies to 
enhance mammalian cell sensitivity to 5-FC (Ge et al. 1997). CD from Saccharomyces 
cerevisiae has since been found to have a higher affinity for 5-FC (Kievit et al. 1999 and 
Kievit et al. 2000).  
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More recent studies have used the yeast enzyme or have attempted to improve the bacterial 
enzyme. Alanine-scanning mutagenesis and random mutagenesis of CD by error prone PCR 
has produced several CD mutants with favourable properties (Mahan et al. 2004a and Mahan 
et al. 2004b).  
 
Uracil phosphoribosyl transferase (UPRT) has been used to help sensitise cells to lower 
concentrations of 5-FU by converting 5-FU to 5-FUMP, increasing the cytotoxic effects of 5-
FC (Koyama et al. 2000). A fusion of the CD and UPRT genes has been created resulting in 
greater sensitisation to 5-FC (Erbs et al. 2000 and Chung-Faye et al. 2001b).  
 
Over the last 7 years a double suicide gene therapy system has been proposed, looking at 
synergistic cytotoxicity, using a combination of cytosine deaminase and herpes simplex virus 
thymidine kinase enzymes. This system used a replication competent adenovirus delivering 
the two enzymes as a fusion gene (Freytag et al. 2002a). A second generation replication 
competent adenovirus has been constructed which contains an improved yeast cytosine 
deaminase, the herpes simplex virus thymidine kinase gene and the adenovirus death protein 
gene (Barton et al. 2006). This system has entered phase I clinical trials for prostate cancer 
(Freytag et al. 2002b and Freytag et al. 2007). A recent study has shown a synergistic 
cytotoxic interaction (Boucher et al. 2006). 
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7.6 VIRAL VECTORS AND THEIR DELIVERY 
The clinical trial here in Birmingham used a replication defective adenovirus CTL102 
(Palmer et al. 2004, Patel et al. 2009). Low efficiency of gene delivery and poor distribution 
of the virus was seen. Ideally the perfect vector system would be administered by a non-
invasive route, would target only desired cells within the target tissue, and would express a 
therapeutic amount of transgene product with desired regulation for a desired length of time 
(Vorburger and Hunt 2002). No vector with all these properties is currently available. 
 
A conditionally replicating virus ONYX-015 has been developed which was expected to 
target cells containing dysfunctional p53 (Barker and Berk 1987, Heise et al. 1997 and 
Freytag et al. 1998). The mechanism of tumour selectivity is now believed to depend more on 
complementation by tumour cells with defects in nuclear export of viral RNA in the absence 
of E1B 55K protein (O‟Shea et al. 2004). Modest anti-tumour activity was observed; 
particularly when combined with chemotherapy (Khuri et al. 2000). In 2005 a modified 
version of the oncolytic ONYX-015 virus was approved for the treatment of head and neck 
cancer in Shanghai (Garber 2006). Survival data was not given but combination with 
chemotherapy showed an improvement relative to chemotherapy alone.  
 
Further research here in Birmingham using a virus (CRAd), similar to ONYX-015, encoding 
NfsB NTR showed oncolytic growth properties and the virus expressed substantially more 
NTR than a comparable replication-defective adenovirus. The combination of viral oncolysis 
and NTR expression resulted in significantly greater sensitization of colorectal cancer cells to 
the prodrug CB1954 in vitro (Chen et al. 2004). 
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Onyx Pharmaceuticals have engineered a second oncolytic virus ONYX-411 which 
selectively replicates in tumor cells, depending upon the status of the cells‟ retinoblastoma 
tumour suppressor protein (pRB) pathway. Early and late viral gene expression was 
significantly reduced, resulting in a restricted replication profile similar to that of 
nonreplicating adenoviruses in normal cells both in vitro and in vivo (Johnson et al. 2002). 
ONYX-411 is also better at expressing in tumour cells compared to ONYX-015 (Zhan et al. 
2005). Reddi and colleagues have report that ONYX-411 is able to induce cell death in eight 
human anaplastic carcinoma cell lines in vitro (Reddi et al. 2008). ONYX-411
NTR
 has been 
tested in combination with the prodrug SN27686. Robust, durable NTR expression was seen 
in ONYX-411
NTR
 infected neoplastic cell lines, but not primary human cell lines. The water-
soluble phosphate ester SN28343 was substantially more active than CB1954 against 
xenografts containing a minority of stable NTR-expressing cells (Singleton et al. 2007).  
 
Systemic administration of oncolytic viruses have so far been limited by the cellular immune 
response. Adenoviruses are readily cleared from the bloodstream after interacting with blood 
clotting factors and neutralisation by pre-existing antibodies. Lyons and colleagues have 
shown that the highest level of adenovirus binding was in erythrocytes (accounting for 70-
95%), however binding was also seen in human neutrophils and peripheral blood 
mononuclear cells (PBMCs) (Lyons et al. 2006). Therefore any virus administered 
systemically must be protected from the immune system. A possible way around this would 
be to polymer-shield viral vectors to prevent interaction with antibodies, but to still allow 
viral production once in the target tumour cells. 
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Modification of adenoviruses with hydrophilic synthetic polymers such as N-(2-
hydroxypropyl) methacrylamide copolymer (HPMA) significantly prolongs plasma 
circulation times and prevents non-specific cell entry. In mouse studies a polymer-coated 
adenovirus showed nearly 50% plasma circulation, representing 3.5-fold greater levels when 
compared to unmodified adenovirus. This has allowed active and passive targeting to tumour 
cells (Green et al. 2004 and Fisher et al. 2007). Polymers have been further improved by 
including side chains bearing reactive carbonyl thiazolidine-2-thione groups and the inclusion 
of side chains bearing positively charged quaternary ammonium groups (Subr et al. 2009). 
Antibody-resistant polymer coated viruses that circulate well in plasma and can be targeted 
directly to tumour cells have real potential for the treatment of metastatic cancer. First 
generation vectors are currently being developed which could prove to be a big step towards 
curative cancer gene therapy (Fisher and Seymour 2010).  
 
7.7 GENE THERAPY PROGRESS 
Gene therapy has come a long way since it was originally conceived as a treatment for 
monogenic disease in 1989. Rapid progress has allowed greater understanding of disease 
processes, with the first gene therapy trial being performed in 1990 for children with 
adenosine deaminase deficiency (ADA) (Blaese et al. 1995). As our knowledge has improved, 
research has moved towards more complex diseases with cancer now being the focus for the 
vast majority of gene therapy clinical trials.  
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There have been many successes and failures during the last 20 years of gene therapy. The 
death of a clinical trial patient in 1999 was a major blow to gene therapy research. Jesse 
Gelsinger suffered from a partial deficiency of ornithine transcarbamylase (OTC). Gelsinger 
suffered an adverse reaction to the adenovirus used in the trial which lead to multiple organ 
failure (Thomas et al. 2003).   
 
In 2000 the successful treatment of ten patients with SCID was probably the highest point for 
gene therapy (Cavazzana-Calvo et al. 2000). However the excitement turned to alarm at the 
end of 2002 when two of the ten children developed leukaemia-like conditions, linked to the 
retroviral vector used during the treatment (Hacein-Bey-Abina et al. 2003a and Hacein-Bey-
Abina et al. 2003b). Regulatory bodies halted the trial, but in 2004 the trial was reopened on 
the grounds that benefits outweigh the risks. This gave fresh hope that gene therapy can offer 
a realistic chance of survival to babies born with SCID. However this incident has spawned 
much further work to understand retrovirus integration site preferences and to allow the 
development of vectors less likely to result in oncogene activation.  
 
In 2003 Gendicine (recombinant adenovirus encoding human tumor suppressor gene p53) 
gene therapy and in 2005 Oncorine (Recombinant oncolytic virus) gene therapy have both 
been made commercially available in China for the treatment of a large range of cancers (Guo 
and Xin 2006). In 2009 HSV-TK with ganciclovir prodrug activation therapy was granted 
orphan drug status, showing clinical efficacy (Arktherapeutics website 
www.arktherapeutics.com/CEREPRO September 2010).  
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Despite a huge amount of research over the last 20 years further improvement would be 
required before gene therapy could be used as a curative procedure for cancer. Ideally 
improved vectors and delivery systems could prove crucial to future gene therapy successes.  
 
In conclusion, I have further improved the NTR/CB1954 enzyme prodrug system by 
generating improve NTR variants. These improved enzymes have been kinetically determined 
and their ability to sensitise human cancer cell lines examined. The merits of these enzymes 
should be considered when designing future clinical trials, using NTR for prodrug activation. 
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Figure 8.1 Agarose gels of PCR’s using primers JG2A with PS1296F and JG2A with JG2B 
PCR products were run on 0.7% agarose gel. JG2A/PS1296F: NfsB insert no band, NfsA insert expect band of 607 bp and empty vector no band. 
JG2A/JG2B: NfsB insert expert band of 1093 bp, NfsA insert expect band of 1126 bp and empty vector 385 bp. NfsB NTR and empty vector can‟t prime 
with PS1296F 
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Figure 8.2 Replica plating of individual lysogens after twenty-one rounds of selection using 25 
µM CB1954 
No CB1954, 5 µM, 12 µM and 25 µM CB1954 was used for replica plating. The first two lysogens on 
the top left of each plate are controls WT and T41G N71S respectively 
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Figure 8.3 Replica plating of individual lysogens after twenty-one rounds of selection using 50 
µM CB1954 
No CB1954, 5 µM, 12 µM and 25 µM CB1954 was used for replica plating. The first two lysogens on 
the top left of each plate are controls WT and T41G N71S respectively 
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Figure 8.4 Replica plating of individual lysogens after twenty-one rounds of selection using 75 
µM CB1954 
No CB1954, 5 µM, 12 µM and 25 µM CB1954 was used for replica plating. The first two lysogens on 
the top left of each plate are controls WT and T41G N71S respectively 
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Figure 8.5 Replica plating of individual lysogens after twenty-one rounds of selection using 100 
µM CB1954 
No CB1954, 5 µM, 12 µM and 25 µM CB1954 was used for replica plating. The first two lysogens on 
the top left of each plate are controls WT and T41G N71S respectively 
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